{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "'''\n",
    "This notebook was used to prototype the search engine, please run it after you've ran the first two \n",
    "notebooks (create_pubmed_db and create_kw_similarity_model) to ensure you have the databases and the model\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pickle\n",
    "from transformers import *\n",
    "import torch\n",
    "import numpy as np\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "from sklearn.neighbors import NearestNeighbors\n",
    "import random"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('dict_articles_V2.pkl', 'rb') as handle:\n",
    "    dict_articles = pickle.load(handle)\n",
    "    \n",
    "with open('dictionary.pkl', 'rb') as handle:\n",
    "    dict_vocab = pickle.load(handle)\n",
    "    \n",
    "with open('dict_authors_v4.pickle', 'rb') as handle:\n",
    "    dict_authors = pickle.load(handle)\n",
    "\n",
    "with open('neighbor_model.pkl','rb') as handle:\n",
    "    neighbor_model = pickle.load(handle)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "scibert_tokenizer = AutoTokenizer.from_pretrained('dmis-lab/biobert-v1.1')\n",
    "scibert_model = AutoModel.from_pretrained('dmis-lab/biobert-v1.1')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tokenize_string(string):\n",
    "    token_keyword = torch.tensor(scibert_tokenizer.encode(string)).unsqueeze(0)\n",
    "    out = scibert_model(token_keyword)\n",
    "    vector = out[0][0][1:-1].detach().numpy().mean(axis=0)\n",
    "    return vector\n",
    "\n",
    "def get_preliminary_keywords(vector,max_distance=100):\n",
    "    twenty_nearest_neighbors = neighbor_model.kneighbors(vector.reshape(1,-1))\n",
    "    preliminary_lst_keywords = []\n",
    "    for distance,pos in zip(twenty_nearest_neighbors[0][0],twenty_nearest_neighbors[1][0]):\n",
    "        if distance < max_distance:\n",
    "            preliminary_lst_keywords.append(list(dict_vocab.keys())[pos])\n",
    "            \n",
    "    return preliminary_lst_keywords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['ivermectin',\n",
       " 'ivermectina',\n",
       " 'citoquine storm',\n",
       " 'chloroquine.',\n",
       " 'chloroquine derivatives',\n",
       " 'clq, chloroquine',\n",
       " 'insecticide-treated nets',\n",
       " 'oh chloroquine',\n",
       " 'chloroquine sulfate',\n",
       " 'cloroquina',\n",
       " 'ipac, infection prevention and control',\n",
       " 'case report | fluconazole',\n",
       " 'chloroquine',\n",
       " 'clarithromycin covid19.',\n",
       " 'imi, imiquimod 5% cream',\n",
       " 'covid19, wuhan virus, hydroxychloroquine, remedesevir, antihelminth, anti-cytokine therapy, antiviral.',\n",
       " 'asinex antiviral library',\n",
       " 'artemisinin derivatives',\n",
       " 'lumiradx antigen test',\n",
       " 'cq, chloroquine']"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_query = 'ivermectin treatment efficacy'\n",
    "vector = tokenize_string(search_query)\n",
    "prelim_kw = get_preliminary_keywords(vector,max_distance=120)\n",
    "prelim_kw"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['10.3760/cma.j.issn.1001-0939.2020.0019',\n",
       " '10.5582/bst.2020.01047',\n",
       " '10.1016/j.cmi.2020.05.016',\n",
       " '10.1016/j.pharmthera.2020.107587',\n",
       " '10.1007/s00210-020-01902-5',\n",
       " '10.1007/s12011-020-02194-9',\n",
       " '10.1080/24734306.2020.1757967',\n",
       " '10.1016/j.jiph.2020.05.005',\n",
       " '10.1016/j.ijantimicag.2020.106028',\n",
       " '10.1016/j.hrthm.2020.05.008',\n",
       " '10.1161/CIRCEP.120.008688',\n",
       " '10.3389/fmed.2020.00192',\n",
       " '10.3390/ph13050098',\n",
       " '10.3390/ph13050096',\n",
       " '10.1016/j.ijsu.2020.05.018',\n",
       " '10.1016/j.lfs.2020.117775',\n",
       " '10.1016/j.therap.2020.05.004',\n",
       " '10.1007/s10840-020-00765-3',\n",
       " '10.31138/mjr.31.1.94',\n",
       " '10.1016/j.biopha.2020.110267',\n",
       " '10.1016/j.sapharm.2020.04.031',\n",
       " '10.1016/j.mehy.2020.109815',\n",
       " '10.1016/j.ijantimicag.2020.106020',\n",
       " '10.7759/cureus.7608',\n",
       " '10.1177/0194599820928989',\n",
       " '10.1007/s40495-020-00216-7',\n",
       " '10.1111/resp.13845',\n",
       " '10.3389/fmed.2020.00184',\n",
       " '10.1016/j.ijantimicag.2020.106012',\n",
       " '10.1177/1060028020925558',\n",
       " '10.1016/j.tmaid.2020.101735',\n",
       " '10.1186/s13054-020-02932-4',\n",
       " '10.1016/j.hrthm.2020.04.046',\n",
       " '10.15190/d.2020.5',\n",
       " '10.7573/dic.2020-4-5',\n",
       " '10.1186/s40779-020-00251-x',\n",
       " '10.1093/ofid/ofaa130',\n",
       " '10.4103/ijabmr.IJABMR_141_20',\n",
       " '10.1016/j.hrcr.2020.03.016',\n",
       " '10.1016/j.clinthera.2020.04.010',\n",
       " '10.1016/j.phrs.2020.104859',\n",
       " '10.1007/s10389-020-01293-0',\n",
       " '10.1007/s12471-020-01429-7',\n",
       " '10.1007/s12325-020-01351-9',\n",
       " '10.1161/CIRCEP.120.008662',\n",
       " '10.7759/cureus.7386',\n",
       " '10.1515/cclm-2020-0442',\n",
       " '10.1016/j.acvd.2020.04.001',\n",
       " '10.1186/s12941-020-00358-y',\n",
       " '10.1016/j.jclinepi.2020.04.016',\n",
       " '10.3390/jcm9041131',\n",
       " '10.1016/j.nmni.2020.100680',\n",
       " '10.1016/j.nmni.2020.100684',\n",
       " '10.5582/bst.2020.03082',\n",
       " '10.5582/ddt.2020.03010',\n",
       " '10.1016/j.dsx.2020.04.014',\n",
       " '10.1016/j.ijantimicag.2020.105982',\n",
       " '10.7861/clinmed.2020-0129',\n",
       " '10.3760/cma.j.cn112147-20200218-00119',\n",
       " '10.1016/j.onehlt.2020.100131',\n",
       " '10.3390/ph13040065',\n",
       " '10.5582/bst.2020.03072',\n",
       " '10.1111/jcmm.15312',\n",
       " '10.1111/1756-185X.13842',\n",
       " '10.7759/cureus.7560',\n",
       " '10.3399/bjgpopen20X101069',\n",
       " '10.1016/j.dsx.2020.03.011',\n",
       " '10.7326/M20-1334',\n",
       " '10.7326/M20-1223',\n",
       " '10.1016/j.ajog.2020.03.021',\n",
       " '10.1016/j.ijantimicag.2020.105945',\n",
       " '10.1016/j.jcrc.2020.03.005',\n",
       " '10.1016/j.ijantimicag.2020.105938',\n",
       " '10.3760/cma.j.issn.1001-0939.2020.03.009',\n",
       " '10.1016/j.antiviral.2020.104762',\n",
       " '10.2217/nnm-2020-0247',\n",
       " '10.1016/j.drup.2020.100719',\n",
       " '10.3389/fimmu.2020.01409',\n",
       " '10.1080/15548627.2020.1796014',\n",
       " '10.3390/antiox9070624',\n",
       " '10.1177/1708538120941635',\n",
       " '10.1016/j.ijantimicag.2020.106101',\n",
       " '10.1016/j.jcrc.2020.06.019',\n",
       " '10.1016/j.lfs.2020.118096',\n",
       " '10.1080/07391102.2020.1792993',\n",
       " '10.1128/AAC.00741-20',\n",
       " '10.1016/j.marpolbul.2020.111375',\n",
       " '10.1007/s10840-020-00822-x',\n",
       " '10.2174/1389200221666200711160440',\n",
       " '10.1016/j.ejim.2020.07.001',\n",
       " '10.1177/2058738420941754',\n",
       " '10.1007/s12471-020-01462-6',\n",
       " '10.1016/j.tmaid.2020.101812',\n",
       " '10.1002/rmv.2136',\n",
       " '10.1186/s13063-020-04478-w',\n",
       " '10.7554/eLife.58631',\n",
       " '10.2174/1381612826666200707121636',\n",
       " '10.2174/1381612826666200707132920',\n",
       " '10.1080/14787210.2020.1792291',\n",
       " '10.3390/jcm9072084',\n",
       " '10.1016/j.cellsig.2020.109706',\n",
       " '10.1016/j.ijantimicag.2020.106078',\n",
       " '10.1080/10408347.2020.1781592',\n",
       " '10.1016/j.hrthm.2020.07.001',\n",
       " '10.1080/1744666X.2020.1792778',\n",
       " '10.1002/ijgo.13293',\n",
       " '10.5582/ddt.2020.03046',\n",
       " '10.1016/j.ijid.2020.06.063',\n",
       " '10.1080/07391102.2020.1782265',\n",
       " '10.3389/fpubh.2020.00252',\n",
       " '10.1016/j.ijantimicag.2020.106057',\n",
       " '10.1016/j.eplepsyres.2020.106399',\n",
       " '10.1080/03602532.2020.1770782',\n",
       " '10.1111/dth.13829',\n",
       " '10.3892/etm.2020.8692',\n",
       " '10.1016/j.ihj.2020.04.006',\n",
       " '10.1016/j.ijantimicag.2020.106054',\n",
       " '10.1002/jcph.1687',\n",
       " '10.24911/SJP.106-1587122398',\n",
       " '10.1080/17476348.2020.1782199',\n",
       " '10.24875/ACM.M20000061',\n",
       " '10.1186/s42358-020-00134-8',\n",
       " '10.5455/JPMA.22',\n",
       " '10.1007/s13181-020-00790-8',\n",
       " '10.1186/s13063-020-04421-z',\n",
       " '10.1186/s13063-020-04420-0',\n",
       " '10.1016/j.ssci.2020.104842',\n",
       " '10.1080/00325481.2020.1778982',\n",
       " '10.4103/ijph.IJPH_496_20',\n",
       " '10.1007/s10067-020-05202-4',\n",
       " '10.1016/j.therap.2020.05.010',\n",
       " '10.1186/s12941-020-00368-w',\n",
       " '10.7759/cureus.10005',\n",
       " '10.1016/j.nmni.2020.100758',\n",
       " '10.3389/fimmu.2020.02159',\n",
       " '10.2147/RRTM.S269936',\n",
       " '10.1111/jcpt.13267',\n",
       " '10.2174/1389450121666200924113243',\n",
       " '10.1038/s41401-020-00519-x',\n",
       " '10.3390/antiox9090894',\n",
       " '10.3390/biom10091346',\n",
       " '10.1111/bcp.14546',\n",
       " '10.1681/ASN.2020050564',\n",
       " '10.1080/15563650.2020.1817479',\n",
       " '10.1021/acs.jproteome.0c00683',\n",
       " '10.1002/jcp.30055',\n",
       " '10.1016/j.lfs.2020.118469',\n",
       " '10.1016/j.amjms.2020.08.019',\n",
       " '10.1007/s10792-020-01593-0',\n",
       " '10.3390/cells9092100',\n",
       " '10.1016/j.heliyon.2020.e04900',\n",
       " '10.1177/1049909120952773',\n",
       " '10.1016/j.jksus.2020.09.002',\n",
       " '10.1016/j.taap.2020.115237',\n",
       " '10.2196/19791',\n",
       " '10.1002/hpm.3057',\n",
       " '10.1016/j.dsx.2020.08.033',\n",
       " '10.1007/s42399-020-00485-9',\n",
       " '10.1098/rsob.200174',\n",
       " '10.1007/s12035-020-02093-z',\n",
       " '10.1016/j.xphs.2020.08.024',\n",
       " '10.1007/s11606-020-06146-w',\n",
       " '10.1186/s41021-020-00164-0',\n",
       " '10.3390/ph13090228',\n",
       " '10.1089/jir.2020.0105',\n",
       " '10.21873/invivo.12134',\n",
       " '10.1016/j.jsbmb.2020.105751',\n",
       " '10.21315/mjms2020.27.4.15',\n",
       " '10.1016/j.rce.2020.07.007',\n",
       " '10.1016/j.cmi.2020.08.022',\n",
       " '10.1093/femspd/ftaa046',\n",
       " '10.32598/bcn.11.covid19.2500.1',\n",
       " '10.1186/s40001-020-00438-x',\n",
       " '10.3389/fmed.2020.00482',\n",
       " '10.3389/fmed.2020.00480',\n",
       " '10.3389/fphar.2020.01167',\n",
       " '10.1002/emp2.12081',\n",
       " '10.1016/j.mayocpiqo.2020.07.004',\n",
       " '10.1007/s42399-020-00392-z',\n",
       " '10.1016/j.jdcr.2020.07.024',\n",
       " '10.1016/j.gendis.2020.07.001',\n",
       " '10.1016/j.gendis.2020.06.007',\n",
       " '10.1016/j.jceh.2020.07.001',\n",
       " '10.1007/s12291-020-00919-0',\n",
       " '10.1016/j.hermed.2020.100382',\n",
       " '10.1016/j.nmni.2020.100714',\n",
       " '10.1016/j.cplett.2020.137869',\n",
       " '10.1177/2049936120947517',\n",
       " '10.2174/1574891X15999200819102507',\n",
       " '10.1016/j.dib.2020.106116',\n",
       " '10.1016/j.psym.2020.06.022',\n",
       " '10.1016/j.ejphar.2020.173467',\n",
       " '10.1055/s-0040-1714142',\n",
       " '10.4103/jfmpc.jfmpc_422_20',\n",
       " '10.7573/dic.2020-5-8',\n",
       " '10.1007/s12272-020-01258-7',\n",
       " '10.1016/j.semerg.2020.06.016',\n",
       " '10.1016/j.ijid.2020.07.054',\n",
       " '10.1016/j.ijantimicag.2020.106119',\n",
       " '10.3389/fpubh.2020.00365',\n",
       " '10.1007/s12011-020-02512-1',\n",
       " '10.1016/j.mehy.2020.110364',\n",
       " '10.2174/1381612826666201125112719',\n",
       " '10.1186/s13063-020-04813-1',\n",
       " '10.2174/1389557520666201124141103',\n",
       " '10.1111/cod.13748',\n",
       " '10.1016/j.biopha.2020.110891',\n",
       " '10.1111/maq.12622',\n",
       " '10.2174/1871530320999201117142305',\n",
       " '10.1016/j.jsps.2020.11.003',\n",
       " '10.1080/07391102.2020.1844804',\n",
       " '10.1007/s10787-020-00774-8',\n",
       " '10.31138/mjr.31.3.257',\n",
       " '10.3389/fphys.2020.587709',\n",
       " '10.3389/fphar.2020.554172',\n",
       " '10.1016/j.pt.2020.10.005',\n",
       " '10.1007/s00228-020-03032-6',\n",
       " '10.1186/s13104-020-05379-6',\n",
       " '10.1016/j.mayocpiqo.2020.10.005',\n",
       " '10.3389/fphar.2020.562777',\n",
       " '10.1080/15548627.2020.1844940',\n",
       " '10.7705/biomedica.5478',\n",
       " '10.1080/07391102.2020.1841028',\n",
       " '10.2147/PGPM.S275964',\n",
       " '10.1080/07391102.2020.1839564',\n",
       " '10.12688/wellcomeopenres.15936.1',\n",
       " '10.1093/ehjcr/ytaa218',\n",
       " '10.1016/j.nmni.2020.100709',\n",
       " '10.1016/j.molstruc.2020.129459',\n",
       " '10.1016/j.jgar.2020.09.030',\n",
       " '10.1016/j.ipej.2020.10.002',\n",
       " '10.3389/fpsyg.2020.565128',\n",
       " '10.1016/j.cmi.2020.10.004',\n",
       " '10.1016/j.chest.2020.10.009',\n",
       " '10.7759/cureus.10378',\n",
       " '10.1186/s12985-020-01415-w',\n",
       " '10.2196/21648',\n",
       " '10.1016/j.imu.2020.100446',\n",
       " '10.1111/bcp.14598',\n",
       " '10.1016/j.ad.2020.09.004',\n",
       " '10.1016/j.ejphar.2020.173634',\n",
       " '10.2174/1381612826666201006125644',\n",
       " '10.1016/j.scitotenv.2020.142436',\n",
       " '10.1016/j.ijid.2020.09.1460',\n",
       " '10.1016/j.ijid.2020.09.1470',\n",
       " '10.1007/s00253-021-11094-4',\n",
       " '10.1093/trstmh/traa193',\n",
       " '10.1016/j.abst.2020.08.001',\n",
       " '10.4149/BLL_2021_015',\n",
       " '10.19540/j.cnki.cjcmm.20200828.601',\n",
       " '10.1016/j.eclinm.2020.100720',\n",
       " '10.1016/j.xphs.2021.01.017',\n",
       " '10.1016/j.berh.2020.101658',\n",
       " '10.1093/jtm/taab005',\n",
       " '10.11604/pamj.2020.37.177.26066',\n",
       " '10.4103/sja.SJA_317_20',\n",
       " '10.2147/JEP.S255209',\n",
       " '10.1042/BST20200568',\n",
       " '10.1016/j.jemep.2020.100622',\n",
       " '10.1007/s41061-020-00318-2',\n",
       " '10.1080/1120009X.2020.1868237',\n",
       " '10.1002/prp2.705',\n",
       " '10.1007/s00210-020-02034-6',\n",
       " '10.1186/s40249-020-00788-y',\n",
       " '10.1177/1179547620972397',\n",
       " '10.1186/s13063-020-04988-7',\n",
       " '10.5603/ARM.a2020.0139',\n",
       " '10.1093/ckj/sfaa227',\n",
       " '10.1007/s43440-020-00195-y',\n",
       " '10.1007/s11030-020-10169-0',\n",
       " '10.31083/j.rcm.2020.04.260',\n",
       " '10.1007/s12012-020-09621-2',\n",
       " '10.5005/jp-journals-10071-23664',\n",
       " '10.1016/j.xcrm.2020.100146',\n",
       " '10.1093/tropej/fmaa089',\n",
       " '10.3389/fphar.2020.597985',\n",
       " '10.3389/fphar.2020.569665',\n",
       " '10.2147/CPAA.S284809',\n",
       " '10.1016/j.biopha.2020.111138',\n",
       " '10.1016/j.redox.2020.101810',\n",
       " '10.1016/j.jemermed.2020.10.048',\n",
       " '10.1016/j.jiph.2020.11.009',\n",
       " '10.1016/j.bbrc.2020.10.042',\n",
       " '10.1016/j.ijid.2020.12.018',\n",
       " '10.1093/ajcp/aqaa253',\n",
       " '10.1016/j.jchromb.2020.122469',\n",
       " '10.11604/pamj.supp.2020.37.9.25718',\n",
       " '10.2174/1389200221999201208211537',\n",
       " '10.3389/fneur.2020.596528',\n",
       " '10.1016/j.ijid.2020.11.191',\n",
       " '10.1016/j.mehy.2020.110434',\n",
       " '10.1016/j.ijantimicag.2020.106248',\n",
       " '10.1007/s43441-020-00158-8',\n",
       " '10.1186/s12985-021-01515-1',\n",
       " '10.1016/j.jmii.2021.01.012',\n",
       " '10.1007/s40121-021-00413-x',\n",
       " '10.1093/eurjpc/zwaa118',\n",
       " '10.11604/pamj.supp.2020.35.24064',\n",
       " '10.3389/fmolb.2020.636738',\n",
       " '10.1016/j.molliq.2021.115636',\n",
       " '10.5582/ddt.2021.01005',\n",
       " '10.1093/qjmed/hcab035',\n",
       " '10.1016/j.ijid.2021.02.014',\n",
       " '10.1080/20477724.2021.1884807',\n",
       " '10.2174/1573406417666210208223924',\n",
       " '10.1016/j.ejphar.2021.173928',\n",
       " '10.1016/j.compbiomed.2021.104222',\n",
       " '10.7759/cureus.12403',\n",
       " '10.3390/molecules26030673',\n",
       " '10.1016/j.mayocpiqo.2020.11.001',\n",
       " '10.1016/j.nmni.2021.100843',\n",
       " '10.3389/fphar.2020.600372',\n",
       " '10.1016/j.molstruc.2021.129979',\n",
       " '10.3390/v13040610',\n",
       " '10.1177/0897190021997399',\n",
       " '10.1016/j.scp.2021.100438',\n",
       " '10.1007/s11224-021-01776-0',\n",
       " '10.1016/j.ijid.2021.04.035',\n",
       " '10.3389/fimmu.2021.663586',\n",
       " '10.1093/rheumatology/keab348',\n",
       " '10.21037/apm-21-400',\n",
       " '10.1016/j.medidd.2021.100085',\n",
       " '10.1016/j.cclet.2021.04.008',\n",
       " '10.1186/s13063-021-05236-2',\n",
       " '10.1016/j.ejim.2021.03.028',\n",
       " '10.1177/1120672120958323',\n",
       " '10.4103/ijmr.IJMR_2294_20',\n",
       " '10.25100/cm.v51i4.4613',\n",
       " '10.31083/j.rcm.2021.01.262',\n",
       " '10.1007/s10517-021-05125-3',\n",
       " '10.1016/j.amjoto.2020.102640',\n",
       " '10.1007/s43440-021-00245-z',\n",
       " '10.26444/aaem/127766',\n",
       " '10.1055/s-0041-1723086',\n",
       " '10.3389/fmicb.2020.592908',\n",
       " '10.1080/14656566.2021.1898589',\n",
       " '10.1016/j.toxrep.2021.03.003',\n",
       " '10.1016/j.fct.2021.112106',\n",
       " '10.1080/13543784.2021.1901883',\n",
       " '10.1080/14787210.2021.1902805',\n",
       " '10.1016/j.virusres.2021.198384',\n",
       " '10.1002/ijgo.13670',\n",
       " '10.1093/jmcb/mjab016']"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "articles_of_interest = []\n",
    "for key,values in dict_articles.items():\n",
    "    if any([keyword in values['Keywords'] for keyword in prelim_kw]):\n",
    "        articles_of_interest.append(key)\n",
    "articles_of_interest   "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "def add_first_author(authors_search_results,first_author,article_doi):\n",
    "    if len(first_author.strip())>2:\n",
    "        name = first_author.split(' - ')[0]\n",
    "        affiliation = first_author.split(' - ')[1]\n",
    "        if first_author in authors_search_results:\n",
    "            authors_search_results[name]['Score'] += 4\n",
    "            authors_search_results[name]['Articles'].append(article_doi)\n",
    "            authors_search_results[name]['Affiliation'].append(affiliation)\n",
    "        else:\n",
    "            authors_search_results[name] = {'Score':4,'Articles':[article_doi],'Affiliation':[affiliation]}\n",
    "    return authors_search_results\n",
    "\n",
    "def add_other_authors(authors_search_results,other_authors,article_doi):\n",
    "    for author in other_authors:\n",
    "        if len(author.strip())>2:\n",
    "            name = author.split(' - ')[0]\n",
    "            affiliation = author.split(' - ')[1]\n",
    "            if author in authors_search_results:\n",
    "                authors_search_results[name]['Score'] += 1\n",
    "                authors_search_results[name]['Articles'].append(article_doi)\n",
    "                authors_search_results[name]['Affiliation'].append(affiliation)\n",
    "            else:\n",
    "                authors_search_results[name] = {'Score':1,'Articles':[article_doi],'Affiliation':[affiliation]}\n",
    "    return authors_search_results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "J Jianjun Gao 4 ['Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China.']\n",
      "Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Bioscience trends 2020-04-14\n",
      "C C Rodrigo 4 ['Department of Pathology, School of Medical Sciences, UNSW Sydney, Australia.']\n",
      "Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-05-30\n",
      "T Tianxiao Liu 4 [\"Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.\"]\n",
      "Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacology & therapeutics 2020-05-30\n",
      "E Emanuele Rizzo 4 ['Department of Prevention, Local Health Authority of Lecce (ASL Lecce), Lecce, Italy. emanuele.rizzo@email.com.\\nItalian Society of Environmental Medicine (SIMA), Milan, Italy. emanuele.rizzo@email.com.']\n",
      "Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg's archives of pharmacology 2020-05-29\n",
      "MT Mohammad Tariqur Rahman 4 ['Faculty of Dentistry, University of Malaya, Kuala Lumpur, 50603, Malayasia.']\n",
      "Potential benefits of combination of  Journal of herbal medicine 2020-08-25\n",
      "R Rachid Tahiri Joutei Hassani 4 ['Ambulatory Surgery Department, Avranches Granville Hospital, Granville, France. Electronic address: granville-tahiri@levisiologiste.com.']\n",
      "Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed. Journal of infection and public health 2020-05-27\n",
      "S Satyajit Tripathy 4 ['Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa.']\n",
      "A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International journal of antimicrobial agents 2020-05-26\n",
      "L Lior Jankelson 4 ['NYU Langone Health, NYU School of Medicine, New York, New York. Electronic address: Lior.Jankelson@nyulangone.org.']\n",
      "QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart rhythm 2020-05-22\n",
      "ML Matthijs L Becker 4 ['Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands. mbecker@sahz.nl.\\nDepartment of Hospital Pharmacy, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands. mbecker@sahz.nl.']\n",
      "QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular toxicology 2021-01-03\n",
      "O Ohad Oren 4 ['Division of Hematology and Oncology, Mayo Clinic, Rochester, MN (O.O.).']\n",
      "Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. Circulation. Arrhythmia and electrophysiology 2020-05-22\n",
      "VM Vasilios M Polymeropoulos 4 ['Vanda Pharmaceuticals, Washington, DC, United States.']\n",
      "Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19. Frontiers in medicine 2020-05-20\n",
      "JJ Jean Jacques Vanden Eynde 4 ['Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.']\n",
      "COVID-19: A Brief Overview of the Discovery Clinical Trial. Pharmaceuticals (Basel, Switzerland) 2020-04-16\n",
      "M Maha Saber-Ayad 4 ['Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAE.\\nCollege of Medicine, Cairo University, Cairo 12613, Egypt.']\n",
      "The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals (Basel, Switzerland) 2020-05-20\n",
      "E Ebrahim Abbasi-Oshaghi 4 ['Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran; Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Electronic address: a.oshaghi@umsha.ac.ir.']\n",
      "Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. International journal of surgery (London, England) 2020-05-19\n",
      "VM Vaishali M Patil 4 ['Computer Aided Drug Design Lab, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, India. Electronic address: vaishuwise@gmail.com.']\n",
      "A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life sciences 2020-05-19\n",
      "I Isabelle Lacroix 4 ['Unité «\\xa0Médicaments, grossesse et allaitement\\xa0», service de pharmacologie médicale et clinique, CHU de Toulouse, faculté de médecine, Inserm 1027, 37, allées Jules-Guesde, 31000 Toulouse, France. Electronic address: isabelle.lacroix@univ-tlse3.fr.']\n",
      "Chloroquine and hydroxychloroquine during pregnancy: What do we know? Therapie 2020-05-19\n",
      "E Enrique Asensio 4 ['Division of Internal Medicine, Hospital H, Querétaro, Mexico.']\n",
      "Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-05-18\n",
      "DP Dimitrios P Bogdanos 4 ['Department of Rheumatology and Clinical Immunology.']\n",
      "When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterranean journal of rheumatology 2020-05-16\n",
      "R Rachana Salvi 4 ['Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India.']\n",
      "Emerging pharmacotherapies for COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-05-16\n",
      "SM Scott M Vouri 4 ['Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL, USA; Center for Drug Evaluation and Safety, University of Florida, Gainesville, FL, USA; University of Florida Health Physicians, Gainesville, FL, USA.']\n",
      "An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. Research in social & administrative pharmacy : RSAP 2020-05-16\n",
      "R R Derwand 4 ['Alexion Pharma Germany GmbH, Landsberger Str. 300, 80687 Munich, Germany.']\n",
      "Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? Medical hypotheses 2020-05-15\n",
      "J Jacques Fantini 4 ['INSERM UMR_S 1072, 13015 Marseille, France.']\n",
      "Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. International journal of antimicrobial agents 2020-05-15\n",
      "ZR Zohra R Malik 4 [\"Internal Medicine, St. John's Episcopal Hospital, Far Rockaway, USA.\"]\n",
      "A Case of a COVID-19-positive Patient. Cureus 2020-05-14\n",
      "TL Thomas L Eby 4 ['Department of Otolaryngology and Communicative Sciences, University of Mississippi Medical Center, Jackson, Mississippi, USA.']\n",
      "Otologic and Audiologic Considerations for COVID-19. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2020-05-13\n",
      "R Renyi Wu 4 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "S Srinadh Annangi 4 ['Division of Pulmonary, Critical Care and Sleep Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.']\n",
      "Chloroquine and hydroxychloroquine for COVID-19: A word of caution. Respirology (Carlton, Vic.) 2020-05-13\n",
      "ME Mathieu E Rebeaud 4 ['DBMV, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.']\n",
      "SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment. Frontiers in medicine 2020-05-12\n",
      "R Ran Yu 4 ['Department of Bioengineering, Beijing Polytechnic, Daxing District, Beijing 100176, China. Electronic address: yuran1230@hotmail.com.']\n",
      "Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International journal of antimicrobial agents 2020-05-12\n",
      "CR Christopher R Piszczatoski 4 ['University of Florida, Gainesville, FL, USA.']\n",
      "Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. The Annals of pharmacotherapy 2020-05-12\n",
      "AM Anwar M Hashem 4 ['Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Vaccines and Immunnotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: amhashem@kau.edu.sa.']\n",
      "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel medicine and infectious disease 2020-05-11\n",
      "A Andrea Cortegiani 4 ['Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Italy. Electronic address: andrea.cortegiani@unipa.it.']\n",
      "Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of critical care 2020-07-20\n",
      "Y Yishay Szekely 4 ['Department of Cardiology, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: yishays@tlvmc.gov.il.']\n",
      "Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart rhythm 2020-05-08\n",
      "H Hasnain Jan 4 ['Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan.']\n",
      "COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova, Romania) 2020-05-08\n",
      "AM Ashutosh M Shukla 4 ['North Florida South Georgia VHS, Gainesville, FL, USA.\\nDepartment of Medicine, University of Florida, Gainesville, FL, USA.']\n",
      "Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in context 2020-05-07\n",
      "X Xinni Xu 4 ['Department of Otolaryngology-Head and Neck Surgery, National University Hospital System, Singapore, Singapore.']\n",
      "Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Military Medical Research 2020-05-07\n",
      "KA Katelyn A Pastick 4 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "DK Dinesh Kumar Badyal 4 ['Department of Pharmacology, CMCL-FAIMER Regional Institute, Christian Medical College, Ludhiana, Punjab, India.\\nDepartment of Medical Education, CMCL-FAIMER Regional Institute, Christian Medical College, Ludhiana, Punjab, India.']\n",
      "Chloroquine: Can it be a Novel Drug for COVID-19. International journal of applied & basic medical research 2020-05-05\n",
      "RL Raman L Mitra 4 ['Northshore University Hospital, Northwell Health, Manhasset, New York.']\n",
      "An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. HeartRhythm case reports 2020-05-05\n",
      "RI Richard I Shader 4 ['Tufts University School of Medicine, Boston, MA, United States. Electronic address: Richard.Shader@tufts.edu.']\n",
      "COVID-19 and Depression. Clinical therapeutics 2020-05-05\n",
      "DL Dwight L McKee 4 ['Integrative Cancer Consulting, Aptos, CA, USA.']\n",
      "Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological research 2020-05-04\n",
      "S Sivabakya T K 4 ['Department of Epidemiology, The Tamil Nadu Dr. M.G.R. Medical University, No. 69, Anna Salai, Guindy, Chennai, Tamil Nadu 600032 India.']\n",
      "Will the antimalarial drug take over to combat COVID-19? Zeitschrift fur Gesundheitswissenschaften = Journal of public health 2020-05-01\n",
      "MPH M P H van den Broek 4 ['Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands. mp.van.den.broek@antoniusziekenhuis.nl.']\n",
      "Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-05-01\n",
      "Z Zakir Khan 4 ['Tıbbi Farmakoloji Anabilim Dalı, Tıp Fakültesi, Çukurova Üniversitesi, Sarıçam, Adana, Turkey. zakirkhan300@gmail.com.\\nDepartment of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan. zakirkhan300@gmail.com.']\n",
      "Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. Advances in therapy 2020-05-01\n",
      "M Moussa Saleh 4 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).\\nDivision of Electrophysiology, Department of Cardiology, Lenox Hill Hospital, Northwell Health, New York, NY (M.S., P.M., N.S., S.M.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "DN Damian N Valencia 4 ['Internal Medicine, Kettering Medical Center, Dayton, USA.']\n",
      "Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. Cureus 2020-04-28\n",
      "ED Ettore D Capoluongo 4 ['CEINGE, Biotecnologie Avanzate, Naples, Italy.\\nDipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, and Department of Laboratory and Transfusion Medicine']\n",
      "The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Clinical chemistry and laboratory medicine 2020-04-26\n",
      "C Christian Funck-Brentano 4 ['Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France. Electronic address: christian.funck-brentano@aphp.fr.']\n",
      "Response to the editorial \"COVID-19 in patients with cardiovascular diseases\": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Archives of cardiovascular diseases 2020-04-26\n",
      "J José Millán-Oñate 4 ['Infectious Diseases Division, Centro Médico Imbanaco, Cali, Valle del Cauca, Colombia.\\nAsociación Colombiana de Infectología, Bogotá DC, Colombia.']\n",
      "Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Annals of clinical microbiology and antimicrobials 2020-04-26\n",
      "PE Paul Elias Alexander 4 ['Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; GUIDE Research Methods Group, McMaster University, Hamilton, Ontario, Canada. Electronic address: alexap@mcmaster.ca.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "J Jiansheng Huang 4 ['Department of Medicine, Vanderbilt University Medical Center, 318 Preston Research Building, 2200 Pierce Avenue, Nashville, TN 37232, USA.\\nSchool of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, Jiangsu, China.']\n",
      "Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. Journal of clinical medicine 2020-04-25\n",
      "S S Saqrane 4 ['Sultan Moulay Slimane University, Team of Environmental Microbiology and Toxicology, Laboratory of Chemistry, Modeling and Environmental Sciences, Polydisciplinary Faculty, Khouribga, Morocco.']\n",
      "Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. New microbes and new infections 2020-04-24\n",
      "R R Choudhary 4 ['Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala Haryana, India.']\n",
      "Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New microbes and new infections 2020-04-24\n",
      "K Kenichiro Sato 4 ['Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.']\n",
      "Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Bioscience trends 2020-04-24\n",
      "MN Mohammed Noor Embi 4 ['Department of Biological Sciences and Biotechnology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Selangor, Malaysia.']\n",
      "Is GSK3β a molecular target of chloroquine treatment against COVID-19? Drug discoveries & therapeutics 2020-04-24\n",
      "M Maja Baretić 4 ['Department of Endocrinology and Diabetology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, 10 000, Croatia; School of Medicine, University of Zagreb, Kišpatićeva 12, Zagreb, 10 000, Croatia. Electronic address: maja.baretic@kbc-zagreb.hr.']\n",
      "Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic? Diabetes & metabolic syndrome 2020-04-22\n",
      "M Ming Zhao 4 ['Department of Pharmacy, Beijing Hospital, National Centre of Gerontology, Beijing, P.R. China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China. Electronic address: zhaoming4287@bjhmoh.cn.']\n",
      "Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. International journal of antimicrobial agents 2020-04-20\n",
      "BR Beattie Rh Sturrock 4 ['Brighton and Sussex Medical School, Brighton UK and Royal Sussex County Hospital, Brighton, UK.']\n",
      "Chloroquine and COVID-19 - a potential game changer? Clinical medicine (London, England) 2020-04-19\n",
      "YJ Y J Liu 4 ['Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.']\n",
      "[What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2020-04-17\n",
      "S Stephane Picot 4 ['Malaria Research Unit, ICBMS, UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Villeurbanne, France.\\nInstitute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "EN Eva N Kassi 4 ['Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.']\n",
      "G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? Journal of cellular and molecular medicine 2020-04-14\n",
      "S Sanket Shah 4 ['Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.']\n",
      "A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International journal of rheumatic diseases 2020-04-14\n",
      "P Pramath Kakodkar 4 ['Medicine, National University of Ireland Galway, Galway, IRL.']\n",
      "A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus 2020-04-10\n",
      "K Kome Gbinigie 4 ['GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK Oghenekome.gbinigie@phc.ox.ac.uk.']\n",
      "Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP open 2020-04-09\n",
      "AK Awadhesh Kumar Singh 4 ['G. D Hospital & Diabetes Institute, Kolkata, India. Electronic address: draksingh_2001@yahoo.com.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome 2020-04-05\n",
      "J Jinoos Yazdany 4 ['Zuckerberg San Francisco General Hospital, University of California, San Francisco, California (J.Y.).']\n",
      "Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Annals of internal medicine 2020-04-02\n",
      "SE Sebastian E Sattui 4 ['Division of Rheumatology, Department of Medicine, Hospital for Special Surgery , New York, NY, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "P Pradip Dashraath 4 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore. Electronic address: pradip_dashraath_vijayakumar@nuhs.edu.sg.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "Z Zahra Sahraei 4 ['Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: zahra.sahraei@yahoo.com.']\n",
      "Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International journal of antimicrobial agents 2020-03-21\n",
      "CA Christian A Devaux 4 ['Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France; CNRS, Marseille, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: christian.devaux@mediterranee-infection.com.']\n",
      "New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International journal of antimicrobial agents 2020-03-17\n",
      "F Franck Touret 4 ['Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France. Electronic address: franck.touret@univ-amu.fr.']\n",
      "Of chloroquine and COVID-19. Antiviral research 2020-03-10\n",
      "NH Noura H Abd Ellah 4 ['Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt.']\n",
      "Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine (London, England) 2020-07-30\n",
      "S Sylwester Drożdżal 4 ['Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University in Szczecin, Poland.']\n",
      "FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020-07-28\n",
      "V Vincent Gies 4 ['Université de Strasbourg, INSERM UMR']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "D Daolin Tang 4 ['The Third Affiliated Hospital, Guangzhou Medical University , Guangzhou, Guangdong, China.\\nDepartment of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.']\n",
      "Chloroquine in fighting COVID-19: good, bad, or both? Autophagy 2020-07-28\n",
      "F Francesca Silvagno 4 ['Department of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.']\n",
      "The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. Antioxidants (Basel, Switzerland) 2020-07-28\n",
      "S Sherif Sultan 4 ['Western Vascular Institute, Department of Vascular and Endovascular Surgery, University Hospital Galway, National University of Ireland, Galway, Ireland.\\nDepartment of Vascular Surgery and Endovascular Surgery, Galway Clinic, Doughiska, Ireland.']\n",
      "Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. Vascular 2020-07-22\n",
      "Y Yogesh Acharya 4 ['Vascular and Endovascular Department, Western Vascular Institute, National University of Ireland, Galway, H91 TK33, Ireland.']\n",
      "Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. Therapeutic advances in infectious disease 2020-08-22\n",
      "MS Mohammad Sultan Khuroo 4 [\"Digestive Diseases Centre, Dr. Khuroo's Medical Clinic, Srinagar, Union Territory of Jammu and Kashmir, India. Electronic address: khuroo@yahoo.com.\"]\n",
      "Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. International journal of antimicrobial agents 2020-07-21\n",
      "S Suvojit Hazra 4 ['CPEPA-UGC Centre for \"Electro-physiological and Neuro-imaging studies including Mathematical Modelling\", University of Calcutta, Kolkata, West Bengal, India; Department of Physiology, University of Calcutta, Kolkata, West Bengal, India.']\n",
      "Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. Life sciences 2020-07-18\n",
      "I Ismail Celı K 4 ['Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.\\nDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.']\n",
      "Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. Journal of biomolecular structure & dynamics 2020-07-18\n",
      "P Pattaraporn Vanachayangkul 4 ['Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "N Naceur Essid 4 ['University of Carthage, Faculty of Sciences of Bizerte, Laboratory of Environment Biomonitoring, Coastal Ecology and Ecotoxicology Unit, 7021 Zarzouna, Tunisia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "BC Brian C Hsia 4 ['Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, 111 East 210th Street, Room N2, Bronx, NY, 10467, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "X Xueting Yao 4 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "TP T P Afra 4 ['Department of Dermatology, IQRAA Aesthetics, IQRAA International Hospital, and Research Centre, Calicut, Kerala, INDIA.']\n",
      "Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal. European journal of internal medicine 2020-07-12\n",
      "A Andrea Ciorba 4 ['ENT & Audiology Department, University Hospital of Ferrara, Cona, Italy. Electronic address: andrea.ciorba@unife.it.']\n",
      "Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency. Journal of global antimicrobial resistance 2020-10-20\n",
      "FS F S Sinkeler 4 ['Department of Clinical Pharmacy, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands. f.sinkeler@etz.nl.']\n",
      "The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-07-11\n",
      "K Khalid Eljaaly 4 ['Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; College of Pharmacy, University of Arizona, Tucson, AZ, USA. Electronic address: khalid-eljaaly@live.com.']\n",
      "Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. Travel medicine and infectious disease 2020-07-10\n",
      "RA Richard A Giovane 4 ['Department of Family Medicine, Regional Medical Center of Central Alabama, Greenville, Alabama, USA.']\n",
      "Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in medical virology 2020-07-10\n",
      "X Xi Liu 4 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "JA James A Watson 4 ['Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.\\nCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.']\n",
      "Concentration-dependent mortality of chloroquine in overdose. eLife 2020-07-09\n",
      "ECW Evellyn Claudia Wietzikoski Lovato 4 ['Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.']\n",
      "Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current pharmaceutical design 2020-07-08\n",
      "GP Gricelis P Martinez 4 ['Institute of Immunology, Faculty of Medicine, Central University of Venezuela, 50109, Los Chaguaramos 1050-A, Caracas, Venezuela']\n",
      "The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Current pharmaceutical design 2020-07-08\n",
      "S Sara Naghipour 4 ['Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences , Mashhad, Iran.']\n",
      "Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. Expert review of anti-infective therapy 2020-07-08\n",
      "CA Cristina Adriana Dehelean 4 ['Faculty of Pharmacy, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "X Xuesong Chen 4 ['Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, United States of America. Electronic address: xuesong.chen@und.edu.']\n",
      "Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. Cellular signalling 2020-07-07\n",
      "TJ Teodoro J Oscanoa 4 ['Department of Pharmacology, Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Peru, and Drug Safety Research Center, Facultad de Medicina Humana, Universidad de San Martín de Porres, Hospital Almenara, ESSALUD, Lima, Peru. Electronic address: tjoscanoae2017@gmail.com.']\n",
      "A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? International journal of antimicrobial agents 2020-07-07\n",
      "C Cafer Saka 4 ['Faculty of Health Sciences, Siirt University, Siirt, Turkey.']\n",
      "Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19. Critical reviews in analytical chemistry 2020-07-07\n",
      "JA Joost A Offerhaus 4 ['Amsterdam UMC, location AMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.']\n",
      "Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. Heart rhythm 2020-07-06\n",
      "CC Chidebe C Anikwe 4 ['Department of Obstetrics and Gynaecology, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi, Nigeria.']\n",
      "Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2020-07-02\n",
      "I Itsuro Kazama 4 ['School of Nursing, Miyagi University, Taiwa-cho, Miyagi, Japan.']\n",
      "Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy? Drug discoveries & therapeutics 2020-06-26\n",
      "A Asma Tariq 4 ['Institute of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan. Electronic address: asmi_mahmood@yahoo.com.']\n",
      "Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-06-25\n",
      "M Mallikarjuna Nimgampalle 4 ['Department of Biology, Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati, India;']\n",
      "Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. Journal of biomolecular structure & dynamics 2020-06-25\n",
      "P Pattarawadee Prayuenyong 4 ['Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.\\nNIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.\\nDepartment of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.\\nDepartment of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.']\n",
      "Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. Frontiers in public health 2020-06-24\n",
      "K Kanigula Mubagwa 4 ['Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium; Department of Basic Sciences, Faculty of Medicine, Université Catholique de Bukavu, Bukavu, DR Congo. Electronic address: kanigula.mubagwa@kuleuven.be.']\n",
      "Cardiac effects and toxicity of chloroquine: a short update. International journal of antimicrobial agents 2020-06-23\n",
      "S Sandipan Pati 4 ['Department of Neurology, University of Alabama at Birmingham, AL, United States; Epilepsy and Cognitive Neurophysiology Laboratory, University of Alabama at Birmingham, AL, United States. Electronic address: spati@uabmc.edu.']\n",
      "Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. Epilepsy research 2020-06-20\n",
      "A Abu Hazafa 4 ['Department of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "J Jelena Stojkovic-Filipovic 4 ['Clinic of Dermatovenereology, Clinical Centre of Serbia, Belgrade, Serbia.\\nDepartment of Dermatovenereology, School of Medicine, University of Belgrade, Belgrade, Serbia.']\n",
      "Treatment of COVID 19-Repurposing drugs commonly used in dermatology. Dermatologic therapy 2020-06-17\n",
      "E Eliza Tsitoura 4 ['Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Crete, Greece.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "A Amit Malviya 4 ['Department of Cardiology, North Eastern Indira Gandhi Regional Institute of Health And Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India. Electronic address: dramit_malviya@rediffmail.com.']\n",
      "The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-08-02\n",
      "CM C Michael White 4 ['University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.\\nHartford Hospital Department of Research Administration, Hartford, Connecticut, USA.']\n",
      "Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous. Journal of clinical pharmacology 2020-06-13\n",
      "AA Ahmed Awad Adeel 4 ['Independent Consultant in Malaria and Tropical Diseases, Lawrenceville, GA.\\nFormerly, Professor, Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.']\n",
      "Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. Sudanese journal of paediatrics 2020-06-13\n",
      "D Dindial Ramotar 4 ['College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU) , Doha, Qatar.']\n",
      "The status surrounding chloroquine and other drugs as potential anti-infective agents for COVID-19. Expert review of respiratory medicine 2020-06-12\n",
      "A Argelia Medeiros-Domingo 4 ['Director Médico. Swiss DNAlysis, Dübendorf/Suiza.\\nSociedad Mexicana de Cardiología.']\n",
      "Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2. Archivos de cardiologia de Mexico 2020-06-12\n",
      "ET Edgard Torres Dos Reis Neto 4 ['Disciplina de Reumatologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "K Khalid Shaikh 4 ['Department of Medicine, Royal Oman Police Hospital, Muscat, Oman.']\n",
      "Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus. JPMA. The Journal of the Pakistan Medical Association 2020-06-10\n",
      "PR Peter R Chai 4 [\"Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA. pchai@bwh.harvard.edu.\\nDepartment of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, MA, USA. pchai@bwh.harvard.edu.\\nThe Fenway Institute, Boston, MA, USA. pchai@bwh.harvard.edu.\\nThe Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Boston, MA, USA. pchai@bwh.harvard.edu.\"]\n",
      "Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2020-06-10\n",
      "MN Magnus Nakrem Lyngbakken 4 ['Division of Medicine, Akershus University Hospital, Lørenskog, Norway.\\nInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "V Vangelis Karalis 4 ['Laboratory of Biopharmaceutics-Pharmacokinetics, School of Health Sciences, National and Kapodistrian University of Athens, Greece.']\n",
      "Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. Safety science 2020-06-06\n",
      "J JingKang Sun 4 [\"Xi'an Medical University , Xi'an, China.\\nDepartment of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China.\"]\n",
      "Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgraduate medicine 2020-06-05\n",
      "PB Praveen Balabaskaran Nina 4 ['Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.']\n",
      "Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? Indian journal of public health 2020-06-05\n",
      "S Sebastián Ibáñez 4 ['Medicine Faculty Clínica Alemana, Universidad del Desarrollo, Av. Manquehue Norte 1410, piso 7,, 7650567, Vitacura, Santiago, Chile. sibanez@alemana.cl.\\nRheumatology Department, Padre Hurtado Hospital, Santiago, Chile. sibanez@alemana.cl.']\n",
      "Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Clinical rheumatology 2020-06-05\n",
      "M M Roustit 4 ['Pharmacologie clinique, Université Grenoble Alpes, CHU de Grenoble, 38043 Grenoble, France. Electronic address: mroustit@chu-grenoble.fr.']\n",
      "Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. Therapie 2020-06-01\n",
      "K Khan Sharun 4 ['Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "N Nowair Hussain 4 [\"Medicine, St. John's Episcopal Hospital, New York, USA.\"]\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "J Joana Vitte 4 ['Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.\\nIHU-Méditerranée Infection, Marseille, France.']\n",
      "Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Frontiers in immunology 2020-09-29\n",
      "A Anteneh Belayneh 4 ['Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.']\n",
      "Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation. Research and reports in tropical medicine 2020-09-29\n",
      "RR Rashmi R Shah 4 ['Pharmaceutical Consultant, Gerrards Cross, UK.']\n",
      "Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. Journal of clinical pharmacy and therapeutics 2020-09-28\n",
      "U Upinder Kaur 4 ['Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.']\n",
      "Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Current drug targets 2020-09-26\n",
      "XL Xiao-Lei Zhang 4 ['Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Lab of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou, 510006, China.']\n",
      "Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta pharmacologica Sinica 2020-09-25\n",
      "CB Christina B Klouda 4 ['Department of Pediatrics, East Tennessee State University, Johnson City, TN 37614, USA.']\n",
      "Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. Antioxidants (Basel, Switzerland) 2020-09-25\n",
      "O Ognjen Perišić 4 ['Big Blue Genomics, Vojvode Brane 32, 11000 Belgrade, Serbia.']\n",
      "Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues. Biomolecules 2020-09-25\n",
      "A Adam Goldman 4 ['Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Israel.\\nSchool of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel.']\n",
      "Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. British journal of clinical pharmacology 2020-09-24\n",
      "I Ingrid Berling 4 ['Department of Emergency Medicine, Calvary Mater Newcastle, Waratah, New South Wales, Australia.\\nDepartment of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Waratah, New South Wales, Australia.\\nSchool of Medicine and Public Health, University of Newcastle Newcastle, New South Wales, Australia.']\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "C Cassandra Doyno 4 ['Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.']\n",
      "Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clinical toxicology (Philadelphia, Pa.) 2020-09-23\n",
      "AS A S Achutha 4 ['PG and Research Department of Chemistry, Sree Narayana College, Kollam, Kerala 691001, India.']\n",
      "Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors. Journal of proteome research 2020-09-23\n",
      "N Na Li 4 ['University Creative Research Initiatives Center, Shandong First Medical University, Jinan, Shandong, China.\\nKey Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan, China.\\nState Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, Hunan, China.']\n",
      "Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Journal of cellular physiology 2020-09-23\n",
      "A Assia Belhassan 4 ['Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University of Meknes, Morocco.']\n",
      "Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. Life sciences 2020-09-22\n",
      "BK Biplab K Saha 4 ['Pulmonary and Critical Care Medicine, Ozarks Medical Center, West Plains, Missouri. Electronic address: spanophiliac@yahoo.com.']\n",
      "Antimalarials as Antivirals for COVID-19: Believe it or Not! The American journal of the medical sciences 2020-09-21\n",
      "M Massimo Nicolò 4 ['IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy. massimonicolo@gmail.com.\\nDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy. massimonicolo@gmail.com.\\nMacula Onlus Foundation, Genova, Italy. massimonicolo@gmail.com.']\n",
      "Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. International ophthalmology 2020-09-19\n",
      "DA David A Jans 4 ['Nuclear Signaling Lab., Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia. Electronic address: David.Jans@monash.edu.']\n",
      "The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ? Biochemical and biophysical research communications 2020-12-21\n",
      "X Xiping Zhan 4 ['Department of Physiology and Biophysics, Howard University College of Medicine, Washington, DC 20059.']\n",
      "Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? Heliyon 2020-09-17\n",
      "E Eric Prommer 4 ['Greater Los Angeles Healthcare, Los Angeles, CA, USA.']\n",
      "Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. The American journal of hospice & palliative care 2020-09-16\n",
      "SA Sultan Ayoub Meo 4 ['Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "K Katarina Baralić 4 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "RA Rafael A Badell-Grau 4 ['School of Biosciences, Cardiff University, Cardiff, United Kingdom.']\n",
      "Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infoveillance Study. Journal of medical Internet research 2020-09-12\n",
      "I Issam Nessaibia 4 ['Laboratory of Applied Neuro-Endocrinology, Badji-Mokhtar University, Annaba, Algeria.\\nGabinetto di psicologia (REFLETO), Via Francesco Saverio Nitti 28, Rome, Italy.']\n",
      "Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19? The International journal of health planning and management 2020-09-12\n",
      "DSK Dr Subodh Kumar Pathak 4 ['MMIMSR, MM Deemed to be University, Ambala, Haryana, India. Electronic address: drsubodh08@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "MS Md Shafiul Hossen 4 ['Department of Pharmacy, Faculty of Science, Noakhali Science and Technology University, Sonapur, Noakhali 3814 Bangladesh.']\n",
      "A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN comprehensive clinical medicine 2020-09-10\n",
      "R Ravikant Piyush 4 ['School of Biotechnology, Madurai Kamaraj University, Madurai, Tamil Nadu 625021, India.']\n",
      "Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open biology 2020-09-09\n",
      "WY Wei-Yi Ong 4 ['Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore. antongwy@nus.edu.sg.\\nNeurobiology Programme, Life Sciences Institute, National University of Singapore, Singapore, 119260, Singapore. antongwy@nus.edu.sg.']\n",
      "Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Molecular neurobiology 2020-09-09\n",
      "B Brian Jermain 4 ['Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.']\n",
      "Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of pharmaceutical sciences 2020-09-07\n",
      "A Arunmozhimaran Elavarasi 4 ['Department of Neurology, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "A Allan Giri 4 ['Department of Biomedical Science, Kansas City University of Medicine and Biosciences, Kansas City, MO 64106 USA.']\n",
      "Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. Genes and environment : the official journal of the Japanese Environmental Mutagen Society 2020-09-05\n",
      "A Aleksandra Hecel 4 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "U Urooj Fatima 4 ['Department of Botany, Aligarh Muslim University, Aligarh 202002, U.P. India.']\n",
      "Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design 2020-11-27\n",
      "S Steven Lehrer 4 ['Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, U.S.A. steven.lehrer@mssm.edu.']\n",
      "Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In vivo (Athens, Greece) 2020-09-03\n",
      "M Marta Entrenas Castillo 4 ['UGC de Neumología, Instituto Maimónides de Investigación Biomédica de Córdoba 9 (IMIBIC). Hospital Universitario Reina Sofía, Universidad de Córdoba, Avda. Menéndez 10 Pidal s/n, 14004 11, Córdoba, Spain.']\n",
      "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\". The Journal of steroid biochemistry and molecular biology 2020-09-02\n",
      "A Alok Dixit 4 ['Department of Pharmacology, Uttar Pradesh University of Medical Sciences, Uttar Pradesh, India.']\n",
      "Ivermectin: Potential Role as Repurposed Drug for COVID-19. The Malaysian journal of medical sciences : MJMS 2020-08-31\n",
      "J J Carretero Gómez 4 ['Servicio de Medicina Interna. Hospital Comarcal de Zafra, Badajoz, España. Electronic address: juanicarretero@gmail.com.']\n",
      "[Inflammation, malnutrition, and SARS-CoV-2 infection: a disastrous combination]. Revista clinica espanola 2020-08-31\n",
      "T Thibault Fiolet 4 ['CESP (Centre for Research in Epidemiology and Population Health), Faculté de Médecine-Université Paris-Sud, Faculté de Médecine-UVSQ, INSERM, Université Paris Saclay, Villejuif, France; Gustave Roussy, Villejuif, France. Electronic address: Thibault.fiolet@gustaveroussy.fr.']\n",
      "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-08-30\n",
      "V Vadim Makarov 4 ['Federal Research Center Fundamentals of Biotechnology of the Russian Academy of Sciences, 33-2 Leninsky Prospect, Moscow 119071, Russia.']\n",
      "The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathogens and disease 2020-08-30\n",
      "N Niayesh Mohebbi 4 ['Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.\\nResearch Center for Rational Use of Drugs; Tehran University of Medical Sciences, Tehran, Iran.']\n",
      "Drug Interactions of Psychiatric and COVID-19 Medications. Basic and clinical neuroscience 2020-08-29\n",
      "RB Regina B Podlasin 4 ['IV-th Department, Hospital for Infectious Diseases, Warsaw, Poland.']\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "RR Rashmi Ranjan Das 4 ['Department of Pediatrics, AIIMS Bhubaneswar, Bhubaneswar, India.']\n",
      "Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. Frontiers in medicine 2020-08-28\n",
      "MJ Mukarram Jamat Ali 4 ['Department of Medicine, King Edward Medical University, Lahore, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "Y Yan Chen 4 ['Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "JC James C Crosby 4 ['Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA.']\n",
      "COVID-19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians open 2020-08-25\n",
      "VC Van C Willis 4 ['IBM Watson Health, Center for AI, Research, and Evaluation, Cambridge, MA.']\n",
      "A Narrative Review of Emerging Therapeutics for COVID-19. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-08-25\n",
      "P Pugazhenthan Thangaraju 4 ['Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.']\n",
      "COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings? Journal of family medicine and primary care 2020-08-06\n",
      "WJ William J Nahm 4 ['New York University Grossman School of Medicine, New York, New York.\\nDr Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.\\nShen Dermatology, Temecula, California.']\n",
      "Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing. JAAD case reports 2020-08-25\n",
      "W Winglam Chan 4 ['Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.']\n",
      "Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes & diseases 2020-08-25\n",
      "AA Alexios A Panoutsopoulos 4 ['Department of Pathology and Laboratory Medicine, University of California, Davis, CA, USA.\\nInstitute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Northern California, 2425 Stockton Boulevard, Sacramento, CA, 95817, USA.']\n",
      "Known drugs and small molecules in the battle for COVID-19 treatment. Genes & diseases 2020-08-25\n",
      "S Swapnil Dhampalwar 4 ['Institute of Liver Transplantation & Regenerative Medicine, Medanta- The Medicity, Gurugram, India.']\n",
      "Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. Journal of clinical and experimental hepatology 2020-08-25\n",
      "SK Subir Kumar Das 4 ['Department of Biochemistry, College of Medicine and JNM Hospital, WBUHS, Kalyani, Nadia, West Bengal 741235 India.']\n",
      "The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). Indian journal of clinical biochemistry : IJCB 2020-08-25\n",
      "S Samaneh Bagheri Novir 4 ['Iranian Center for Quantum Technologies (ICQTs), Tehran, Iran.']\n",
      "Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19. Chemical physics letters 2020-08-25\n",
      "M Masood Bagheri 4 ['Department of Ophthalmology, Imam Khomeini Eye Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.']\n",
      "Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? Recent patents on anti-infective drug discovery 2020-08-21\n",
      "UM U M Musazzi 4 ['Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy.']\n",
      "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data in brief 2020-08-18\n",
      "BS Brandon S Hamm 4 ['Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: brandon.hamm@northwestern.edu.']\n",
      "Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. Psychosomatics 2020-08-18\n",
      "VA Vanessa Aparecida Marcolino 4 ['Instituto Federal do Paraná (IFPR), Campus Paranavaí, 87703-536, Paranavaí, Paraná, Brazil.']\n",
      "What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. European journal of pharmacology 2020-08-11\n",
      "EMR Eduardo Machado Rossi Monteiro 4 ['Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.']\n",
      "Chloroquine and COVID-19: Should We Care about Ototoxicity? International archives of otorhinolaryngology 2020-08-11\n",
      "AK Alexander Kc Leung 4 [\"The University of Calgary, The Alberta Children's Hospital, Calgary, Alberta, Canada.\"]\n",
      "Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. Drugs in context 2020-08-04\n",
      "L Li Zou 4 ['Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.']\n",
      "Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Archives of pharmacal research 2020-08-03\n",
      "S S Mayayo-Vicente 4 ['Gerencia de Atención Primaria, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España; Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "HLB Helyson Lucas Bezerra Braz 4 ['Postgraduate Program in Morphological Science, Department of Morphology, School of Medicine, Federal University of Ceara, Delmiro de Farias St., 60.430-170, Fortaleza-CE, Brazil; Drug Research and Development Center, Federal University of Ceara, Coronel Nunes de Melo St., 1000, 60.430-275, Fortaleza-CE, Brazil.']\n",
      "In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. International journal of antimicrobial agents 2020-08-02\n",
      "L Lianzhou Huang 4 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "S Sherief Abd-Elsalam 4 ['Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "N Niti Mittal 4 ['Department of Pharmacology, Pt. B D Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India. Electronic address: drniti.mittal@gmail.com.']\n",
      "Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Medical hypotheses 2020-11-29\n",
      "J Julio Vallejos 4 ['Instituto de Cardiología de Corrientes \"Juana F. Cabral\", Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "N Nitin Tandon 4 ['School of Chemical Engineering and Physical Sciences, Lovely Professional University, Phagwara-144411. India.']\n",
      "Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak. Mini reviews in medicinal chemistry 2020-11-26\n",
      "F Francesca Bruni 4 ['Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.']\n",
      "Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: Allergic contact dermatitis to fluconazole. Contact dermatitis 2020-11-25\n",
      "M Mukesh Kumar 4 ['Dr. B.R Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India.']\n",
      "Decoding the silent walk of COVID-19: Halting its spread using old bullets. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-11-24\n",
      "L Luc Berlivet 4 ['CERMES3 (CNRS/EHESS), Paris, France.']\n",
      "Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. Medical anthropology quarterly 2020-11-20\n",
      "M Michael Takla 4 ['Faculty of Health and Medical Science, University of Surrey, Guildford GU2 7AL, United Kingdom.']\n",
      "Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2020-11-19\n",
      "D Dhaval Patel 4 ['Department of Biological Sciences and Biotechnology, Indian Institute of Advanced Research, Gandhinagar, India.']\n",
      "Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2. Journal of biomolecular structure & dynamics 2020-11-18\n",
      "D Desley Butters 4 ['School of Medicine, Griffith University, Gold Coast, QLD, Australia.']\n",
      "COVID-19 and nutriceutical therapies, especially using zinc to supplement antimicrobials. Inflammopharmacology 2020-11-17\n",
      "AM Ahmed M Abbas 4 ['Department of Obstetrics and Gynaecology, Faculty of Medicine, Assiut University, Egypt.\\nCOvid-19 Research of Assiut University Association (CORAUNA) group.']\n",
      "Rheumatoid Arthritis in the Era of COVID-19 Pandemic. Mediterranean journal of rheumatology 2020-11-17\n",
      "H Henry Sutanto 4 ['Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.']\n",
      "Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. Frontiers in physiology 2020-11-17\n",
      "H Hongwei Peng 4 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "RJ Richard J Martin 4 ['Department of Biomedical Science, Iowa State University, Ames, IA 50011, USA. Electronic address: rjmartin@iastate.edu.']\n",
      "Ivermectin: An Anthelmintic, an Insecticide, and Much More. Trends in parasitology 2020-11-16\n",
      "WY Woon Yi Law 4 ['Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, 94300, Kota Samarahan, Sarawak, Malaysia. mendah_wylaw@hotmail.com.']\n",
      "Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M BMC research notes 2020-11-13\n",
      "IM Imad M Tleyjeh 4 ['Infectious Diseases Section, Department of Medical Specialties, King Fahad Medical City, Riyadh, Saudi Arabia.\\nDivision of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN.\\nDivision of Epidemiology, Mayo Clinic College of Medicine and Science, Rochester, MN.\\nCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "L Lu Ren 4 ['Department of Internal Medicine, Cardiology, University of California, Davis, Davis, CA, United States.']\n",
      "Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2020-11-07\n",
      "E Elizabeth Delorme-Axford 4 ['Department of Biological Sciences, Oakland University , Rochester, MI, USA.']\n",
      "Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection? Autophagy 2020-11-07\n",
      "J Juan Pimentel 4 ['Community Information and Epidemiological Technologies']\n",
      "Chloroquine and its derivatives in the management of COVID-19: A scoping review Biomedica : revista del Instituto Nacional de Salud 2020-11-06\n",
      "F Faizul Azam 4 ['Department of Pharmaceutical Chemistry & Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "M Mariana Babayeva 4 ['Touro College of Pharmacy, New York, NY, USA.']\n",
      "Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. Pharmacogenomics and personalized medicine 2020-10-31\n",
      "PS Parth Sarthi Sen Gupta 4 ['Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, India.']\n",
      "Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with  Journal of biomolecular structure & dynamics 2020-10-29\n",
      "E Evelyne Kestelyn 4 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.\\nCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "E Edimir Semedo 4 ['Department of Cardiology, Medisch Spectrum Twente, Enschede, The Netherlands.']\n",
      "Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report. European heart journal. Case reports 2020-10-23\n",
      "M M Million 4 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "TA Tariq A Altalhi 4 ['Department of Chemistry, Collage of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.']\n",
      "Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. Journal of molecular structure 2020-10-22\n",
      "S Sourabh Agstam 4 ['Department of Cardiology, VMMC & Safdarjung Hospital, New Delhi, India.']\n",
      "Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. Indian pacing and electrophysiology journal 2020-10-20\n",
      "P Paul Bertin 4 [\"LAPCOS, Université Côte d'Azur, Nice, France.\"]\n",
      "Conspiracy Beliefs, Rejection of Vaccination, and Support for hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19 Pandemic Context. Frontiers in psychology 2020-10-20\n",
      "EJ Edgar Jg Peters 4 ['Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands. Electronic address: e.peters@amsterdamumc.nl.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "JC Juliana Cepelowicz Rajter 4 ['Broward Health Medical Center, Fort Lauderdale, FL.']\n",
      "Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest 2020-10-17\n",
      "KO Karim O Elkholy 4 ['Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.']\n",
      "Ivermectin: A Closer Look at a Potential Remedy. Cureus 2020-10-17\n",
      "S Sumanth Khadke 4 ['Our Lady of Fatima University, 120 MacArthur Highway, 1440, Valenzuela, Metro Manila, Philippines.']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "JY Junaed Younus Khan 4 ['Department of Computer Science and Engineering, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "RM Rania M Hathout 4 ['Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.']\n",
      "Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. Informatics in medicine unlocked 2020-10-15\n",
      "DR Daniela R Junqueira 4 ['Department of Emergency Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.']\n",
      "Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. British journal of clinical pharmacology 2020-10-14\n",
      "M M Ortega-Peña 4 ['Escuela de Medicina, Universidad Mayor, Santiago, Chile.']\n",
      "Familiar Dermatologic Drugs as Therapies for COVID-19. Actas dermo-sifiliograficas 2020-10-13\n",
      "Y Yan Wang 4 ['Center for Translation Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, PR China. Electronic address: yan.wang@siat.ac.cn.']\n",
      "Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. European journal of pharmacology 2020-10-09\n",
      "ANS Aline Nefertiti Silva da Gama 4 ['Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro. Brazil.']\n",
      "Quinoline-based Compounds as Key Candidates to Tackle Drug Discovery Programs of Microbicidal Agents. Current pharmaceutical design 2020-10-08\n",
      "EJ Edward J Calabrese 4 ['Department of Environmental Sciences, University of Massachusetts, Amherst, MA 01003, United States of America. Electronic address: edwardc@schoolph.umass.edu.']\n",
      "Chloroquine commonly induces hormetic dose responses. The Science of the total environment 2020-10-06\n",
      "AJJ A J J Lammers 4 ['Isala, Zwolle, The Netherlands. Electronic address: a.j.j.lammers@isala.nl.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "F Faizan Mazhar 4 ['Department of Biomedical and Clinical Sciences L. Sacco, \"Luigi Sacco\" University Hospital, Università di Milano, Milan, Italy.']\n",
      "Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "CS Chia Siang Kow 4 ['School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia. chiasiang_93@hotmail.com.']\n",
      "The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological reports : PR 2021-03-30\n",
      "A Amin Gasmi 4 ['Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Applied microbiology and biotechnology 2021-01-31\n",
      "JID Jonathan I D Hamley 4 [\"London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk Place, London W2\\xa01PG, UK.\\nMRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk Place, London W2\\xa01PG, UK.\"]\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "L Luoping Zhang 4 ['Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, 94720, USA.']\n",
      "Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Advances in biomarker sciences and technology 2021-01-30\n",
      "MA M A Gedikli 4 [' ']\n",
      "Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratislavske lekarske listy 2021-01-28\n",
      "YM Yuan-Min Yang 4 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Artemisinin Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "J Jorge Errecalde 4 ['Cátedra de Farmacología Básica, General y Farmacodinamia, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina; INCAM S.A, Cañuelas, Argentina. Electronic address: jerrecal@fcv.unlp.edu.ar.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "BH Bugra Han Egeli 4 ['Graduate Medical Sciences, Boston University School of Medicine, 72 E Concord St L-317, Boston, MA, 02118, USA. Electronic address: bhegeli@bu.edu.']\n",
      "Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best practice & research. Clinical rheumatology 2021-01-24\n",
      "S S Rakedzon 4 ['Division of Internal Medicine, Rambam Health Care Campus, Haifa, Israel.']\n",
      "From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Journal of travel medicine 2021-01-23\n",
      "HG Hugues Ghislain Atakla 4 ['Neurology Department, University Hospital Center Hubert Koutoukou MAGA, Cotonou, Benin.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "SB Shagun Bhatia Shah 4 ['Department of Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, New Delhi, India.']\n",
      "Cancer in corona times. Saudi journal of anaesthesia 2021-01-16\n",
      "P Pasquale Pagliano 4 ['Department of Medicine, Surgery and Dentistry, \"Scuola Medica Salernitana\", Unit of Infectious Diseases, University of Salerno, Baronissi, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "AJ Alexander J Martin 4 ['Nuclear Signaling Lab., Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia.']\n",
      "Antivirals that target the host IMPα/β1-virus interface. Biochemical Society transactions 2021-01-14\n",
      "HM H M Silva 4 ['University Center of Formiga, Dr. Arnaldo de Senna avenue, 329, 35.570-000 Formiga, MG, Brazil.']\n",
      "Medicines and illusions in the fight against COVID-19 in Brazil. Ethics, medicine, and public health 2021-01-13\n",
      "D Dingzhong Li 4 [\"State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, People's Republic of China.\"]\n",
      "Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in current chemistry (Cham) 2021-01-12\n",
      "MS Muhammad Sani Ismaila 4 ['Deparment of Basic Veterinary Sciences, School of Veterinary Medicine, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.']\n",
      "Therapeutic options for COVID-19: a quick review. Journal of chemotherapy (Florence, Italy) 2021-01-12\n",
      "H Haleh Rezaee 4 ['Infectious Diseases and Tropical Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.\\nDepartment of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacology research & perspectives 2021-01-10\n",
      "M Mohammad Bahadoram 4 ['Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.']\n",
      "Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? Naunyn-Schmiedeberg's archives of pharmacology 2021-01-09\n",
      "B Benyun Shi 4 ['School of Computer Science and Technology, Nanjing Tech University, Nanjing, 211800, Jiangsu, China.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "N Nuraini Yasmin Kusumawardhani 4 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "FS Fatemeh Sadat Hosseini 4 ['Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "R Ram Niwas 4 ['Department of Pulmonary Medicine, All India Institute of Medical Sciences Jodhpur, India. rniwasaiims@gmail.com.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "DA Dawn A Laney 4 ['Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "H Harpinder Kaur 4 ['Department of Pharmacology, Post Graduate Institute of Medical Education and Reseasrch (PGIMER), Chandigarh, 160012, India.']\n",
      "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological reports : PR 2021-01-04\n",
      "AM Amgad M Rabie 4 [\"Dr. Amgad Rabie's Research Lab. for Drug Discovery (DARLD), Mansoura, Egypt. amgadpharmacist1@yahoo.com.\\nPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. amgadpharmacist1@yahoo.com.\\n, Dikernis, Egypt. amgadpharmacist1@yahoo.com.\"]\n",
      "CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy. Molecular diversity 2021-01-04\n",
      "BC Brian C Procter 4 ['McKinney Family Medicine, McKinney, 75070, TX, USA.']\n",
      "Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular medicine 2021-01-04\n",
      "NS Nang S Choupoo 4 ['Department of Anesthesia and Critical Care, Atal Bihari Vajpayee Institute of Medical Sciences and Dr RML Hospital, New Delhi, India.']\n",
      "Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021-01-02\n",
      "N Nils Rother 4 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "NB Neils Ben Quashie 4 ['Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, Accra, Ghana.\\nNoguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.\\nWest African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana.']\n",
      "Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. Journal of tropical pediatrics 2020-12-29\n",
      "NK Nour K Younis 4 ['Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.']\n",
      "Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Frontiers in pharmacology 2020-12-29\n",
      "NA Niteen A Vaidya 4 ['ChiroSolve, San Jose, CA, United States.']\n",
      "Computational Studies of Hydroxychloroquine and Chloroquine Metabolites as Possible Candidates for Coronavirus (COVID-19) Treatment. Frontiers in pharmacology 2020-12-29\n",
      "T Tafere Mulaw Belete 4 ['Department of Pharmacology, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.']\n",
      "An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease. Clinical pharmacology : advances and applications 2020-12-29\n",
      "RB Roberto Barbosa Bazotte 4 ['Department of Pharmacology and Therapeutics, State University of Maringá, PR, Brazil. Electronic address: rbbazotte@gmail.com.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "A Asokan Devarajan 4 ['UCLA Cardiac Arrhythmia Center, University of California, Los Angeles, CA, USA; Neurocardiology Research Center of Excellence, University of California, Los Angeles, CA, USA. Electronic address: adevarajan@mednet.ucla.edu.']\n",
      "Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights. Redox biology 2020-12-29\n",
      "KM Keenan M Mahan 4 ['Harvard Medical School, Boston, Massachusetts; Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "I Iqbal Hussain 4 ['Department of General Studies, Jubail Industrial College, Jubail Industrial City, Jubail, 31961, Saudi Arabia.']\n",
      "Impact of repurposed drugs on the symptomatic COVID-19 patients. Journal of infection and public health 2020-12-21\n",
      "S Stefano Celotto 4 ['Primary Care Department, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "U Urooba Nadeem 4 ['Department of Pathology, University of Chicago, Chicago, IL.']\n",
      "Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. American journal of clinical pathology 2020-12-15\n",
      "J Jia Fu 4 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "ME Mary Eyram Ashinyo 4 ['Institutional Care Division, Ghana Health Service Headquarters, Private Mail Bag, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "S Slobodan Rendic 4 ['Independent Scientist, Zagreb, Croatia.']\n",
      "Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. Current drug metabolism 2020-12-10\n",
      "G Giona Pedrioli 4 ['Neurodegeneration Research Group, Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Torricella-Taverne, Switzerland.\\nInternational PhD Program of the Biozentrum, University of Basel, Basel, Switzerland.']\n",
      "Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective. Frontiers in neurology 2020-12-08\n",
      "S Sabeena Ahmed 4 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "M Miroslaw Kiedrowski 4 ['Ewdomed Ewa Szulecka Foundation and Home Hospice, Al. Wojska Polskiego 6, 05-520 Konstancin-Jeziorna, Poland; Clinical Department of Oncology and Hematology, Central Clinical Hospital of the Ministry of the Anterior and Administration in Warsaw, ul. Woloska 137, 02-507 Warsaw, Poland. Electronic address: mkiedrow@mp.pl.']\n",
      "Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Medical hypotheses 2020-12-06\n",
      "MD Martin D Hellwig 4 ['Plymouth State University, 17 High Street, Plymouth, NH, USA. Electronic address: mdhellwig@plymouth.edu.']\n",
      "A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. International journal of antimicrobial agents 2020-12-02\n",
      "P Peter Yamoah 4 ['School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana. pyamoah@uhas.edu.gh.\\nCollege of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. pyamoah@uhas.edu.gh.']\n",
      "Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. Therapeutic innovation & regulatory science 2020-12-02\n",
      "C Chao Shang 4 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "G Grégory Dubourg 4 ['IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n",
      "PK Paul K Drain 4 ['Department of Global Health, University of Washington, Seattle, WA, USA. pkdrain@uw.edu.\\nDepartment of Medicine, University of Washington, Seattle, WA, USA. pkdrain@uw.edu.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "F Fariba Ahmadizar 4 ['Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. European journal of preventive cardiology 2021-02-25\n",
      "R Roukaya Benjelloun 4 ['Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.']\n",
      "Psychiatric side effects of chloroquine in COVID-19 patients: two case reports. The Pan African medical journal 2021-02-25\n",
      "RR Rajashri R Naik 4 ['Department of Biopharmaceutics and Clinical Pharmacy, Pharmacological and Diagnostic Research Center, Al-Ahliyya Amman University, Amman, Jordan.']\n",
      "Therapeutic Strategies in the Management of COVID-19. Frontiers in molecular biosciences 2021-02-23\n",
      "S Sajjad Ahmad 4 ['Foundation University Medical College, Foundation University Islamabad, Islambad, Pakistan.']\n",
      "Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. Journal of molecular liquids 2021-02-23\n",
      "M Masashi Ohe 4 ['Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.']\n",
      "Multidrug treatment for COVID-19. Drug discoveries & therapeutics 2021-02-23\n",
      "OE O E Babalola 4 ['Department of Ophthalmology, Bingham University, Karu/Jos.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "R René Lima-Morales 4 ['Secretaría de Salud de Tlaxcala, Dirección General, Tlaxcala, Mexico. Electronic address: limamorales.saludtlax@gmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "PR Paulo Roberto Bignardi 4 ['School of Medicine, Pontifical Catholic University of Paraná, Londrina, Brazil.']\n",
      "Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. Pathogens and global health 2021-02-13\n",
      "M Mojgan Nejabat 4 ['Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, . Iran.']\n",
      "Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An in Silico Study. Medicinal chemistry (Shariqah (United Arab Emirates)) 2021-02-11\n",
      "P Pawan Sharma 4 ['Center for Translational Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Jane & Leonard Korman Respiratory Institute, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA. Electronic address: pawan.sharma@jefferson.edu.']\n",
      "Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? European journal of pharmacology 2021-02-06\n",
      "M Meetali Sinha 4 ['Computational Toxicology Facility, CSIR- Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India.']\n",
      "Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in biology and medicine 2021-02-04\n",
      "R Riadh Badraoui 4 [\"Laboratory of General Biology, Department of Biology, University of Ha'il, Ha'il 81451, Saudi Arabia.\\nSection of Histology-Cytology, Medicine College of Tunis, University of Tunis El Manar, Djebel Lakhdhar Road, La Rabta-Tunis 1007, Tunisia.\\nLaboratory of Histo-Embryology and Cytogenetic, Medicine College of Sfax, University of Sfax, Majida Boulila Road, Sfax 3029, Tunisia.\"]\n",
      "Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism. Molecules (Basel, Switzerland) 2021-02-03\n",
      "CK Christina K Zorn 4 ['Chief Administrative Officer, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "B B Bouazza 4 ['Biochemistry and Microbiology Department, Mouloud Mammeri University of Tizi-Ouzou, Algeria.']\n",
      "Chloroquine and COVID-19: role as a bitter taste receptor agonist? New microbes and new infections 2021-02-02\n",
      "D Damir Bojadzic 4 ['Diabetes Research Institute, University of Miami, Miami, FL, United States.']\n",
      "Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Frontiers in pharmacology 2021-02-02\n",
      "RK R K Hussein 4 ['Imam Mohammad Ibn Saud Islamic University (IMSIU), College of Science, Physics department, P.O. Box 90950, Riyadh 11623, Saudi Arabia.']\n",
      "Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19. Journal of molecular structure 2021-02-02\n",
      "J Julia Werner 4 ['Department of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "R Rana Aljadeed 4 ['College of Pharmacy, 37850King Saud University, Riyadh, Saudi Arabia.']\n",
      "The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. Journal of pharmacy practice 2021-04-29\n",
      "S Saioa Domingo-Echaburu 4 ['Pharmacy Service. Alto Deba-Integrated Health Care Organization, Arrasate, Gipuzkoa, Spain.']\n",
      "Ivermectin & COVID-19: Let's keep a One Health perspective. Sustainable chemistry and pharmacy 2021-04-27\n",
      "JK Joyanta Kumar Saha 4 ['Department of Chemistry, Jagannath University, Dhaka, 1100 Bangladesh.']\n",
      "The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2. Structural chemistry 2021-04-20\n",
      "RCS Raymond Chee Seong Seet 4 ['Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Neurology, Department of Medicine, National University Hospital, Singapore. Electronic address: raymond_seet@nus.edu.sg.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "Z Zena Wehbe 4 ['Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon.']\n",
      "Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Frontiers in immunology 2021-04-17\n",
      "SS Stefania Spila Alegiani 4 ['Pharmacoepidemiology Unit, National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "M Ming Li 4 [\"Department of Respiratory and Critical Care Medicine, Shanghai 10th People's Hospital, Shanghai, China.\"]\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "S Subham Das 4 ['Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.\\nManipal McGill Centre for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.']\n",
      "The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Medicine in drug discovery 2021-04-14\n",
      "CHT Cheryl H T Kwong 4 ['State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "PJ Patricia J Garcia 4 ['School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru. Patricia.garcia@upch.pe.']\n",
      "Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials 2021-04-11\n",
      "FLB Fernando Luiz Barros Edington 4 ['Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil; Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brazil. Electronic address: flbedington@uesc.br.']\n",
      "Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis. European journal of internal medicine 2021-04-10\n",
      "I Isabel Fambuena-Muedra 4 ['Ophthalmology Mediterranean Foundation (FOM), Valencia, Spain.\\nDepartment of Optometry and Vision Science, Universitat de Valencia, Valencia, Spain.']\n",
      "What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. European journal of ophthalmology 2021-04-09\n",
      "AR Atiya R Faruqui 4 [\"Department of Pharmacology, St. John's Medical College, Bengaluru, Karnataka, India.\"]\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "R Rodrigo Guerrero 4 ['Universidad del Valle, Instituto de Investigación y Desarrollo en Prevención de la Violencia y Promoción de la Convivencia Social, CISALVA, Cali, Colombia.']\n",
      "COVID-19: The Ivermectin African Enigma. Colombia medica (Cali, Colombia) 2021-04-03\n",
      "AC Andrew C Berry 4 ['Division of Gastroenterology, Larkin Community Hospital, South Miami, 33143 FL, USA.']\n",
      "Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations. Reviews in cardiovascular medicine 2021-04-02\n",
      "JV J V Bukanova 4 ['Research Center of Neurology, Moscow, Russia.']\n",
      "Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons. Bulletin of experimental biology and medicine 2021-04-01\n",
      "P Pietro De Luca 4 ['Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy. Electronic address: dr.dlp@hotmail.it.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "D Dominik Majewski 4 ['Department of Rheumatology and Internal Medicine, Poznan University of Medical Sciences, Poznań, Poland.']\n",
      "Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective. Annals of agricultural and environmental medicine : AAEM 2021-03-30\n",
      "A Amir Khodavirdipour 4 [\"Department of Animal Biology, Molecular Genetics Subdivision, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.\\nDepartment of Anatomy, Division of Human Genetics, St. John's Hospital, Bangalore, India.\"]\n",
      "Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19. Global medical genetics 2021-03-23\n",
      "AF Ahmad F Eweas 4 ['Department of Pharmaceutical and Medicinal Chemistry, National Research Centre, Cairo, Egypt.\\nDepartment of Science, University of Technology and Applied Sciences Rustaq, Rustaq, Oman.']\n",
      "Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. Frontiers in microbiology 2021-03-23\n",
      "WH William Hk Schilling 4 ['Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.\\nCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.']\n",
      "Does hydroxychloroquine still have any role in the COVID-19 pandemic? Expert opinion on pharmacotherapy 2021-03-17\n",
      "H Henrique Pott-Junior 4 ['Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "G Gaurav Joshi 4 ['School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, 248002, India; Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: garvpharma29@gmail.com.']\n",
      "Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2021-03-17\n",
      "BT Binh T Ngo 4 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.\\nThe Rose Salter Medical Research Foundation, Newport Coast, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "N Nida Bokharee 4 ['Insitute of Pharmacy, Lahore College for Women University, Lahore 54000, Punjab, Pakistan.']\n",
      "Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert review of anti-infective therapy 2021-03-16\n",
      "K Kadir Yesilbag 4 ['Department of Virology, Bursa Uludag University, Faculty of Veterinary Medicine, 16059, Bursa, Turkey. Electronic address: kyesilbag@uludag.edu.tr.']\n",
      "Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro. Virus research 2021-03-14\n",
      "M Marta Papaccio 4 ['Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.']\n",
      "Pregnancy and COVID-19: Do not overlook malaria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021-03-14\n",
      "D Dania Altulea 4 ['Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.']\n",
      "What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. Journal of molecular cell biology 2021-03-12\n",
      "Z Zhenxue Tian 1 ['Department of Pharmacy, Qingdao Municipal Hospital, Qingdao, China.']\n",
      "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends 2020-02-20\n",
      "X Xu Yang 1 ['Department of Pharmacy, Qingdao Municipal Hospital, Qingdao, China.']\n",
      "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends 2020-02-20\n",
      "SD S D Fernando 1 ['Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka.']\n",
      "Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-05-30\n",
      "S S Rajapakse 1 ['Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka. Electronic address: senaka@med.cmb.ac.lk.']\n",
      "Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-05-30\n",
      "S Songyuan Luo 1 [\"Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.\"]\n",
      "Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacology & therapeutics 2020-05-30\n",
      "P Peter Libby 1 [\"Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.\"]\n",
      "Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacology & therapeutics 2020-05-30\n",
      "GP Guo-Ping Shi 1 [\"Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: gshi@bwh.harvard.edu.\"]\n",
      "Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacology & therapeutics 2020-05-30\n",
      "SZ Syed Zahir Idid 1 ['Faculty of Allied Health Sciences, International Islamic University Malaysia, 25200, Kuantan, Malaysia.']\n",
      "Can Zn Be a Critical Element in COVID-19 Treatment? Biological trace element research 2020-05-28\n",
      "TB T B Erickson 1 [\"Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.\\nHarvard Humanitarian Institute, Boston, MA, USA.\"]\n",
      "Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2020-06-10\n",
      "PR P R Chai 1 [\"Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.\\nThe Fenway Institute, Boston, MA, USA.\\nKoch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.\\nDepartment of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, MA, USA.\"]\n",
      "Chloroquine, hydroxychloroquine and COVID-19. Toxicology communications 2020-05-28\n",
      "EW E W Boyer 1 [\"Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.\\nThe Fenway Institute, Boston, MA, USA.\"]\n",
      "Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2020-06-10\n",
      "A Ahmed Bennis 1 ['Cardiology Department, Jerada Clinic, Casablanca, Morocco.']\n",
      "Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed. Journal of infection and public health 2020-05-27\n",
      "B Barsha Dassarma 1 ['Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa.']\n",
      "A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International journal of antimicrobial agents 2020-05-26\n",
      "S Somenath Roy 1 ['Ex-Professor, Department of Human Physiology with Community Health, Vidyasagar University, Paschim Medinipur 721102, India.']\n",
      "A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International journal of antimicrobial agents 2020-05-26\n",
      "H Hlupheka Chabalala 1 ['IK-based Technology Innovations, Department of Science and Innovations, Brummeria, Pretoria 0001, South Africa.']\n",
      "A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International journal of antimicrobial agents 2020-05-26\n",
      "MG Motlalepula Gilbert Matsabisa 1 ['Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa. Electronic address: MatsabisaMG@ufs.ac.za.']\n",
      "A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International journal of antimicrobial agents 2020-05-26\n",
      "G Giorgio Karam 1 ['Dalhousie University, College of Pharmacy, Halifax, Nova Scotia, Canada. Electronic address: Giorgio.Karam@dal.ca.']\n",
      "QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart rhythm 2020-05-22\n",
      "LA Larry A Chinitz 1 ['Cardiac Electrophysiology and Heart Rhythm Center at NYU Langone Health, NYU School of Medicine, New York, New York.']\n",
      "QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart rhythm 2020-05-22\n",
      "MC Meng-Chiao Tsai 1 ['Dalhousie University, Faculty of Medicine, Halifax, Nova Scotia, Canada.']\n",
      "QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart rhythm 2020-05-22\n",
      "EH Eric H Yang 1 ['Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.).']\n",
      "Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. Circulation. Arrhythmia and electrophysiology 2020-05-22\n",
      "TJ Ty J Gluckman 1 ['Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St Joseph Health, Portland, OR (T.J.G.).']\n",
      "Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. Circulation. Arrhythmia and electrophysiology 2020-05-22\n",
      "ED Erin D Michos 1 ['The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M., R.S.B.).']\n",
      "Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. Circulation. Arrhythmia and electrophysiology 2020-05-22\n",
      "RS Roger S Blumenthal 1 ['The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M., R.S.B.).']\n",
      "Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. Circulation. Arrhythmia and electrophysiology 2020-05-22\n",
      "BJ Bernard J Gersh 1 ['Department of Cardiovascular Medicine, Mayo Clinic & Mayo Clinic College of Medicine, Rochester, MN (B.J.G.).']\n",
      "Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. Circulation. Arrhythmia and electrophysiology 2020-05-22\n",
      "MA Mohamed A Saleh 1 ['Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAE.\\nDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.']\n",
      "The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals (Basel, Switzerland) 2020-05-20\n",
      "E Eman Abu-Gharbieh 1 ['Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAE.']\n",
      "The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals (Basel, Switzerland) 2020-05-20\n",
      "F Fatemeh Mirzaei 1 ['Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran; Department of Anatomical Sciences, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.']\n",
      "Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. International journal of surgery (London, England) 2020-05-19\n",
      "F Farhad Farahani 1 ['Hearing Impairment Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.']\n",
      "Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. International journal of surgery (London, England) 2020-05-19\n",
      "I Iraj Khodadadi 1 ['Nutrition Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.']\n",
      "Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. International journal of surgery (London, England) 2020-05-19\n",
      "H Heidar Tayebinia 1 ['Department of Clinical Biochemistry, Hamadan University of Medical Sciences, Hamadan, Iran.']\n",
      "Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. International journal of surgery (London, England) 2020-05-19\n",
      "S Shipra Singhal 1 ['Computer Aided Drug Design Lab, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, India.']\n",
      "A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life sciences 2020-05-19\n",
      "N Neeraj Masand 1 ['Department of Pharmacy, Lala Lajpat Rai Memorial Medical College, Meerut, Uttar Pradesh, India.']\n",
      "A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life sciences 2020-05-19\n",
      "J Justine Bénévent 1 ['Unité «\\xa0Médicaments, grossesse et allaitement\\xa0», service de pharmacologie médicale et clinique, CHU de Toulouse, faculté de médecine, Inserm 1027, 37, allées Jules-Guesde, 31000 Toulouse, France.']\n",
      "Chloroquine and hydroxychloroquine during pregnancy: What do we know? Therapie 2020-05-19\n",
      "C Christine Damase-Michel 1 ['Unité «\\xa0Médicaments, grossesse et allaitement\\xa0», service de pharmacologie médicale et clinique, CHU de Toulouse, faculté de médecine, Inserm 1027, 37, allées Jules-Guesde, 31000 Toulouse, France.']\n",
      "Chloroquine and hydroxychloroquine during pregnancy: What do we know? Therapie 2020-05-19\n",
      "R Rafael Acunzo 1 ['Division of Cardiology, Hospital Ramos Mejía, Buenos Aires, Argentina.']\n",
      "Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-05-18\n",
      "W William Uribe 1 ['CES Cardiología, Medellín, Colombia.']\n",
      "Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-05-18\n",
      "EB Eduardo B Saad 1 ['Arrhythmias Service, Hospital Pró-Cardíaco, Río de Janeiro, Brazil.']\n",
      "Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-05-18\n",
      "LC Luis C Sáenz 1 ['International Center of Arrhythmias, Fundación CardioInfantilI-Instituto de Cardiología, Bogotá, Colombia. lcsaenz@cardioinfantil.org.']\n",
      "Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-05-18\n",
      "Z Zoi Daniil 1 ['Department of Respiratory Medicine, and.']\n",
      "When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterranean journal of rheumatology 2020-05-16\n",
      "E Epaminondas Zakynthinos 1 ['Intensive Care Unit, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.']\n",
      "When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterranean journal of rheumatology 2020-05-16\n",
      "K Konstantinos Gourgoulianis 1 ['Department of Respiratory Medicine, and.']\n",
      "When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterranean journal of rheumatology 2020-05-16\n",
      "LI Lazaros I Sakkas 1 ['Department of Rheumatology and Clinical Immunology.']\n",
      "When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterranean journal of rheumatology 2020-05-16\n",
      "P Panini Patankar 1 ['Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India. Electronic address: dr.panini1992@gmail.com.']\n",
      "Emerging pharmacotherapies for COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-05-16\n",
      "TN Thuy N Thai 1 ['Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL, USA.']\n",
      "An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. Research in social & administrative pharmacy : RSAP 2020-05-16\n",
      "AG Almut G Winterstein 1 ['Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL, USA; Center for Drug Evaluation and Safety, University of Florida, Gainesville, FL, USA. Electronic address: almut@cop.ufl.edu.']\n",
      "An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. Research in social & administrative pharmacy : RSAP 2020-05-16\n",
      "M M Scholz 1 ['LEUKOCARE AG, Am Klopferspitz 19, Martinsried, Munich, Germany. Electronic address: martin.scholz@leukocare.com.']\n",
      "Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? Medical hypotheses 2020-05-15\n",
      "H Henri Chahinian 1 ['Aix-Marseille Université, 13015 Marseille, France.']\n",
      "Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. International journal of antimicrobial agents 2020-05-15\n",
      "N Nouara Yahi 1 ['Aix-Marseille Université, 13015 Marseille, France.']\n",
      "Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. International journal of antimicrobial agents 2020-05-15\n",
      "Z Zareen Razaq 1 ['Internal Medicine, Ghurki Trust Teaching Hospital, Lahore, PAK.']\n",
      "A Case of a COVID-19-positive Patient. Cureus 2020-05-14\n",
      "N Nassim Mokraoui 1 [\"Internal Medicine, St. John's Episcopal Hospital, Far Rockaway, USA.\"]\n",
      "A Case of a COVID-19-positive Patient. Cureus 2020-05-14\n",
      "T Tomasz Zrodlowski 1 [\"Internal Medicine, St. John's Episcopal Hospital, Far Rockaway, USA.\"]\n",
      "A Case of a COVID-19-positive Patient. Cureus 2020-05-14\n",
      "S Snehal Bansod 1 [\"Internal Medicine, St. John's Episcopal Hospital, Far Rockaway, USA.\"]\n",
      "A Case of a COVID-19-positive Patient. Cureus 2020-05-14\n",
      "AA Alberto A Arteaga 1 ['Department of Otolaryngology and Communicative Sciences, University of Mississippi Medical Center, Jackson, Mississippi, USA.']\n",
      "Otologic and Audiologic Considerations for COVID-19. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2020-05-13\n",
      "C Christopher Spankovich 1 ['Department of Otolaryngology and Communicative Sciences, University of Mississippi Medical Center, Jackson, Mississippi, USA.']\n",
      "Otologic and Audiologic Considerations for COVID-19. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2020-05-13\n",
      "L Lujing Wang 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "HD Hsiao-Chen Dina Kuo 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "A Ahmad Shannar 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "R Rebecca Peter 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "PJ Pochung Jordan Chou 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "S Shanyi Li 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "R Rasika Hudlikar 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "X Xia Liu 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.\\n2Department of Pharmacology, School of Basic Medical Science, Lanzhou University, Lanzhou, 730000 China.']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "Z Zhigang Liu 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.\\n3Department of Food and Pharmaceutical Engineering, Guiyang University, Guiyang, 550005 China.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "GJ George J Poiani 1 ['4Robert Wood Johnson University Hospital Somerset, Somerville, NJ 08876 USA.\\n5Robert Wood Johnson Medical School, New Brunswick, NJ 08901 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "L Louis Amorosa 1 ['5Robert Wood Johnson Medical School, New Brunswick, NJ 08901 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "L Luigi Brunetti 1 ['4Robert Wood Johnson University Hospital Somerset, Somerville, NJ 08876 USA.\\n6Department of Pharmacy Practice, Ernest Mario School of Pharmacy, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "AN Ah-Ng Kong 1 ['1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854 USA.']\n",
      "An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports 2020-05-13\n",
      "F Florian Zores 1 ['Groupe médical spécialisé, Strasbourg, France.']\n",
      "SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment. Frontiers in medicine 2020-05-12\n",
      "L Liang Chen 1 ['Department of Bioengineering, Beijing Polytechnic, Daxing District, Beijing 100176, China.']\n",
      "Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International journal of antimicrobial agents 2020-05-12\n",
      "R Rong Lan 1 ['Department of Bioengineering, Beijing Polytechnic, Daxing District, Beijing 100176, China.']\n",
      "Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International journal of antimicrobial agents 2020-05-12\n",
      "R Rong Shen 1 ['Department of Bioengineering, Beijing Polytechnic, Daxing District, Beijing 100176, China.']\n",
      "Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International journal of antimicrobial agents 2020-05-12\n",
      "P Peng Li 1 ['SDIC Xinkai Water Environment Investment Co., Ltd, Tongzhou District, Beijing, 101101, China.']\n",
      "Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International journal of antimicrobial agents 2020-05-12\n",
      "J Jason Powell 1 ['University of Florida, Gainesville, FL, USA.']\n",
      "Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. The Annals of pharmacotherapy 2020-05-12\n",
      "BS Badrah S Alghamdi 1 ['Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Pre-Clinical Research Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: basalghamdi@kau.edu.sa.']\n",
      "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel medicine and infectious disease 2020-05-11\n",
      "AA Abdullah A Algaissi 1 ['Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia; Medical Research Center, Jazan University, Jazan, Saudi Arabia. Electronic address: AAlgaissi@jazanu.edu.sa.']\n",
      "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel medicine and infectious disease 2020-05-11\n",
      "FS Fahad S Alshehri 1 ['Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. Electronic address: fsshehri@uqu.edu.sa.']\n",
      "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel medicine and infectious disease 2020-05-11\n",
      "A Abdullah Bukhari 1 ['Department of Medicine, Faculty of Medicine, Imam Mohammed Ibn Saud Islamic University, Riyadh, Saudi Arabia. Electronic address: aibukhari@imamu.edu.sa.']\n",
      "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel medicine and infectious disease 2020-05-11\n",
      "MA Mohamed A Alfaleh 1 ['Vaccines and Immunnotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; Faculty of Pharmacy; King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: maalfaleh@kau.edu.sa.']\n",
      "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel medicine and infectious disease 2020-05-11\n",
      "ZA Ziad A Memish 1 ['King Saud Medical City, Research & Innovation Center, Ministry of Health, Saudi Arabia; Al-Faisal University, Riyadh, Saudi Arabia; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. Electronic address: zmemish@yahoo.com.']\n",
      "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel medicine and infectious disease 2020-05-11\n",
      "M Mariachiara Ippolito 1 ['Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Italy.']\n",
      "Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of critical care 2020-07-20\n",
      "G Giulia Ingoglia 1 ['Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Italy.']\n",
      "Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of critical care 2020-07-20\n",
      "S Sharon Einav 1 ['Intensive Care Unit of the Shaare Zedek Medical Medical Centre and Hebrew University Faculty of Medicine, Jerusalem, Israel.']\n",
      "Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of critical care 2020-07-20\n",
      "Y Yael Lichter 1 ['Department of Intensive Care, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.']\n",
      "Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart rhythm 2020-05-08\n",
      "BA Bander Abu Shrkihe 1 ['Department of Internal Medicine, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.']\n",
      "Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart rhythm 2020-05-08\n",
      "H Hila Bruck 1 ['Department of Internal Medicine, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.']\n",
      "Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart rhythm 2020-05-08\n",
      "HS Howard S Oster 1 ['Department of Internal Medicine, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.']\n",
      "Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart rhythm 2020-05-08\n",
      "S Sami Viskin 1 ['Department of Cardiology, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.']\n",
      "Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart rhythm 2020-05-08\n",
      "S Shah Faisal 1 ['Department of Biotechnology, Bacha Khan University, Charsadda, Pakistan.']\n",
      "COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova, Romania) 2020-05-08\n",
      "A Ayyaz Khan 1 ['Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan.']\n",
      "COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova, Romania) 2020-05-08\n",
      "S Shahzar Khan 1 ['Department of Microbiology, Abdul Wali Khan University, Mardan, Pakistan.']\n",
      "COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova, Romania) 2020-05-08\n",
      "H Hazrat Usman 1 ['Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan.']\n",
      "COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova, Romania) 2020-05-08\n",
      "R Rabia Liaqat 1 ['Department of Botany, Bacha Khan University, Charsadda, Pakistan.']\n",
      "COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova, Romania) 2020-05-08\n",
      "SA Sajjad Ali Shah 1 ['Department of Biotechnology, Bacha Khan University, Charsadda, Pakistan.']\n",
      "COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova, Romania) 2020-05-08\n",
      "LK Lennox K Archibald 1 ['North Florida South Georgia VHS, Gainesville, FL, USA.\\nDepartment of Medicine, University of Florida, Gainesville, FL, USA.']\n",
      "Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in context 2020-05-07\n",
      "A Aparna Wagle Shukla 1 ['Department of Neurology, University of Florida, Gainesville, FL, USA.']\n",
      "Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in context 2020-05-07\n",
      "HJ Hiren J Mehta 1 ['Department of Medicine, University of Florida, Gainesville, FL, USA.']\n",
      "Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in context 2020-05-07\n",
      "K Kartikeya Cherabuddi 1 ['Department of Medicine, University of Florida, Gainesville, FL, USA.']\n",
      "Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in context 2020-05-07\n",
      "YK Yew Kwang Ong 1 ['Department of Otolaryngology-Head and Neck Surgery, National University Hospital System, Singapore, Singapore. entoyk@nus.edu.sg.']\n",
      "Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Military Medical Research 2020-05-07\n",
      "Y De Yun Wang 1 ['Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. entwdy@nus.edu.sg.']\n",
      "Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Military Medical Research 2020-05-07\n",
      "EC Elizabeth C Okafor 1 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "F Fan Wang 1 ['Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "SM Sarah M Lofgren 1 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "CP Caleb P Skipper 1 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "MR Melanie R Nicol 1 ['Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "MF Matthew F Pullen 1 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "R Radha Rajasingham 1 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "EG Emily G McDonald 1 ['Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Canada.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "TC Todd C Lee 1 ['Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Canada.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "IS Ilan S Schwartz 1 ['Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "LE Lauren E Kelly 1 ['Department of Pediatrics and Child Health, Department of Pharmacology, University of Manitoba, Winnipeg, Canada.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "SA Sylvain A Lother 1 ['Department of Medicine, Sections of Critical Care and Infectious Diseases, University of Manitoba, Winnipeg, Canada.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "O Oriol Mitjà 1 ['Fight AIDS and Inf Dis Foundation, Hospital Germans Trias i Pujol, Barcelona, Spain.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "E Emili Letang 1 ['Department of Infectious Diseases, Hospital del Mar/Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.\\nISGlobal, Barcelona Institute for Global Health, Universitat de Barcelona, Barcelona, Spain.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "M Mahsa Abassi 1 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "DR David R Boulware 1 ['Department of Medicine, University of Minnesota, Minneapolis, Minnesota.']\n",
      "Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases 2020-05-05\n",
      "R Rajiv Mahajan 1 ['Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India.']\n",
      "Chloroquine: Can it be a Novel Drug for COVID-19. International journal of applied & basic medical research 2020-05-05\n",
      "SA Steven A Greenstein 1 ['Northshore University Hospital, Northwell Health, Manhasset, New York.']\n",
      "An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. HeartRhythm case reports 2020-05-05\n",
      "LM Laurence M Epstein 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "A Ariane Sternberg 1 ['Center and Network for Targeted Oncology, Muehlackerweg 8, D-69239, Heidelberg, Germany.']\n",
      "Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological research 2020-05-04\n",
      "U Ulrike Stange 1 ['Center and Network for Targeted Oncology, Muehlackerweg 8, D-69239, Heidelberg, Germany.']\n",
      "Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological research 2020-05-04\n",
      "S Stefan Laufer 1 ['Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität, Tübingen and Tuebingen Center for Academic Drug Discovery, Auf Der Morgenstelle 8, 72076, Tuebingen, Germany.']\n",
      "Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological research 2020-05-04\n",
      "C Cord Naujokat 1 ['Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-69120, Heidelberg, Germany. Electronic address: prof.naujokat@gmx.de.']\n",
      "Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological research 2020-05-04\n",
      "S Srinivas G 1 ['Department of Epidemiology, The Tamil Nadu Dr. M.G.R. Medical University, No. 69, Anna Salai, Guindy, Chennai, Tamil Nadu 600032 India.']\n",
      "Will the antimalarial drug take over to combat COVID-19? Zeitschrift fur Gesundheitswissenschaften = Journal of public health 2020-05-01\n",
      "JE J E Möhlmann 1 ['Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands.']\n",
      "Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-05-01\n",
      "BGS B G S Abeln 1 ['Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.']\n",
      "Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-05-01\n",
      "M M Liebregts 1 ['Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.']\n",
      "Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-05-01\n",
      "VF V F van Dijk 1 ['Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.']\n",
      "Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-05-01\n",
      "EMW E M W van de Garde 1 ['Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands.\\nDivision of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.']\n",
      "Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-05-01\n",
      "Y Yusuf Karataş 1 ['Tıbbi Farmakoloji Anabilim Dalı, Tıp Fakültesi, Çukurova Üniversitesi, Sarıçam, Adana, Turkey.\\nPharmacovigilance specialist, Balcalı Hospital, Cukurova University, Adana, Turkey.']\n",
      "Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. Advances in therapy 2020-05-01\n",
      "H Hazir Rahman 1 ['Department of Microbiology, Faculty of Chemical and Life Sciences, Abdul Wali Khan University Mardan (AWKUM), Mardan, KPK, Pakistan.']\n",
      "Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. Advances in therapy 2020-05-01\n",
      "J James Gabriels 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "D David Chang 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "B Beom Soo Kim 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "A Amtul Mansoor 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "E Eitezaz Mahmood 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "P Parth Makker 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).\\nDivision of Electrophysiology, Department of Cardiology, Lenox Hill Hospital, Northwell Health, New York, NY (M.S., P.M., N.S., S.M.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "H Haisam Ismail 1 ['Division of Electrophysiology, Department of Cardiology, Long Island Jewish Medical Center, Northwell Health, New Hyde Park (H.I., B.G.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "B Bruce Goldner 1 ['Division of Electrophysiology, Department of Cardiology, Long Island Jewish Medical Center, Northwell Health, New Hyde Park (H.I., B.G.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "J Jonathan Willner 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "S Stuart Beldner 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "R Raman Mitra 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "R Roy John 1 ['Division of Electrophysiology, Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY (M.S., J.G., D.C., B.S.K., A.M., E.M., P.M., J.W., S.B., R.M., R.J., L.M.E.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "J Jason Chinitz 1 ['Division of Electrophysiology, Department of Cardiology, Southside Hospital, Northwell Health, Bay Shore (J.C.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "N Nicholas Skipitaris 1 ['Division of Electrophysiology, Department of Cardiology, Lenox Hill Hospital, Northwell Health, New York, NY (M.S., P.M., N.S., S.M.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "S Stavros Mountantonakis 1 ['Division of Electrophysiology, Department of Cardiology, Lenox Hill Hospital, Northwell Health, New York, NY (M.S., P.M., N.S., S.M.).']\n",
      "Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circulation. Arrhythmia and electrophysiology 2020-04-30\n",
      "F Felice Amato 1 ['CEINGE, Biotecnologie Avanzate, Naples, Italy.\\nDipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, Naples, Italy.']\n",
      "The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Clinical chemistry and laboratory medicine 2020-04-26\n",
      "G Giuseppe Castaldo 1 ['CEINGE, Biotecnologie Avanzate, Naples, Italy.\\nDipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, Naples, Italy.']\n",
      "The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Clinical chemistry and laboratory medicine 2020-04-26\n",
      "JE Joe-Elie Salem 1 ['Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France.']\n",
      "Response to the editorial \"COVID-19 in patients with cardiovascular diseases\": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Archives of cardiovascular diseases 2020-04-26\n",
      "LS Lee S Nguyen 1 ['Intensive Care Medicine department, Cochin University Hospital, AP-HP Centre, 75014 Paris, France.']\n",
      "Response to the editorial \"COVID-19 in patients with cardiovascular diseases\": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Archives of cardiovascular diseases 2020-04-26\n",
      "MD Milou-Daniel Drici 1 [\"Department of Pharmacology and Toxicology, PharmacoVigilance Centre, Hôpital de Cimiez, University of Nice Côte d'Azur Medical Centre, 06003, Nice, France.\"]\n",
      "Response to the editorial \"COVID-19 in patients with cardiovascular diseases\": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Archives of cardiovascular diseases 2020-04-26\n",
      "DM Dan M Roden 1 ['Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA.']\n",
      "Response to the editorial \"COVID-19 in patients with cardiovascular diseases\": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Archives of cardiovascular diseases 2020-04-26\n",
      "W William Millan 1 ['Fundación Hospital San Jose de Buga, Buga, Valle del Cauca, Colombia.']\n",
      "Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Annals of clinical microbiology and antimicrobials 2020-04-26\n",
      "LA Luis Alfonso Mendoza 1 ['Fundación Hospital San Jose de Buga, Buga, Valle del Cauca, Colombia.']\n",
      "Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Annals of clinical microbiology and antimicrobials 2020-04-26\n",
      "CG Carlos Guillermo Sánchez 1 ['Fundación Hospital San Jose de Buga, Buga, Valle del Cauca, Colombia.']\n",
      "Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Annals of clinical microbiology and antimicrobials 2020-04-26\n",
      "H Hugo Fernandez-Suarez 1 ['Radiology Division, Centro Médico Imbanaco, Cali, Valle del Cauca, Colombia.']\n",
      "Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Annals of clinical microbiology and antimicrobials 2020-04-26\n",
      "DK D Katterine Bonilla-Aldana 1 ['Semillero de Zoonosis, Grupo de Investigación BIOECOS, Fundación Universitaria Autónoma de las Américas, Sede Pereira, Pereira, Risaralda, Colombia.\\nPublic Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "AJ Alfonso J Rodríguez-Morales 1 ['Asociación Colombiana de Infectología, Bogotá DC, Colombia. arodriguezm@utp.edu.co.\\nPublic Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia. arodriguezm@utp.edu.co.\\nGrupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia. arodriguezm@utp.edu.co.']\n",
      "Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Annals of clinical microbiology and antimicrobials 2020-04-26\n",
      "VB Victoria Borg Debono 1 ['Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; Department of Anesthesia, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "MJ Manoj J Mammen 1 ['Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "A Alfonso Iorio 1 ['Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "K Komal Aryal 1 ['Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "D Dianna Deng 1 ['Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "E Eva Brocard 1 ['Graduate Student (International Intern), France.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "W Waleed Alhazzani 1 ['Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; GUIDE Research Methods Group, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.']\n",
      "COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology 2020-04-25\n",
      "W Wenliang Song 1 ['Department of Medicine, Vanderbilt University Medical Center, 318 Preston Research Building, 2200 Pierce Avenue, Nashville, TN 37232, USA.']\n",
      "Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. Journal of clinical medicine 2020-04-25\n",
      "H Hui Huang 1 ['Center of Structural Biology, Vanderbilt University, 2200 Pierce Avenue, Nashville, TN 37232, USA.']\n",
      "Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. Journal of clinical medicine 2020-04-25\n",
      "Q Quancai Sun 1 ['School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, Jiangsu, China.']\n",
      "Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. Journal of clinical medicine 2020-04-25\n",
      "MA M A El Mhammedi 1 ['Sultan Moulay Slimane University, Team of Analytical Chemistry and Random Modeling, Laboratory of Chemistry, Modeling and Environmental Sciences, Polydisciplinary Faculty, Khouribga, Morocco.']\n",
      "Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. New microbes and new infections 2020-04-24\n",
      "AK A K Sharma 1 ['Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala Haryana, India.']\n",
      "Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New microbes and new infections 2020-04-24\n",
      "T Tatsuo Mano 1 ['Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.']\n",
      "Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Bioscience trends 2020-04-24\n",
      "A Atsushi Iwata 1 ['Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.\\nDepartment of Neurology, Tokyo Metropolitan Geriatric Medical Center Hospital, Tokyo, Japan.']\n",
      "Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Bioscience trends 2020-04-24\n",
      "T Tatsushi Toda 1 ['Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.']\n",
      "Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Bioscience trends 2020-04-24\n",
      "N Nagesswary Ganesan 1 ['Department of Biological Sciences and Biotechnology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Selangor, Malaysia.']\n",
      "Is GSK3β a molecular target of chloroquine treatment against COVID-19? Drug discoveries & therapeutics 2020-04-24\n",
      "HM Hasidah Mohd Sidek 1 ['Department of Biological Sciences and Biotechnology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Selangor, Malaysia.']\n",
      "Is GSK3β a molecular target of chloroquine treatment against COVID-19? Drug discoveries & therapeutics 2020-04-24\n",
      "TJ Timothy Jt Chevassut 1 ['Brighton and Sussex Medical School, Brighton UK and consultant haematologist, Royal Sussex County Hospital, Brighton, UK t.chevassut@bsms.ac.uk.']\n",
      "Chloroquine and COVID-19 - a potential game changer? Clinical medicine (London, England) 2020-04-19\n",
      "YL Y L Yang 1 ['Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.']\n",
      "[What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2020-04-17\n",
      "Y Y Xu 1 ['Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.']\n",
      "[What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2020-04-17\n",
      "A Aileen Marty 1 ['Translational Medicine, HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, FL, United States.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "AL Anne-Lise Bienvenu 1 ['Malaria Research Unit, ICBMS, UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Villeurbanne, France.\\nGroupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, 69004 Lyon, France.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "LH Lucille H Blumberg 1 ['Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, 2131 Johannesburg, South Africa.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "J Jean Dupouy-Camet 1 ['Faculté de Médecine Paris Descartes, Académie Vétérinaire de France, Paris, France.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "P Pierre Carnevale 1 ['Institute of Research for Development (former), Montpellier Centre, BP 64501, 34394 Montpellier, France.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "S Shigeyuki Kano 1 ['Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "MK Malcolm K Jones 1 ['School of Veterinary Science, The University of Queensland, Brisbane, QLD, Australia.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "CT Cláudio Tadeu Daniel-Ribeiro 1 ['Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz & Centro de Pesquisa de Diagnóstico e Treinamento, Fiocruz. Av. Brasil 4365. CEP 21.040-360, Rio de Janeiro, Brazil.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "S Santiago Mas-Coma 1 ['Departamento de Parasitología, Facultad de Farmacia, Universidad de Valencia, 46100, Valencia, Spain.']\n",
      "Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One health (Amsterdam, Netherlands) 2020-04-16\n",
      "S Shasha Hu 1 ['Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, China.']\n",
      "Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Bioscience trends 2020-04-14\n",
      "KA Kostas A Papavassiliou 1 ['Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.']\n",
      "G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? Journal of cellular and molecular medicine 2020-04-14\n",
      "AG Athanasios G Papavassiliou 1 ['Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.']\n",
      "G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? Journal of cellular and molecular medicine 2020-04-14\n",
      "S Saibal Das 1 ['Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.']\n",
      "A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International journal of rheumatic diseases 2020-04-14\n",
      "A Avinash Jain 1 ['Department of Clinical Immunology and Rheumatology, Mahatma Gandhi Medical College and Hospital, Jaipur, India.']\n",
      "A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International journal of rheumatic diseases 2020-04-14\n",
      "DP Durga Prasanna Misra 1 ['Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.']\n",
      "A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International journal of rheumatic diseases 2020-04-14\n",
      "VS Vir Singh Negi 1 ['Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.']\n",
      "A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International journal of rheumatic diseases 2020-04-14\n",
      "N Nagham Kaka 1 ['Medicine, National University of Ireland Galway, Galway, IRL.']\n",
      "A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus 2020-04-10\n",
      "MN M N Baig 1 ['Orthopaedics, University Hospital Galway, Galway, IRL.']\n",
      "A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus 2020-04-10\n",
      "K Kerstin Frie 1 ['Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.']\n",
      "Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP open 2020-04-09\n",
      "A Akriti Singh 1 ['College of Medicine & JNM Hospital, Kalyani, Nadia, West Bengal, India.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome 2020-04-05\n",
      "A Altamash Shaikh 1 ['Saifee Hospital, Mumbai, India.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome 2020-04-05\n",
      "R Ritu Singh 1 ['G. D Hospital & Diabetes Institute, Kolkata, India.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome 2020-04-05\n",
      "A Anoop Misra 1 ['Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome 2020-04-05\n",
      "AHJ Alfred H J Kim 1 ['Division of Rheumatology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8045, St Louis, MO, 63110, USA. Electronic address: akim@dom.wustl.edu.']\n",
      "Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best practice & research. Clinical rheumatology 2021-01-24\n",
      "JA Jeffrey A Sparks 1 [\"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Road, #6016U, Boston, MA, 02115, USA. Electronic address: jsparks@bwh.harvard.edu.\"]\n",
      "Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best practice & research. Clinical rheumatology 2021-01-24\n",
      "JW Jean W Liew 1 ['Section of Rheumatology, Boston University School of Medicine, 650 Albany St, X200, Boston, MA, 02118, USA. Electronic address: jwliew@bu.edu.']\n",
      "Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best practice & research. Clinical rheumatology 2021-01-24\n",
      "MS Michael S Putman 1 ['Department of Medicine, Northwestern University , Chicago, IL, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "F Francis Berenbaum 1 ['Department of Rheumatology, Sorbonne University, INSERM CRSA, AP-HP , Paris, France.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "A Alí Duarte-García 1 ['Division of Rheumatology, Mayo Clinic , Rochester, MN, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "ER Elizabeth R Graef 1 ['Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "P Peter Korsten 1 ['Department of Nephrology and Rheumatology, University Medical Center Göttingen , Göttingen, Germany.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "E Emily Sirotich 1 ['Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON, Canada.\\nCanadian Arthritis Patient Alliance , Toronto, ON, Canada.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "MF Manuel F Ugarte-Gil 1 ['School of Medicine, Universidad Científica Del Sur and Hospital Nacional Guillermo Almenara Irigoyen , EsSalud, Lima, Peru.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "K Kate Webb 1 ['Department of Paediatric Rheumatology, University of Cape Town , Cape Town, South Africa.\\nFrancis Crick Institute , London, UK.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "R Rebecca Grainger 1 ['University of Otago, Wellington, New Zealand (R.G.).']\n",
      "A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Annals of internal medicine 2020-04-01\n",
      "JLJ Jing Lin Jeslyn Wong 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "MXK Mei Xian Karen Lim 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "LM Li Min Lim 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "S Sarah Li 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "A Arijit Biswas 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "M Mahesh Choolani 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "C Citra Mattar 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "LL Lin Lin Su 1 ['Department of Obstetrics & Gynaecology, National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.']\n",
      "Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology 2020-03-29\n",
      "M Minoosh Shabani 1 ['Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: meinoosh53@yahoo.com.']\n",
      "Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International journal of antimicrobial agents 2020-03-21\n",
      "S Shervin Shokouhi 1 ['Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: shsh.50@gmail.com.']\n",
      "Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International journal of antimicrobial agents 2020-03-21\n",
      "A Ali Saffaei 1 ['Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: alisaffaei.ss@gmail.com.']\n",
      "Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International journal of antimicrobial agents 2020-03-21\n",
      "A Antonino Giarratano 1 ['Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Italy.']\n",
      "Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of critical care 2020-07-20\n",
      "JM Jean-Marc Rolain 1 ['IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France. Electronic address: jean-marc.rolain@univ-amu.fr.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n",
      "P Philippe Colson 1 ['Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.']\n",
      "New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International journal of antimicrobial agents 2020-03-17\n",
      "D Didier Raoult 1 ['IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France. Electronic address: didier.raoult@gmail.com.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n",
      "X Xavier de Lamballerie 1 ['Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France. Electronic address: xavier.de-lamballerie@univ-amu.fr.']\n",
      "Of chloroquine and COVID-19. Antiviral research 2020-03-10\n",
      "SF Sheryhan F Gad 1 ['Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt.\\nDepartment of Industrial & Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.']\n",
      "Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine (London, England) 2020-07-30\n",
      "K Khalid Muhammad 1 ['Department of Biology, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates.']\n",
      "Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine (London, England) 2020-07-30\n",
      "G Gaber E Batiha 1 ['National Research Center for Protozoan Diseases, Obihiro University of Agriculture & Veterinary Medicine, Nishi 2-13, Inada-cho, Obihiro, Hokkaido, 080-8555, Japan.\\nDepartment of Pharmacology & Therapeutics, Faculty of Veterinary Medicines, Damanhour University, Damanhour, 22511, Egypt.']\n",
      "Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine (London, England) 2020-07-30\n",
      "HF Helal F Hetta 1 ['Department of Medical Microbiology & Immunology, Faculty of Medicine, Assiut University, Assiut, 71526, Egypt.\\nDepartment of Internal Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0595, USA.']\n",
      "Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine (London, England) 2020-07-30\n",
      "J Jakub Rosik 1 ['Department of Pathology, Pomeranian Medical University in Szczecin, Poland.']\n",
      "FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020-07-28\n",
      "K Kacper Lechowicz 1 ['Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, Poland.']\n",
      "FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020-07-28\n",
      "F Filip Machaj 1 ['Department of Pathology, Pomeranian Medical University in Szczecin, Poland.']\n",
      "FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020-07-28\n",
      "K Katarzyna Kotfis 1 ['Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, Poland.']\n",
      "FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020-07-28\n",
      "S Saeid Ghavami 1 ['Department of Human Anatomy and Cell Science, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.']\n",
      "Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? European journal of pharmacology 2021-02-06\n",
      "MJ Marek J Łos 1 ['Biotechnology Centre, Silesian University of Technology, Krzywoustego 8 Str., 44-100, Gliwice, Poland. Electronic address: mjelos@gmail.com.']\n",
      "FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020-07-28\n",
      "N Nassima Bekaddour 1 ['Université de Paris, CNRS UMR-8601, Paris, France.\\nTeam Chemistry & Biology, Modeling & Immunology for Therapy, CBMIT, Paris, France.']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "Y Yannick Dieudonné 1 ['Université de Strasbourg, INSERM UMR']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "A Aurélien Guffroy 1 ['Université de Strasbourg, INSERM UMR']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "Q Quentin Frenger 1 ['Université de Strasbourg, INSERM UMR']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "F Frédéric Gros 1 ['Université de Strasbourg, INSERM UMR']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "MP Mathieu Paul Rodero 1 ['Université de Paris, CNRS UMR-8601, Paris, France.\\nTeam Chemistry & Biology, Modeling & Immunology for Therapy, CBMIT, Paris, France.']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "JP Jean-Philippe Herbeuval 1 ['Université de Paris, CNRS UMR-8601, Paris, France.\\nTeam Chemistry & Biology, Modeling & Immunology for Therapy, CBMIT, Paris, France.']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "AS Anne-Sophie Korganow 1 ['Université de Strasbourg, INSERM UMR']\n",
      "Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontiers in immunology 2020-07-28\n",
      "J Jingbo Li 1 ['Department of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.']\n",
      "Chloroquine in fighting COVID-19: good, bad, or both? Autophagy 2020-07-28\n",
      "R Ruoxi Zhang 1 ['Department of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.']\n",
      "Chloroquine in fighting COVID-19: good, bad, or both? Autophagy 2020-07-28\n",
      "R Rui Kang 1 ['Department of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.']\n",
      "Chloroquine in fighting COVID-19: good, bad, or both? Autophagy 2020-07-28\n",
      "DJ Daniel J Klionsky 1 ['Life Sciences Institute, University of Michigan , Ann Arbor, MI, USA.']\n",
      "Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection? Autophagy 2020-11-07\n",
      "A Annamaria Vernone 1 ['Department of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.']\n",
      "The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. Antioxidants (Basel, Switzerland) 2020-07-28\n",
      "GP Gian Piero Pescarmona 1 ['Department of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.']\n",
      "The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. Antioxidants (Basel, Switzerland) 2020-07-28\n",
      "P Pasquale Iozzo 1 ['Department of Anesthesia and Intensive Care, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy.']\n",
      "Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of critical care 2020-07-20\n",
      "AG Alok Ghosh Chaudhuri 1 ['Department of Physiology, Vidyasagar College, Kolkata, West Bengal, India.']\n",
      "Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. Life sciences 2020-07-18\n",
      "BK Basant K Tiwary 1 ['Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Pondicherry, India. Electronic address: basant68@email.com.']\n",
      "Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. Life sciences 2020-07-18\n",
      "N Nilkanta Chakrabarti 1 ['CPEPA-UGC Centre for \"Electro-physiological and Neuro-imaging studies including Mathematical Modelling\", University of Calcutta, Kolkata, West Bengal, India; Department of Physiology, University of Calcutta, Kolkata, West Bengal, India. Electronic address: ncphysiolcu@gmail.com.']\n",
      "Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. Life sciences 2020-07-18\n",
      "A Arzu Onay-Besı Kcı 1 ['Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Turkey.']\n",
      "Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. Journal of biomolecular structure & dynamics 2020-07-18\n",
      "G Gulgun Ayhan-Kilcigı L 1 ['Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.']\n",
      "Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. Journal of biomolecular structure & dynamics 2020-07-18\n",
      "R Rawiwan Im-Erbsin 1 ['Department of Veterinary Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "A Anchalee Tungtaeng 1 ['Department of Veterinary Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "C Chanikarn Kodchakorn 1 ['Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "A Alison Roth 1 ['Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.\\nCenter for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, Florida, USA.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "J John Adams 1 ['Center for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, Florida, USA.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "C Chaiyaporn Chaisatit 1 ['Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "P Piyaporn Saingam 1 ['Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "RJ Richard J Sciotti 1 ['Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "GA Gregory A Reichard 1 ['Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "CK Christina K Nolan 1 ['Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "BS Brandon S Pybus 1 ['Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "CC Chad C Black 1 ['Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "LA Luis A Lugo-Roman 1 ['Department of Veterinary Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "MD Matthew D Wegner 1 ['Department of Veterinary Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "PL Philip L Smith 1 ['Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "M Mariusz Wojnarski 1 ['Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "BA Brian A Vesely 1 ['Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "KC Kevin C Kobylinski 1 ['Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand kobylinskikevin@yahoo.com.']\n",
      "Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrobial agents and chemotherapy 2020-07-15\n",
      "M Mohamed Allouche 1 ['University of Carthage, Faculty of Sciences of Bizerte, Laboratory of Environment Biomonitoring, Coastal Ecology and Ecotoxicology Unit, 7021 Zarzouna, Tunisia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "M Mounira Lazzem 1 ['University of Carthage, Faculty of Sciences of Bizerte, Laboratory of Environment Biomonitoring, Coastal Ecology and Ecotoxicology Unit, 7021 Zarzouna, Tunisia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "AH Abdel Halim Harrath 1 ['King Saud University, Zoology Department, College of Science, Box 2455, Riyadh 11451, Saudi Arabia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "L Lamjed Mansour 1 ['King Saud University, Zoology Department, College of Science, Box 2455, Riyadh 11451, Saudi Arabia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "S Saleh Alwasel 1 ['King Saud University, Zoology Department, College of Science, Box 2455, Riyadh 11451, Saudi Arabia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "E Ezzeddine Mahmoudi 1 ['University of Carthage, Faculty of Sciences of Bizerte, Laboratory of Environment Biomonitoring, Coastal Ecology and Ecotoxicology Unit, 7021 Zarzouna, Tunisia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "H Hamouda Beyrem 1 ['University of Carthage, Faculty of Sciences of Bizerte, Laboratory of Environment Biomonitoring, Coastal Ecology and Ecotoxicology Unit, 7021 Zarzouna, Tunisia.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "F Fehmi Boufahja 1 ['University of Carthage, Faculty of Sciences of Bizerte, Laboratory of Environment Biomonitoring, Coastal Ecology and Ecotoxicology Unit, 7021 Zarzouna, Tunisia. Electronic address: fehmiboufahja@yahoo.fr.']\n",
      "Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin 2020-07-14\n",
      "N Nicolas Greige 1 ['Harold and Muriel Block Institute for Clinical and Translational Research, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "JA Jose A Quiroz 1 ['Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "AS Ahmed S Khokhar 1 ['Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "J Johanna Daily 1 ['Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.\\nDepartment of Microbiology & Immunology, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "L Luigi Di Biase 1 ['Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, 111 East 210th Street, Room N2, Bronx, NY, 10467, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "KJ Kevin J Ferrick 1 ['Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, 111 East 210th Street, Room N2, Bronx, NY, 10467, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "JD John D Fisher 1 ['Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, 111 East 210th Street, Room N2, Bronx, NY, 10467, USA.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "A Andrew Krumerman 1 ['Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine & Montefiore Medical Center, 111 East 210th Street, Room N2, Bronx, NY, 10467, USA. akrumerm@montefiore.org.']\n",
      "QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2020-07-13\n",
      "Z Zhe Hou 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.\\nSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "C Cheng Cui 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "M Miao Zhang 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China\\nSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China']\n",
      "Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. Current drug metabolism 2020-07-12\n",
      "S Siqi Tu 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China']\n",
      "Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. Current drug metabolism 2020-07-12\n",
      "H Haiyan Li 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.\\nDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, 100191, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "D Dongyang Liu 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "RV Ram Vasudevan Nampoothiri 1 ['Department of Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, CANADA.']\n",
      "Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal. European journal of internal medicine 2020-07-12\n",
      "M Muhammed Razmi T 1 ['Department of Dermatology, IQRAA Aesthetics, IQRAA International Hospital, and Research Centre, Calicut, Kerala, INDIA. Electronic address: razmi@iqraahospital.in.']\n",
      "Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal. European journal of internal medicine 2020-07-12\n",
      "NAB N A Bishurul Hafi 1 ['Department of Dermatology, IQRAA Aesthetics, IQRAA International Hospital, and Research Centre, Calicut, Kerala, INDIA.']\n",
      "Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal. European journal of internal medicine 2020-07-12\n",
      "V Virginia Corazzi 1 ['ENT & Audiology Department, University Hospital of Ferrara, Ferrara, Italy.']\n",
      "Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic! International journal of immunopathology and pharmacology 2020-07-11\n",
      "PH Piotr Henryk Skarżyński 1 ['Institute of Physiology and Pathology of Hearing, Warsaw, Poland; Department of Heart Failure and Cardiac Rehabilitation, Medical University of Warsaw, Warsaw, Poland; Institute of Sensory Organs, Kajetany, Poland.']\n",
      "Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency. Journal of global antimicrobial resistance 2020-10-20\n",
      "MB Magdalena B Skarżyńska 1 ['Institute of Physiology and Pathology of Hearing, Warsaw, Poland.\\nInstitute of Sensory Organs, Kajetany, Poland.']\n",
      "Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic! International journal of immunopathology and pharmacology 2020-07-11\n",
      "C Chiara Bianchini 1 ['ENT & Audiology Department, University Hospital of Ferrara, Ferrara, Italy.']\n",
      "Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic! International journal of immunopathology and pharmacology 2020-07-11\n",
      "S Stefano Pelucchi 1 ['ENT & Audiology Department, University Hospital of Ferrara, Cona, Italy.']\n",
      "Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency. Journal of global antimicrobial resistance 2020-10-20\n",
      "S Stavros Hatzopoulos 1 ['ENT & Audiology Department, University Hospital of Ferrara, Cona, Italy.']\n",
      "Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency. Journal of global antimicrobial resistance 2020-10-20\n",
      "FA F A Berger 1 ['Department of Clinical Pharmacy, Meander Medical Centre, Amersfoort, The Netherlands.']\n",
      "The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-07-11\n",
      "HJ H J Muntinga 1 ['Department of Cardiology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.']\n",
      "The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-07-11\n",
      "MMPM M M P M Jansen 1 ['Department of Clinical Pharmacy, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.']\n",
      "The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2020-07-11\n",
      "KH Kasim Huseein Alireza 1 ['Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.']\n",
      "Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. Travel medicine and infectious disease 2020-07-10\n",
      "S Samah Alshehri 1 ['Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; College of Pharmacy, University of Arizona, Tucson, AZ, USA.']\n",
      "Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. Travel medicine and infectious disease 2020-07-10\n",
      "JA Jaffar A Al-Tawfiq 1 ['Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.']\n",
      "Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. Travel medicine and infectious disease 2020-07-10\n",
      "S Shadi Rezai 1 ['Department of OB/GYN, Valley Community Healthcare, North Hollywood, California, USA.']\n",
      "Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in medical virology 2020-07-10\n",
      "E Ellen Cleland 1 ['Department of Family Medicine, University of Alabama, Tuscaloosa, Alabama, USA.']\n",
      "Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in medical virology 2020-07-10\n",
      "CE Cassandra E Henderson 1 ['Garden OB/GYN, Mercy Medical Center, New York, New York, USA.']\n",
      "Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in medical virology 2020-07-10\n",
      "H Huili Chen 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "Y Yuqi Shang 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "H Hongqiong Zhu 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "G Gongqi Chen 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "Y Yuanli Chen 1 ['Department of Hospital Infection Control, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "S Shaoxuan Liu 1 ['Office of Clinical Research Center, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "Y Yaoyong Zhou 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "M Mingxing Huang 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China. huangmx5@mail.sysu.edu.cn.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "Z Zhongsi Hong 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China. hongzhs@sysu.edu.cn.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "J Jinyu Xia 1 ['Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China. xiajinyu@mail.sysu.edu.cn.']\n",
      "Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020-07-10\n",
      "J Joel Tarning 1 ['Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.\\nCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.']\n",
      "Concentration-dependent mortality of chloroquine in overdose. eLife 2020-07-09\n",
      "RM Richard M Hoglund 1 ['Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.\\nCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.']\n",
      "Concentration-dependent mortality of chloroquine in overdose. eLife 2020-07-09\n",
      "FJ Frederic J Baud 1 ['Assistance Publique']\n",
      "Concentration-dependent mortality of chloroquine in overdose. eLife 2020-07-09\n",
      "B Bruno Megarbane 1 ['Université de Paris, INSERM UMRS-11 44, Paris, France.\\nReanimation Medicale et Toxicologique, Hopital Lariboisiere, Paris, France.']\n",
      "Concentration-dependent mortality of chloroquine in overdose. eLife 2020-07-09\n",
      "JL Jean-Luc Clemessy 1 ['Assistance Publique']\n",
      "Concentration-dependent mortality of chloroquine in overdose. eLife 2020-07-09\n",
      "NJ Nicholas J White 1 ['Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.\\nCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.']\n",
      "Does hydroxychloroquine still have any role in the COVID-19 pandemic? Expert opinion on pharmacotherapy 2021-03-17\n",
      "LN Lorena Neris Barboza 1 ['Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.']\n",
      "Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current pharmaceutical design 2020-07-08\n",
      "S Samantha Wietzikoski 1 ['Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.']\n",
      "Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current pharmaceutical design 2020-07-08\n",
      "ANV Amanda Nascimento Vasques de Souza 1 ['Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.']\n",
      "Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current pharmaceutical design 2020-07-08\n",
      "PA Pablo Alvarez Auth 1 ['Laboratory of Preclinical Research of Natural Products, Post- Graduate Program in Animal Science with Emphasis on Bioactive Products, Paranaense University, Umuarama, PR, Brazil.']\n",
      "Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current pharmaceutical design 2020-07-08\n",
      "AG Arquimedes Gasparotto Junior 1 ['Laboratory of Electrophysiology and Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, MS, Brazil.']\n",
      "Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current pharmaceutical design 2020-07-08\n",
      "FA Francislaine Aparecida Dos Reis Lívero 1 ['Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.']\n",
      "Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current pharmaceutical design 2020-07-08\n",
      "ME Mercedes E Zabaleta 1 ['Institute of Immunology, Faculty of Medicine, Central University of Venezuela, 50109, Los Chaguaramos 1050-A, Caracas, Venezuela']\n",
      "The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Current pharmaceutical design 2020-07-08\n",
      "C Camilo Di Giulio 1 ['Institute of Immunology, Faculty of Medicine, Central University of Venezuela, 50109, Los Chaguaramos 1050-A, Caracas, Venezuela']\n",
      "The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Current pharmaceutical design 2020-07-08\n",
      "JE Jaime E Charris 1 ['Organic Synthesis Laboratory, Faculty of Pharmacy, Central University of Venezuela, 47206, Los Chaguaramos 1041-A, Caracas, Venezuela']\n",
      "The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Current pharmaceutical design 2020-07-08\n",
      "MR Michael R Mijares 1 ['Institute of Immunology, Faculty of Medicine, Central University of Venezuela, 50109, Los Chaguaramos 1050-A, Caracas, Venezuela\\nBiotechnology Unit, Faculty of Pharmacy, Central University of Venezuela, 47206, Los Chaguaramos 1041-A, Caracas, Venezuela']\n",
      "The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Current pharmaceutical design 2020-07-08\n",
      "M Mahsa Ghodousi 1 ['Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences , Mashhad, Iran.']\n",
      "Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. Expert review of anti-infective therapy 2020-07-08\n",
      "S Sara Rahsepar 1 ['Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences , Mashhad, Iran.']\n",
      "Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. Expert review of anti-infective therapy 2020-07-08\n",
      "S Sepideh Elyasi 1 ['Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences , Mashhad, Iran.']\n",
      "Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. Expert review of anti-infective therapy 2020-07-08\n",
      "V Voichita Lazureanu 1 ['Faculty of Medicine, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.\\n\"Dr. Victor Babes\" Clinical Hospital for Infectious Diseases and Pneumophthisiology, 300310 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "D Dorina Coricovac 1 ['Faculty of Pharmacy, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "M Marius Mioc 1 ['Faculty of Pharmacy, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "R Roxana Oancea 1 ['Faculty of Dental Medicine, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "I Iasmina Marcovici 1 ['Faculty of Pharmacy, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "I Iulia Pinzaru 1 ['Faculty of Pharmacy, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "C Codruta Soica 1 ['Faculty of Pharmacy, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "AM Aristidis M Tsatsakis 1 ['Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion, 71003 Crete, Greece.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "O Octavian Cretu 1 ['Faculty of Medicine, \"Victor Babes\" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania.']\n",
      "SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of clinical medicine 2020-07-08\n",
      "JD Jonathan D Geiger 1 ['Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, United States of America.']\n",
      "Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. Cellular signalling 2020-07-07\n",
      "R Roman Romero-Ortuno 1 [\"Discipline of Medical Gerontology, Mercer's Institute for Successful Ageing, St James's Hospital, Dublin, Ireland, and Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.\"]\n",
      "A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? International journal of antimicrobial agents 2020-07-07\n",
      "A Alfonso Carvajal 1 ['Centro de Estudios sobre la Seguridad de los Medicamentos (CESME), Universidad de Valladolid, Valladolid, Spain.']\n",
      "A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? International journal of antimicrobial agents 2020-07-07\n",
      "A Andrea Savarino 1 ['Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.']\n",
      "A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? International journal of antimicrobial agents 2020-07-07\n",
      "AAM Arthur A M Wilde 1 ['Amsterdam UMC, location AMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARDHEART; https://guardheart.ern-net.eu); European Cardiac Arrhythmia Genetics Focus Group (ECGen) of the European Heart Rhythm Association (EHRA).']\n",
      "Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. Heart rhythm 2020-07-06\n",
      "CA Carol Ann Remme 1 ['Amsterdam UMC, location AMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands; European Cardiac Arrhythmia Genetics Focus Group (ECGen) of the European Heart Rhythm Association (EHRA). Electronic address: c.a.remme@amsterdamumc.nl.']\n",
      "Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. Heart rhythm 2020-07-06\n",
      "A Ariella Coler-Reilly 1 ['Division of Rheumatology, Department of Medicine, Washington University School of Medicine , St. Louis, MO, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "C Carly Harrison 1 ['LupusChat , New York, NY, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "MF Maximilian F Konig 1 ['Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine , Baltimore, MD, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "PC Philip C Robinson 1 ['University of Queensland Faculty of Medicine , Brisbane, Australia.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "KJ Kristen J Young 1 ['Division of Rheumatic Diseases, UT Southwestern Medical Center , Dallas, TX, USA.']\n",
      "Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert review of clinical immunology 2020-07-06\n",
      "CO Christian O Ogah 1 ['Department of Obstetrics and Gynaecology, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi, Nigeria.']\n",
      "Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2020-07-02\n",
      "IH Ifeyinwa H Anikwe 1 ['Department of Administration, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi, Nigeria.']\n",
      "Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2020-07-02\n",
      "BC Bartholomew C Okorochukwu 1 ['Department of Obstetrics and Gynaecology, Federal Medical Centre, Owerri, Imo, Nigeria.']\n",
      "Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2020-07-02\n",
      "CC Cyril C Ikeoha 1 ['Department of Obstetrics and Gynaecology, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi, Nigeria.']\n",
      "Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2020-07-02\n",
      "RM Rana Muhammad Mateen 1 ['Department of Life Sciences, School of Science, University of Management and Technology, Lahore, Pakistan. Electronic address: mateenibb@yahoo.com.']\n",
      "Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-06-25\n",
      "MS Muhammad Sohail Afzal 1 ['Department of Life Sciences, School of Science, University of Management and Technology, Lahore, Pakistan. Electronic address: sohail.ncvi@gmail.com.']\n",
      "Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-06-25\n",
      "M Mahjabeen Saleem 1 ['Institute of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan. Electronic address: mahjabeen.ibb@pu.edu.pk.']\n",
      "Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-06-25\n",
      "V Vasudharani Devanathan 1 ['Department of Biology, Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati, India;']\n",
      "Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. Journal of biomolecular structure & dynamics 2020-06-25\n",
      "A Ambrish Saxena 1 ['Center for Sponsored Research and Consultancy, Indian Institute of Technology (IIT) Tirupati, Tirupati, India.']\n",
      "Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. Journal of biomolecular structure & dynamics 2020-06-25\n",
      "AV Anand V Kasbekar 1 ['Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.\\nNIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.\\nDepartment of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.']\n",
      "Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. Frontiers in public health 2020-06-24\n",
      "DM David M Baguley 1 ['Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.\\nNIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.\\nDepartment of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.']\n",
      "Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. Frontiers in public health 2020-06-24\n",
      "T Thomas Houston 1 ['Department of Neurology, University of Alabama at Birmingham, AL, United States; Epilepsy and Cognitive Neurophysiology Laboratory, University of Alabama at Birmingham, AL, United States.']\n",
      "Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. Epilepsy research 2020-06-20\n",
      "K Khalil Ur-Rahman 1 ['Department of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "IU Ikram-Ul- Haq 1 ['Department of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "N Nazish Jahan 1 ['Department of Chemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "M Muhammad Mumtaz 1 ['Department of Chemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "M Muhammad Farman 1 ['Department of Chemistry, University of Engineering and Technology, Lahore, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "H Huma Naeem 1 ['Department of Computer Science, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "F Faheem Abbas 1 ['Department of Chemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "M Muhammad Naeem 1 ['Department of Biochemistry, Faculty of Sciences, Bahauddin Zakariya University, Multan, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "S Sania Sadiqa 1 ['Department of Chemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "S Saira Bano 1 ['Department of Chemistry, Faculty of Sciences, University of Agriculture, Faisalabad, Pakistan.']\n",
      "The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews 2020-06-18\n",
      "M Martina Bosic 1 ['Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia.']\n",
      "Treatment of COVID 19-Repurposing drugs commonly used in dermatology. Dermatologic therapy 2020-06-17\n",
      "E Eleni Bibaki 1 ['Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Crete, Greece.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "M Maria Bolaki 1 ['Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Crete, Greece.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "E Eirini Vasarmidi 1 ['Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Crete, Greece.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "A Athina Trachalaki 1 ['Interstitial Lung Disease Unit Royal Brompton Hospital, London, UK.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "EK Emmanouil K Symvoulakis 1 ['Clinic of Social and Family Medicine, Faculty of Medicine, University of Crete, Heraklion Crete, Greece.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "DA Demetrios A Spandidos 1 ['Laboratory of clinical Virology, Medical School, University of Crete, Heraklion Crete, Greece.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "KM Katerina M Antoniou 1 ['Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Crete, Greece.']\n",
      "[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Experimental and therapeutic medicine 2020-06-17\n",
      "A Atul Sharma 1 ['Medical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "S Swapnil Tiwari 1 ['School of Studies in Chemistry, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh, India.']\n",
      "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. International journal of antimicrobial agents 2020-06-14\n",
      "MK Manas Kanti Deb 1 ['School of Studies in Chemistry, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh, India.']\n",
      "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. International journal of antimicrobial agents 2020-06-14\n",
      "JL Jean Louis Marty 1 ['Biocapteurs-Analyses-Environnement, Universite de Perpignan Via Domitia, 52 Avenue Paul Alduy, Perpignan CEDEX 66860, France; Sensbiotech, 21rue de Nogarede, 66400 Ceret, France.']\n",
      "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. International journal of antimicrobial agents 2020-06-14\n",
      "AV Adrian V Hernandez 1 ['University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.\\nHartford Hospital Department of Research Administration, Hartford, Connecticut, USA.']\n",
      "Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous. Journal of clinical pharmacology 2020-06-13\n",
      "OF Omar F Carrasco 1 ['Departamento de Farmacología, Facultad de Medicina, UNAM, Centro de Investigación en Políticas, Población y Salud, Facultad de Medicina, UNAM, Ciudad de México/México.']\n",
      "Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2. Archivos de cardiologia de Mexico 2020-06-12\n",
      "A Ana Berni-Betancourt 1 ['Laboratorio de Arritmias. Departamento de Cardiología. Hospital Central Sur de Alta Especialidad Pemex. HCSAE, Ciudad de México/México.\\nSociedad Mexicana de Cardiología.']\n",
      "Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2. Archivos de cardiologia de Mexico 2020-06-12\n",
      "AM Adriana Maria Kakehasi 1 ['Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. amkakehasi@gmail.com.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "M Marcelo de Medeiros Pinheiro 1 ['Disciplina de Reumatologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "GA Gilda Aparecida Ferreira 1 ['Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "CDL Cláudia Diniz Lopes Marques 1 ['Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal de Pernambuco, Recife, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "LMH Licia Maria Henrique da Mota 1 ['Hospital Universitário']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "E Eduardo Dos Santos Paiva 1 ['Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal do Paraná, Curitiba, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "GCS Gecilmara Cristina Salviato Pileggi 1 ['Instituto de Ensino e Pesquisa (IEP), Hospital Amor, Barretos, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "EI Emília Inoue Sato 1 ['Disciplina de Reumatologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "APMG Ana Paula Monteiro Gomides Reis 1 ['Hospital Universitário']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "RM Ricardo Machado Xavier 1 ['Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "JR José Roberto Provenza 1 ['Pontifícia Universidade Católica de Campinas, Campinas, Brazil.']\n",
      "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England) 2020-06-11\n",
      "C Chandrama Shrestha 1 ['Nepal Diabetes Society, Kathmandu, Nepal.']\n",
      "Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus. JPMA. The Journal of the Pakistan Medical Association 2020-06-10\n",
      "D Deep Dutta 1 ['Center for Endocrinology, Diabetes, Arthritis & Rheumatism (CEDAR) Superspeciality Clinics, Dwarka, New Delhi, India.']\n",
      "Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus. JPMA. The Journal of the Pakistan Medical Association 2020-06-10\n",
      "EG E G Ferro 1 [\"Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.\"]\n",
      "Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2020-06-10\n",
      "JM J M Kirshenbaum 1 [\"Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.\"]\n",
      "Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2020-06-10\n",
      "BD B D Hayes 1 ['Department of Emergency Medicine, Harvard Medical School, Boston, MA, USA.\\nDepartment of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.']\n",
      "Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2020-06-10\n",
      "SE S E Culbreth 1 [\"Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.\\nDepartment of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.\"]\n",
      "Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2020-06-10\n",
      "C Carlos Chaccour 1 ['Instituto de Salud Global (ISGlobal), Barcelona, Spain.\\nFacultad de Medicina, Universidad de Navarra, Pamplona, Spain.']\n",
      "Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials 2021-04-11\n",
      "P Paula Ruiz-Castillo 1 ['ISGlobal, Hospital Clínic']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "MA Mary-Ann Richardson 1 ['ISGlobal, Hospital Clínic']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "G Gemma Moncunill 1 ['ISGlobal, Hospital Clínic']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "A Aina Casellas 1 ['ISGlobal, Hospital Clínic']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "F Francisco Carmona-Torre 1 ['Clínica Universidad de Navarra, Pamplona, Spain.\\nIdiSNA, Navarra Institute for Health Research, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "M Miriam Giráldez 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "JS Juana Schwartz Mota 1 ['Instituto de Salud Global de Barcelona, Barcelona, Spain.']\n",
      "The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials 2020-06-10\n",
      "JR José Ramón Yuste 1 ['Instituto de Salud Global de Barcelona, Barcelona, Spain.']\n",
      "The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials 2020-06-10\n",
      "JR José Ramón Azanza 1 ['Instituto de Salud Global de Barcelona, Barcelona, Spain.']\n",
      "The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials 2020-06-10\n",
      "M Miriam Fernández 1 ['Instituto de Salud Global de Barcelona, Barcelona, Spain.']\n",
      "The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials 2020-06-10\n",
      "G Gabriel Reina 1 ['Clínica Universidad de Navarra, Pamplona, Spain.\\nHarvard T.H. Chan School of Public Health, Boston, MA, United States.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "C Carlota Dobaño 1 ['ISGlobal, Hospital Clínic']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "J Joe Brew 1 ['Databrew, Gainesville, FL, United States.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "B Belen Sadaba 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "F Felix Hammann 1 ['Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "R Regina Rabinovich 1 ['Instituto de Salud Global de Barcelona, Barcelona, Spain.']\n",
      "The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials 2020-06-10\n",
      "JE Jan-Erik Berdal 1 ['Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.\\nDepartment of Infectious Diseases, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "A Arne Eskesen 1 ['Department of Infectious Diseases, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "D Dag Kvale 1 ['Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.\\nDepartment of Infectious Diseases, Oslo University Hospital, Oslo, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "IC Inge Christoffer Olsen 1 ['Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "A Anbjørg Rangberg 1 ['Center for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "CM Christine Monceyron Jonassen 1 ['Center for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "T Torbjørn Omland 1 ['Division of Medicine, Akershus University Hospital, Lørenskog, Norway.\\nInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "H Helge Røsjø 1 ['Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. helge.rosjo@medisin.uio.no.\\nDivision of Research and Innovation, Akershus University Hospital, Lørenskog, Norway. helge.rosjo@medisin.uio.no.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "O Olav Dalgard 1 ['Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.\\nDepartment of Infectious Diseases, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.']\n",
      "Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials 2020-06-07\n",
      "G George Ismailos 1 ['Experimental-Research Center ELPEN, ELPEN Pharmaceuticals, Pikermi, Attika, Greece.']\n",
      "Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. Safety science 2020-06-06\n",
      "E Eleni Karatza 1 ['Laboratory of Biopharmaceutics-Pharmacokinetics, School of Health Sciences, National and Kapodistrian University of Athens, Greece.']\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. Safety science 2020-06-06\n",
      "Y YuTing Chen 1 [\"Xi'an Medical University , Xi'an, China.\\nDepartment of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China.\"]\n",
      "Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgraduate medicine 2020-06-05\n",
      "X XiuDe Fan 1 [\"Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China.\"]\n",
      "Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgraduate medicine 2020-06-05\n",
      "X XiaoYun Wang 1 [\"Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China.\"]\n",
      "Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgraduate medicine 2020-06-05\n",
      "Q QunYing Han 1 [\"Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China.\"]\n",
      "Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgraduate medicine 2020-06-05\n",
      "Z ZhengWen Liu 1 [\"Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China.\"]\n",
      "Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgraduate medicine 2020-06-05\n",
      "AP Aditya Prasad Dash 1 ['Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.']\n",
      "Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? Indian journal of public health 2020-06-05\n",
      "O Oriela Martínez 1 ['Rheumatology Department, Padre Hurtado Hospital, Santiago, Chile.']\n",
      "Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Clinical rheumatology 2020-06-05\n",
      "F Francisca Valenzuela 1 ['Rheumatology Department, Padre Hurtado Hospital, Santiago, Chile.']\n",
      "Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Clinical rheumatology 2020-06-05\n",
      "F Francisco Silva 1 ['Medicine Faculty Clínica Alemana, Universidad del Desarrollo, Av. Manquehue Norte 1410, piso 7,, 7650567, Vitacura, Santiago, Chile.\\nRheumatology Department, Padre Hurtado Hospital, Santiago, Chile.']\n",
      "Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Clinical rheumatology 2020-06-05\n",
      "O Omar Valenzuela 1 ['Medicine Faculty Clínica Alemana, Universidad del Desarrollo, Av. Manquehue Norte 1410, piso 7,, 7650567, Vitacura, Santiago, Chile.\\nRheumatology Department, Padre Hurtado Hospital, Santiago, Chile.']\n",
      "Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Clinical rheumatology 2020-06-05\n",
      "R R Guilhaumou 1 ['Aix Marseille Université, hôpital de la Timone, institut de neuroscience des systèmes, 13005 Marseille, France.']\n",
      "Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. Therapie 2020-06-01\n",
      "M M Molimard 1 ['Service de pharmacologie médicale, University Bordeaux, Inserm U1219, 33076 Bordeaux, France.']\n",
      "Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. Therapie 2020-06-01\n",
      "MD M-D Drici 1 ['Pharmacovigilance']\n",
      "Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. Therapie 2020-06-01\n",
      "S S Laporte 1 ['Université Jean Monnet, Université de Lyon, et unité de recherche clinique, innovation, pharmacologie, CHU Saint-Etienne, 42055 Saint-Étienne, France.']\n",
      "Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. Therapie 2020-06-01\n",
      "JL J-L Montastruc 1 [\"Service de pharmacologie médicale et clinque, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, faculté de Médecine, centre hospitalier universitaire de Toulouse, 31000 Toulouse, France.\"]\n",
      "Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. Therapie 2020-06-01\n",
      "K Kuldeep Dhama 1 ['Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India. kdhama@rediffmail.com.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "SK Shailesh Kumar Patel 1 ['Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "M Mamta Pathak 1 ['Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "R Ruchi Tiwari 1 ['Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU), Mathura, 281001, India.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "BR Bhoj Raj Singh 1 ['Division of Epidemiology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "R Ranjit Sah 1 ['Department of Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "AJ Alfonso J Rodriguez-Morales 1 ['Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia. arodriguezm@utp.edu.co.\\nFaculty of Medicine, Grupo de Investigacion Biomedicina, Fundacion Universitaria Autonoma de las Americas, Pereira, Risaralda, Colombia. arodriguezm@utp.edu.co.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "H Hakan Leblebicioglu 1 ['Department of Infectious Diseases, Samsun Liv Hospital, Samsun, Turkey.']\n",
      "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials 2020-06-01\n",
      "E Emily Chung 1 [\"Medicine, St. John's Episcopal Hospital, New York, USA.\"]\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "JJ Jonathan J Heyl 1 [\"Medicine, St. John's Episcopal Hospital, New York, USA.\"]\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "B Bisma Hussain 1 [\"Medicine, St. John's Episcopal Hospital, New York, USA.\"]\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "MC Michael C Oh 1 [\"Medicine, St. John's Episcopal Hospital, New York, USA.\"]\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "C Candis Pinon 1 ['Medicine, Mount Sinai Hospital, New York, USA.']\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "S Soumya Boral 1 ['Medicine, Presidency University, Kolkata, IND.']\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "D David Chun 1 ['Medicine, Northwell Health, New York, USA.']\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "B Benson Babu 1 ['Hospital Medicine, Northwell Health, New York, USA.']\n",
      "A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. Cureus 2020-09-29\n",
      "D D Raoult 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "M Moïse Michel 1 ['Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.\\nIHU-Méditerranée Infection, Marseille, France.']\n",
      "Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Frontiers in immunology 2020-09-29\n",
      "S Soraya Mezouar 1 ['Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.\\nIHU-Méditerranée Infection, Marseille, France.']\n",
      "Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Frontiers in immunology 2020-09-29\n",
      "AB Aïssatou Bailo Diallo 1 ['Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.\\nIHU-Méditerranée Infection, Marseille, France.']\n",
      "Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Frontiers in immunology 2020-09-29\n",
      "A Asma Boumaza 1 ['Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.\\nIHU-Méditerranée Infection, Marseille, France.']\n",
      "Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Frontiers in immunology 2020-09-29\n",
      "JL Jean-Louis Mege 1 ['Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.\\nIHU-Méditerranée Infection, Marseille, France.']\n",
      "Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Frontiers in immunology 2020-09-29\n",
      "B Benoit Desnues 1 ['Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.\\nIHU-Méditerranée Infection, Marseille, France.']\n",
      "Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Frontiers in immunology 2020-09-29\n",
      "SS Sankha Shubhra Chakrabarti 1 ['Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.']\n",
      "Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Current drug targets 2020-09-26\n",
      "B Bisweswar Ojha 1 ['Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, India.']\n",
      "Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Current drug targets 2020-09-26\n",
      "BK Bhairav Kumar Pathak 1 ['Department of Biochemistry and Central Research Cell, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (deemed to be) University, Mullana, Ambala, Haryana, India.']\n",
      "Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Current drug targets 2020-09-26\n",
      "A Amit Singh 1 ['Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, India.']\n",
      "Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Current drug targets 2020-09-26\n",
      "L Luciano Saso 1 ['Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.']\n",
      "Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Current drug targets 2020-09-26\n",
      "S Sasanka Chakrabarti 1 ['Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, India.']\n",
      "Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Current drug targets 2020-09-26\n",
      "ZM Zhuo-Ming Li 1 ['Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Lab of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou, 510006, China.']\n",
      "Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta pharmacologica Sinica 2020-09-25\n",
      "JT Jian-Tao Ye 1 ['Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Lab of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou, 510006, China.']\n",
      "Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta pharmacologica Sinica 2020-09-25\n",
      "J Jing Lu 1 [\"Agricultural College, Yanbian University, Yanji, 133002, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "LL Lingyu Linda Ye 1 ['Center for Phenomics of Traditional Chinese Medicine of the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, China.']\n",
      "Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta pharmacologica Sinica 2020-09-25\n",
      "CX Chun-Xiang Zhang 1 ['Institute of Cardiovascular Research and the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.']\n",
      "Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta pharmacologica Sinica 2020-09-25\n",
      "PQ Pei-Qing Liu 1 ['Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Lab of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou, 510006, China. liupq@mail.sysu.edu.cn.']\n",
      "Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta pharmacologica Sinica 2020-09-25\n",
      "DD Dayue D Duan 1 ['Center for Phenomics of Traditional Chinese Medicine of the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, China. dduan@swmu.edu.cn.']\n",
      "Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta pharmacologica Sinica 2020-09-25\n",
      "WL William L Stone 1 ['Department of Pediatrics, East Tennessee State University, Johnson City, TN 37614, USA.']\n",
      "Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. Antioxidants (Basel, Switzerland) 2020-09-25\n",
      "D David Bomze 1 ['Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Israel.\\nSchool of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel.\\nDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland.']\n",
      "Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. British journal of clinical pharmacology 2020-09-24\n",
      "R Rachel Dankner 1 ['Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Israel.\\nUnit for Cardiovascular Epidemiology, The Gertner Institute for Epidemiology and Health Policy Research, Ramat Gan, Israel.']\n",
      "Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. British journal of clinical pharmacology 2020-09-24\n",
      "H Hanoch Hod 1 ['School of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel.\\nLeviev Heart Center, Sheba Medical Center, Ramat Gan, Israel.']\n",
      "Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. British journal of clinical pharmacology 2020-09-24\n",
      "T Tomer Meirson 1 ['Azrieli Faculty of Medicine, Bar-Ilan University, Israel.']\n",
      "Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. British journal of clinical pharmacology 2020-09-24\n",
      "B Ben Boursi 1 ['School of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel.\\nDepartment of Oncology, Sheba Medical Center, Tel HaShomer, Israel.\\nCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.']\n",
      "Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. British journal of clinical pharmacology 2020-09-24\n",
      "E Elad Maor 1 ['School of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel.\\nLeviev Heart Center, Sheba Medical Center, Ramat Gan, Israel.']\n",
      "Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. British journal of clinical pharmacology 2020-09-24\n",
      "JD Joshua D King 1 ['Department of Medicine, School of Medicine and School of Pharmacy, University of Maryland, Baltimore, Maryland.\\nMaryland Poison Center, Baltimore, Maryland.']\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "G Greene Shepherd 1 ['Division of Practice Advancement and Clinical Education, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina.']\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "RS Robert S Hoffman 1 ['Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, New York University Grossman School of Medicine, New York City, New York.']\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "B Badria Alhatali 1 ['Poison Control Section, Department of Environmental and Occupational Health, Ministry of Health, Muscat, Oman.']\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "V Valery Lavergne 1 [\"Research Center, Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'île-de-Montréal, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.\"]\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "DM Darren M Roberts 1 [\"Department of Renal Medicine and Transplantation, St. Vincent's Hospital, Sydney, New South Wales, Australia.\\nDepartment of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, New South Wales, Australia.\\nSt. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.\"]\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "S Sophie Gosselin 1 ['Centre Intégré de Santé et de Services Sociaux Montérégie-Centre Emergency Department, Hôpital Charles-Lemoyne, Greenfield Park, Quebec, Canada.\\nDepartment of Emergency Medicine, McGill University, Montreal, Quebec, Canada.\\nCentre Antipoison du Québec, Quebec City, Quebec, Canada.']\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "G Gabrielle Wilson 1 [\"Research Center, Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'île-de-Montréal, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada.\"]\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "TD Thomas D Nolin 1 ['Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.\\nDepartment of Medicine Renal-Electrolyte Division, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.']\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "M Marc Ghannoum 1 [\"Research Center, Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'île-de-Montréal, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada marcghannoum@gmail.com.\"]\n",
      "Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Journal of the American Society of Nephrology : JASN 2020-09-24\n",
      "DM Diana M Sobieraj 1 ['Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.']\n",
      "Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clinical toxicology (Philadelphia, Pa.) 2020-09-23\n",
      "WL William L Baker 1 ['Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.']\n",
      "Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clinical toxicology (Philadelphia, Pa.) 2020-09-23\n",
      "VL V L Pushpa 1 ['PG and Research Department of Chemistry, Sree Narayana College, Kollam, Kerala 691001, India.']\n",
      "Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors. Journal of proteome research 2020-09-23\n",
      "S Surendran Suchitra 1 ['PG and Research Department of Chemistry, Sree Narayana College, Kollam, Kerala 691001, India.']\n",
      "Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors. Journal of proteome research 2020-09-23\n",
      "L Lingfeng Zhao 1 ['Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Sothern Medical University, Tianhe, Guangzhou, Guangdong, China.']\n",
      "Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Journal of cellular physiology 2020-09-23\n",
      "X Xianquan Zhan 1 ['University Creative Research Initiatives Center, Shandong First Medical University, Jinan, Shandong, China.\\nKey Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan, China.\\nState Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, Hunan, China.\\nDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.\\nNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.']\n",
      "Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Journal of cellular physiology 2020-09-23\n",
      "F Fatima En-Nahli 1 ['Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University of Meknes, Morocco.']\n",
      "Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. Life sciences 2020-09-22\n",
      "H Hanane Zaki 1 ['Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University of Meknes, Morocco.']\n",
      "Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. Life sciences 2020-09-22\n",
      "T Tahar Lakhlifi 1 ['Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University of Meknes, Morocco.']\n",
      "Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. Life sciences 2020-09-22\n",
      "M Mohammed Bouachrine 1 ['Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University of Meknes, Morocco; EST Khenifra, Sultan Moulay Sliman University, Benimellal, Morocco. Electronic address: m.bouachrine@est-umi.ac.ma.']\n",
      "Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. Life sciences 2020-09-22\n",
      "A Alyssa Bonnier 1 ['Division of Critical Care Nursing, Goldfarb School of Nursing, Barnes Jewish College, St. Louis, Missouri.']\n",
      "Antimalarials as Antivirals for COVID-19: Believe it or Not! The American journal of the medical sciences 2020-09-21\n",
      "W Woon Chong 1 ['Division of Pulmonary and Critical Care Medicine, Albany Medical Center College, Albany, New York.']\n",
      "Antimalarials as Antivirals for COVID-19: Believe it or Not! The American journal of the medical sciences 2020-09-21\n",
      "L Lorenzo Ferro Desideri 1 ['IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.\\nDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.']\n",
      "Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. International ophthalmology 2020-09-19\n",
      "M Matteo Bassetti 1 [\"Infectious Diseases Clinic, Department of Health Sciences, University of Genova and Ospedale Policlinico San Martino- IRCCS Per L'Oncologia, Genova, Italy.\"]\n",
      "Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. International ophthalmology 2020-09-19\n",
      "CE Carlo Enrico Traverso 1 ['IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.\\nDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.']\n",
      "Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. International ophthalmology 2020-09-19\n",
      "KM Kylie M Wagstaff 1 ['Cancer Targeting and Nuclear Therapeutics Lab., Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia. Electronic address: Kylie.Wagstaff@monash.edu.']\n",
      "The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ? Biochemical and biophysical research communications 2020-12-21\n",
      "S Sharon Dowell 1 ['Department of Internal Medicine, Division of Rheumatology, Howard University Hospital, 2041 Georgia Avenue, Washington, DC 20060.']\n",
      "Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? Heliyon 2020-09-17\n",
      "Y Ying Shen 1 ['Department of Physiology, Department of Neurology of the First Affiliated Hospital, NHC and CAMS Key Laboratory of Medical Neurobiology, Zhejiang University School of Medicine, Hangzhou 310058, China.']\n",
      "Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? Heliyon 2020-09-17\n",
      "DL Dexter L Lee 1 ['Department of Physiology and Biophysics, Howard University College of Medicine, Washington, DC 20059.']\n",
      "Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? Heliyon 2020-09-17\n",
      "SZA Syed Ziauddin A Zaidi 1 ['Department of Pathology (Hematology), University of Health Sciences, Lahore, Pakistan.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "T Trisha Shang 1 ['Diabetes Technology Society, Burlingame, CA, USA.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "JY Jennifer Y Zhang 1 ['Diabetes Technology Society, Burlingame, CA, USA.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "T Thamir Al-Khlaiwi 1 ['Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "IA Ishfaq A Bukhari 1 ['Department of Pharmacology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "J Javed Akram 1 ['University of Health Sciences, Lahore, Pakistan.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "DC David C Klonoff 1 ['Diabetes Research Institute, Mills-Peninsula Medical Center San Mateo, California, USA.']\n",
      "Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University. Science 2020-09-15\n",
      "D Dragica Jorgovanović 1 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "K Katarina Živančević 1 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "E Evica Antonijević Miljaković 1 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "B Biljana Antonijević 1 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "A Aleksandra Buha Djordjevic 1 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "M Marijana Ćurčić 1 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "D Danijela Đukić-Ćosić 1 ['Department of Toxicology \"Akademik Danilo Soldatović\", Center for Toxicological Risk Assessment, University of Belgrade']\n",
      "Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicology and applied pharmacology 2020-09-14\n",
      "JP Jordan Patrick Cuff 1 ['School of Biosciences, Cardiff University, Cardiff, United Kingdom.']\n",
      "Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infoveillance Study. Journal of medical Internet research 2020-09-12\n",
      "BP Brendan P Kelly 1 ['School of Biosciences, Cardiff University, Cardiff, United Kingdom.']\n",
      "Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infoveillance Study. Journal of medical Internet research 2020-09-12\n",
      "H Helen Waller-Evans 1 ['Medicine Discovery Institute, Cardiff University, Cardiff, United Kingdom.']\n",
      "Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infoveillance Study. Journal of medical Internet research 2020-09-12\n",
      "E Emyr Lloyd-Evans 1 ['School of Biosciences, Cardiff University, Cardiff, United Kingdom.']\n",
      "Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infoveillance Study. Journal of medical Internet research 2020-09-12\n",
      "D Dafne Siciliano 1 ['Gabinetto di psicologia (REFLETO), Via Francesco Saverio Nitti 28, Rome, Italy.']\n",
      "Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19? The International journal of health planning and management 2020-09-12\n",
      "A Abdelkrim Tahraoui 1 ['Laboratory of Applied Neuro-Endocrinology, Badji-Mokhtar University, Annaba, Algeria.']\n",
      "Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19? The International journal of health planning and management 2020-09-12\n",
      "DAA Dr Abhijeet Ashok Salunke 1 ['Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India. Electronic address: drabhijeetsalunke@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "DP Dr Praveen Thivari 1 ['Department of Orthopaedics, MMIMSR, MM Deemed to be University, Ambala, Haryana, India. Electronic address: praveenthivari@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "A Apurva Pandey 1 ['Department of Radiation Oncology, MMIMSR, MM Deemed to be University, Ambala, Haryana, India. Electronic address: apurvap23@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "DK Dr Kunal Nandy 1 ['Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India. Electronic address: MSkunalnandy@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "D Dr Harish V K Ratna 1 ['Department of Orthopaedics, MMIMSR, MM Deemed to be University, Ambala, Haryana, India. Electronic address: harivk07@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "DS Dr Sanjay Pandey 1 ['Respiratory Medicine Specialist, Chandrmohan Hospital, Varanasi, India. Electronic address: drsmpandey@yahoo.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "DJ Dr Jasneet Chawla 1 ['Department of Orthopaedics, MMIMSR, MM Deemed to be University, Ambala, Haryana, India. Electronic address: jasneetchawla@ymail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "DJ Dr Jalil Mujawar 1 ['Department of Neonatology, Sahyadri Hospital, Pune, Maharashtra, India. Electronic address: drmujawarj@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "DA Dr Anant Dhanwate 1 ['Department of Anatomy, Government Medical College, Akola, Maharashtra, India. Electronic address: dranant1999@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "DV Dr Vivek Menon 1 ['Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India. Electronic address: menonvivek167@gmail.com.']\n",
      "No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials\". Diabetes & metabolic syndrome 2020-09-10\n",
      "MA Md Abdul Barek 1 ['Department of Pharmacy, Faculty of Science, Noakhali Science and Technology University, Sonapur, Noakhali 3814 Bangladesh.']\n",
      "A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN comprehensive clinical medicine 2020-09-10\n",
      "N Nusrat Jahan 1 ['Department of Pharmacy, Faculty of Science, Noakhali Science and Technology University, Sonapur, Noakhali 3814 Bangladesh.']\n",
      "A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN comprehensive clinical medicine 2020-09-10\n",
      "M Mohammad Safiqul Islam 1 ['Department of Pharmacy, Faculty of Science, Noakhali Science and Technology University, Sonapur, Noakhali 3814 Bangladesh.']\n",
      "A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN comprehensive clinical medicine 2020-09-10\n",
      "K Keshav Rajarshi 1 ['School of Community Science and Technology (SOCSAT), Indian Institute of Engineering Science and Technology (IIEST), Shibpur, Howrah, West Bengal 711103, India.']\n",
      "Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open biology 2020-09-09\n",
      "R Rajni Khan 1 ['Motihari College of Engineering, Bariyarpur, Motihari, NH 28A, Furshatpur, Motihari, Bihar 845401, India.']\n",
      "Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open biology 2020-09-09\n",
      "S Shashikant Ray 1 ['Department of Biotechnology, Mahatma Gandhi Central University, Motihari 845401, India.']\n",
      "Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open biology 2020-09-09\n",
      "ML Mei-Lin Go 1 ['Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, 119260, Singapore.']\n",
      "Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Molecular neurobiology 2020-09-09\n",
      "DY De-Yun Wang 1 ['Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore.']\n",
      "Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Molecular neurobiology 2020-09-09\n",
      "IK Irwin Kee-Mun Cheah 1 ['Neurobiology Programme, Life Sciences Institute, National University of Singapore, Singapore, 119260, Singapore.\\nDepartment of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore.']\n",
      "Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Molecular neurobiology 2020-09-09\n",
      "B Barry Halliwell 1 ['Neurobiology Programme, Life Sciences Institute, National University of Singapore, Singapore, 119260, Singapore. bchbh@nus.edu.sg.\\nDepartment of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore. bchbh@nus.edu.sg.']\n",
      "Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Molecular neurobiology 2020-09-09\n",
      "PO Patrick O Hanafin 1 ['Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.']\n",
      "Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of pharmaceutical sciences 2020-09-07\n",
      "Y Yanguang Cao 1 ['Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.']\n",
      "Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of pharmaceutical sciences 2020-09-07\n",
      "A Adrian Lifschitz 1 ['Laboratorio de Farmacología, Centro de Investigación Veterinarias de Tandil (CIVETAN), CONICET-CICPBA-UNCPBA, Facultad de Ciencias Veterinarias, Universidad Nacional Del Centro de La Provincia de Buenos Aires, Tandil, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "C Carlos Lanusse 1 ['Laboratorio de Farmacología, Centro de Investigación Veterinarias de Tandil (CIVETAN), CONICET-CICPBA-UNCPBA, Facultad de Ciencias Veterinarias, Universidad Nacional Del Centro de La Provincia de Buenos Aires, Tandil, Argentina. Electronic address: clanusse@vet.unicen.edu.ar.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "GG Gauri G Rao 1 ['Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: gaurirao@live.unc.edu.']\n",
      "Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of pharmaceutical sciences 2020-09-07\n",
      "M Manya Prasad 1 ['Department of Community Medicine, NDMC Medical College, New Delhi, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "T Tulika Seth 1 ['Clinical Hematology, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "RK Ranjit Kumar Sahoo 1 ['Medical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "K Karan Madan 1 ['Pulmonary Medicine, Critical Care and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "N Neeraj Nischal 1 ['Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "M Manish Soneja 1 ['Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "SK Subir Kumar Maulik 1 ['Pharmacology, All India Institute of Medical Sciences, New Delhi, 110029, India.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "    Shalimar 1 ['Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India. drshalimar@yahoo.com.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "P Pramod Garg 1 ['Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India. pkgarg@aiims.ac.in.']\n",
      "Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of general internal medicine 2020-09-05\n",
      "A Ankita Das 1 ['Department of Environmental Sciences, University of Calcutta, Kolkata, 700019 India.']\n",
      "Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. Genes and environment : the official journal of the Japanese Environmental Mutagen Society 2020-09-05\n",
      "AK Ajoy K Sarkar 1 ['Intensive Care Unit, Peerless Hospital, B.K. Roy Research Centre, Kolkata, 700094 India.']\n",
      "Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. Genes and environment : the official journal of the Japanese Environmental Mutagen Society 2020-09-05\n",
      "AK Ashok K Giri 1 ['Molecular Genetics Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032 India.']\n",
      "Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. Genes and environment : the official journal of the Japanese Environmental Mutagen Society 2020-09-05\n",
      "M Małgorzata Ostrowska 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "K Kamila Stokowa-Sołtys 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "J Joanna Wątły 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "D Dorota Dudek 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "A Adriana Miller 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "S Sławomir Potocki 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "A Agnieszka Matera-Witkiewicz 1 ['Screening Laboratory of Biological Activity Tests and Collection of Biological Material, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "A Alicia Dominguez-Martin 1 ['Department of Inorganic Chemistry, Faculty of Pharmacy, University of Granada, E-18071 Granada, Spain.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "H Henryk Kozłowski 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.\\nDepartment of Physiotherapy, Opole Medical School, Katowicka 68, 40-060 Opole, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "M Magdalena Rowińska-Żyrek 1 ['Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.']\n",
      "Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel, Switzerland) 2020-09-05\n",
      "SSA Syed Saif Abbas Rizvi 1 [\"Department of Surgery, Brigham, and Women's Hospital, Boston, Massachusetts. United States.\"]\n",
      "Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design 2020-11-27\n",
      "S Saher Fatima 1 ['Department Agricultural Microbiology, Aligarh Muslim University, Aligarh 202002, U.P. India.']\n",
      "Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design 2020-11-27\n",
      "MI Md Imtaiyaz Hassan 1 ['Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar New Delhi 110025. India.']\n",
      "Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design 2020-11-27\n",
      "PH Peter H Rheinstein 1 ['Severn Health Solutions, Severna Park, MD, U.S.A.']\n",
      "Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In vivo (Athens, Greece) 2020-09-03\n",
      "LM Luis Manuel Entrenas Costa 1 ['UGC de Neumología, Instituto Maimónides de Investigación Biomédica de Córdoba 9 (IMIBIC). Hospital Universitario Reina Sofía, Universidad de Córdoba, Avda. Menéndez 10 Pidal s/n, 14004 11, Córdoba, Spain. Electronic address: lmentrenas@uco.es.']\n",
      "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\". The Journal of steroid biochemistry and molecular biology 2020-09-02\n",
      "JM José Manuel Vaquero Barrios 1 ['UGC de Neumología, Instituto Maimónides de Investigación Biomédica de Córdoba 9 (IMIBIC). Hospital Universitario Reina Sofía, Universidad de Córdoba, Avda. Menéndez 10 Pidal s/n, 14004 11, Córdoba, Spain.']\n",
      "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\". The Journal of steroid biochemistry and molecular biology 2020-09-02\n",
      "JF Juan Francisco Alcalá Díaz 1 ['Departamento de Medicina Interna. IMIBIC, CIBER de Fisiopatología de la Obesidad y la Nutrición. Hospital Universitario Reina Sofía, Universidad de Córdoba, Fundación Progreso y Salud. Avda. Menéndez Pidal s/n, 14004 14, Córdoba, Spain.']\n",
      "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\". The Journal of steroid biochemistry and molecular biology 2020-09-02\n",
      "J José López Miranda 1 ['Departamento de Medicina Interna. IMIBIC, CIBER de Fisiopatología de la Obesidad y la Nutrición. Hospital Universitario Reina Sofía, Universidad de Córdoba, Fundación Progreso y Salud. Avda. Menéndez Pidal s/n, 14004 14, Córdoba, Spain.']\n",
      "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\". The Journal of steroid biochemistry and molecular biology 2020-09-02\n",
      "R Roger Bouillon 1 ['Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Herestraat, ON1/902, 3000, Leuven, Belgium.']\n",
      "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\". The Journal of steroid biochemistry and molecular biology 2020-09-02\n",
      "JM José Manuel Quesada Gomez 1 ['IMIBIC. CIBER de Fragilidad y Envejecimiento Saludable. Hospital Universitario Reina Sofía, Universidad de Córdoba, Fundación Progreso y Salud. Avda. Menéndez Pidal s/n, 18 14004, Córdoba, Spain.']\n",
      "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\". The Journal of steroid biochemistry and molecular biology 2020-09-02\n",
      "R Ramakant Yadav 1 ['Department of Neurology, Uttar Pradesh University of Medical Sciences, Uttar Pradesh, India.']\n",
      "Ivermectin: Potential Role as Repurposed Drug for COVID-19. The Malaysian journal of medical sciences : MJMS 2020-08-31\n",
      "AV Amit Vikram Singh 1 ['Department of Pharmacology, Uttar Pradesh University of Medical Sciences, Uttar Pradesh, India.']\n",
      "Ivermectin: Potential Role as Repurposed Drug for COVID-19. The Malaysian journal of medical sciences : MJMS 2020-08-31\n",
      "MC M C Mafé Nogueroles 1 ['Servicio de Medicina Interna. Hospital de Atención a Pacientes Crónicos y de Larga Estancia La Pedrera, Denia, Alicante, España.']\n",
      "[Inflammation, malnutrition, and SARS-CoV-2 infection: a disastrous combination]. Revista clinica espanola 2020-08-31\n",
      "F F Garrachón Vallo 1 ['Servicio de Medicina Interna. Unidad de Medicina Perioperatoria. Equipo de Soporte Nutricional. Hospital Universitario Virgen Macarena, Sevilla, España.']\n",
      "[Inflammation, malnutrition, and SARS-CoV-2 infection: a disastrous combination]. Revista clinica espanola 2020-08-31\n",
      "E E Escudero Álvarez 1 ['Servicio de Medicina Interna. Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España.']\n",
      "[Inflammation, malnutrition, and SARS-CoV-2 infection: a disastrous combination]. Revista clinica espanola 2020-08-31\n",
      "E E Maciá Botejara 1 ['Servicio de Medicina Interna. Hospital Universitario de Badajoz, Badajoz, España.']\n",
      "[Inflammation, malnutrition, and SARS-CoV-2 infection: a disastrous combination]. Revista clinica espanola 2020-08-31\n",
      "JP J P Miramontes González 1 ['Servicio de Medicina Interna. Hospital Universitario Río Hortega, Valladolid, España; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España.']\n",
      "[Inflammation, malnutrition, and SARS-CoV-2 infection: a disastrous combination]. Revista clinica espanola 2020-08-31\n",
      "A Anthony Guihur 1 ['Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne, Switzerland.']\n",
      "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-08-30\n",
      "ME Mathieu Edouard Rebeaud 1 ['Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne, Switzerland.']\n",
      "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-08-30\n",
      "M Matthieu Mulot 1 ['Laboratory of Soil Biodiversity, Faculty of Science, University of Neuchâtel, Switzerland.']\n",
      "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-08-30\n",
      "N Nathan Peiffer-Smadja 1 ['Université de Paris, IAME, INSERM, Paris, France; National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College, London, UK; Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, AP-HP, Paris, France.']\n",
      "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-08-30\n",
      "Y Yahya Mahamat-Saleh 1 ['CESP (Centre for Research in Epidemiology and Population Health), Faculté de Médecine-Université Paris-Sud, Faculté de Médecine-UVSQ, INSERM, Université Paris Saclay, Villejuif, France; Gustave Roussy, Villejuif, France.']\n",
      "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-08-30\n",
      "O Olga Riabova 1 ['Federal Research Center Fundamentals of Biotechnology of the Russian Academy of Sciences, 33-2 Leninsky Prospect, Moscow 119071, Russia.']\n",
      "The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathogens and disease 2020-08-30\n",
      "S Sean Ekins 1 ['Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.']\n",
      "The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathogens and disease 2020-08-30\n",
      "N Nikolay Pluzhnikov 1 ['State Research Institute of Military Medicine of the Ministry of Defence of the Russian Federation, St Petersburg 195043, Russia.']\n",
      "The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathogens and disease 2020-08-30\n",
      "S Sergei Chepur 1 ['State Research Institute of Military Medicine of the Ministry of Defence of the Russian Federation, St Petersburg 195043, Russia.']\n",
      "The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathogens and disease 2020-08-30\n",
      "A Ali Talebi 1 ['Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.']\n",
      "Drug Interactions of Psychiatric and COVID-19 Medications. Basic and clinical neuroscience 2020-08-29\n",
      "M Marjan Moghadamnia 1 ['Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.']\n",
      "Drug Interactions of Psychiatric and COVID-19 Medications. Basic and clinical neuroscience 2020-08-29\n",
      "Z Zahra Nazari Taloki 1 ['Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.']\n",
      "Drug Interactions of Psychiatric and COVID-19 Medications. Basic and clinical neuroscience 2020-08-29\n",
      "A Alia Shakiba 1 ['Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.']\n",
      "Drug Interactions of Psychiatric and COVID-19 Medications. Basic and clinical neuroscience 2020-08-29\n",
      "JD Justyna D Kowalska 1 [\"Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. jdkowalska@gmail.com.\"]\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "A Andrzej Pihowicz 1 ['Intensive Care Unit, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland.']\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "B Beata Wojtycha-Kwaśnica 1 ['Department of Diagnostic Imaging, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland.']\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "M Magdalena Thompson 1 ['IV-th Department, Hospital for Infectious Diseases, Warsaw, Poland.']\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "T Tomasz Dyda 1 ['Molecular Diagnostics Laboratory, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland.']\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "H Hanna Czeszko-Paprocka 1 ['Central Analytical Laboratory, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland.']\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "A Andrzej Horban 1 [\"Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.\"]\n",
      "How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. European journal of medical research 2020-08-29\n",
      "N Nishant Jaiswal 1 ['Evidence Based Health Informatics Unit, Department of Telemedicine, PGIMER, Chandigarh, India.']\n",
      "Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. Frontiers in medicine 2020-08-28\n",
      "N Nishanth Dev 1 ['Department of Medicine, VMMC, Safdarjung Hospital, New Delhi, India.']\n",
      "Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. Frontiers in medicine 2020-08-28\n",
      "N Nikita Jaiswal 1 ['Department of Microbiology, MM Institute of Medical Sciences and Research, MMU (Deemed to be University), Ambala, India.']\n",
      "Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. Frontiers in medicine 2020-08-28\n",
      "SS Sushree Samiksha Naik 1 ['Department of Obstetrics and Gynecology, Capital Hospital, Bhubaneswar, India.']\n",
      "Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. Frontiers in medicine 2020-08-28\n",
      "J Jhuma Sankar 1 ['Department of Pediatrics, AIIMS New Delhi, New Delhi, India.']\n",
      "Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. Frontiers in medicine 2020-08-28\n",
      "M Muhammad Hanif 1 ['Department of Medicine, Khyber Medical College, Peshawar, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "MA Muhammad Adnan Haider 1 ['Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "MU Muhammad Umer Ahmed 1 ['Department of Medicine, Ziauddin University, Karachi, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "F Fnu Sundas 1 ['Department of Medicine, Khyber Medical College, Peshawar, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "A Arham Hirani 1 ['Department of Medicine, Ziauddin University, Karachi, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "IA Izhan Ali Khan 1 ['Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "K Khurram Anis 1 ['Department of Gastroenterology, Pakistan Kidney and Liver Institute, Lahore, Pakistan.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "AH Amin H Karim 1 ['Department of Cardiology, Baylor College of Medicine, Houston, TX, United States.']\n",
      "Treatment Options for COVID-19: A Review. Frontiers in medicine 2020-08-28\n",
      "T TaiPeng Shen 1 ['Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "L LiJun Zhong 1 ['Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "Z ZhiXi Liu 1 ['Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "X XinWei Dong 1 ['Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "T TingWenLi Huang 1 ['Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "Q QiuJu Wang 1 ['Department of Clinical Laboratory, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "H HongTao Xiao 1 ['Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.\\nDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China.']\n",
      "Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Frontiers in pharmacology 2020-08-28\n",
      "MA Matthew A Heimann 1 ['Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA.']\n",
      "COVID-19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians open 2020-08-25\n",
      "SL Samuel L Burleson 1 ['Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA.']\n",
      "COVID-19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians open 2020-08-25\n",
      "BC Brendan C Anzalone 1 ['Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA.']\n",
      "COVID-19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians open 2020-08-25\n",
      "JF Jonathan F Swanson 1 ['Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA.']\n",
      "COVID-19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians open 2020-08-25\n",
      "DW Douglas W Wallace 1 ['Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA.']\n",
      "COVID-19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians open 2020-08-25\n",
      "CJ Christopher J Greene 1 ['Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA.']\n",
      "COVID-19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians open 2020-08-25\n",
      "Y Yull Arriaga 1 ['IBM Watson Health, Center for AI, Research, and Evaluation, Cambridge, MA.']\n",
      "A Narrative Review of Emerging Therapeutics for COVID-19. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-08-25\n",
      "D Dilhan Weeraratne 1 ['IBM Watson Health, Center for AI, Research, and Evaluation, Cambridge, MA.']\n",
      "A Narrative Review of Emerging Therapeutics for COVID-19. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-08-25\n",
      "F Fredy Reyes 1 ['IBM Watson Health, Center for AI, Research, and Evaluation, Cambridge, MA.']\n",
      "A Narrative Review of Emerging Therapeutics for COVID-19. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-08-25\n",
      "GP Gretchen P Jackson 1 ['Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN.']\n",
      "A Narrative Review of Emerging Therapeutics for COVID-19. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-08-25\n",
      "N Nanditha Venkatesan 1 ['All India Institute of Medical Sciences, Raipur, India.']\n",
      "Can HCQ Be Considered a \"Safe Weapon\" for COVID-19 in the Indian Population? SN comprehensive clinical medicine 2020-08-25\n",
      "S Sajitha Venkatesan 1 ['Department of Microbiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.']\n",
      "COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings? Journal of family medicine and primary care 2020-08-06\n",
      "MP Meenalotchini Prakash Gurunthalingam 1 ['Department of Pharmacology, All India Institute of Medical Sciences, Raipur, India.']\n",
      "Can HCQ Be Considered a \"Safe Weapon\" for COVID-19 in the Indian Population? SN comprehensive clinical medicine 2020-08-25\n",
      "E Eswaran Thangaraju 1 ['Associate Professor, Department of EEE, AKT Memeorial College of Engineering and Technology, Kallakurichi, Tamil Nadu, India.']\n",
      "COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings? Journal of family medicine and primary care 2020-08-06\n",
      "EV Evangelos V Badiavas 1 ['Dr Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.']\n",
      "Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing. JAAD case reports 2020-08-25\n",
      "RS Robert S Kirsner 1 ['Dr Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.\\nSylvester Comprehensive Cancer Center, Miami, Florida.']\n",
      "Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing. JAAD case reports 2020-08-25\n",
      "AJ Anna J Nichols 1 ['Dr Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.\\nSylvester Comprehensive Cancer Center, Miami, Florida.']\n",
      "Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing. JAAD case reports 2020-08-25\n",
      "ZC Zechariah C Harris 1 ['Wake Forest School of Medicine, Winston-Salem, North Carolina.']\n",
      "Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing. JAAD case reports 2020-08-25\n",
      "AR Andrew R Phillips 1 ['The Ohio State University College of Medicine, Columbus, Ohio.']\n",
      "Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing. JAAD case reports 2020-08-25\n",
      "J John Shen 1 ['Shen Dermatology, Temecula, California.']\n",
      "Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing. JAAD case reports 2020-08-25\n",
      "B Betsy He 1 ['Rensselaer Polytechnic Institute, Troy, NY, USA.']\n",
      "Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes & diseases 2020-08-25\n",
      "X Xiong Wang 1 ['Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.']\n",
      "Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes & diseases 2020-08-25\n",
      "ML Ming-Liang He 1 ['Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.\\nCityU Shenzhen Research Institute, Nanshan, Shenzhen, China.']\n",
      "Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes & diseases 2020-08-25\n",
      "S Sanjiv Saigal 1 ['Institute of Liver Transplantation & Regenerative Medicine, Medanta- The Medicity, Gurugram, India.']\n",
      "Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. Journal of clinical and experimental hepatology 2020-08-25\n",
      "AS Arvinder S Soin 1 ['Institute of Liver Transplantation & Regenerative Medicine, Medanta- The Medicity, Gurugram, India.']\n",
      "Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. Journal of clinical and experimental hepatology 2020-08-25\n",
      "P P Gautret 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "MR Mohammad Reza Aram 1 ['Iranian Center for Quantum Technologies (ICQTs), Tehran, Iran.\\nNuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.']\n",
      "Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19. Chemical physics letters 2020-08-25\n",
      "A Abida Sayed 1 ['Medicine Department, Avalon University School of Medicine, Willemstad, Curacao, Netherlands Antilles.']\n",
      "Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. Therapeutic advances in infectious disease 2020-08-22\n",
      "Z Zahra Rashe 1 ['Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? Recent patents on anti-infective drug discovery 2020-08-21\n",
      "MH Mohammad H Ahur 1 ['Cardiovascular Research Center, Shahid Madani Medical & Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? Recent patents on anti-infective drug discovery 2020-08-21\n",
      "M Mojtaba Eidizadeh 1 ['Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? Recent patents on anti-infective drug discovery 2020-08-21\n",
      "D D Zanon 1 ['Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.']\n",
      "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data in brief 2020-08-18\n",
      "CMG C M G Gennari 1 ['Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy.']\n",
      "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data in brief 2020-08-18\n",
      "M M Fortini 1 ['Farmacia Nuova, Seriate, Italy.\\nSocietà Italiana Farmacisti Preparatori, Milan, Italy.']\n",
      "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data in brief 2020-08-18\n",
      "N N Maximova 1 ['Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.']\n",
      "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data in brief 2020-08-18\n",
      "F F Cilurzo 1 ['Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy.']\n",
      "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data in brief 2020-08-18\n",
      "P P Minghetti 1 ['Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy.']\n",
      "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data in brief 2020-08-18\n",
      "LJ Lisa J Rosenthal 1 ['Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL.']\n",
      "Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. Psychosomatics 2020-08-18\n",
      "TC Tatiana Colombo Pimentel 1 ['Instituto Federal do Paraná (IFPR), Campus Paranavaí, 87703-536, Paranavaí, Paraná, Brazil.']\n",
      "What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. European journal of pharmacology 2020-08-11\n",
      "CE Carlos Eduardo Barão 1 ['Instituto Federal do Paraná (IFPR), Campus Paranavaí, 87703-536, Paranavaí, Paraná, Brazil. Electronic address: carlos.barao@ifpr.edu.br.']\n",
      "What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. European journal of pharmacology 2020-08-11\n",
      "MFL Maria Fernanda Lima Nascimento 1 ['Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.']\n",
      "Chloroquine and COVID-19: Should We Care about Ototoxicity? International archives of otorhinolaryngology 2020-08-11\n",
      "TRC Thayanne Rachel Cangussu Brito 1 ['Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.']\n",
      "Chloroquine and COVID-19: Should We Care about Ototoxicity? International archives of otorhinolaryngology 2020-08-11\n",
      "MC Marcos Correia Lima 1 ['Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.']\n",
      "Chloroquine and COVID-19: Should We Care about Ototoxicity? International archives of otorhinolaryngology 2020-08-11\n",
      "LR Laura Rodrigues Sefair 1 ['Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.']\n",
      "Chloroquine and COVID-19: Should We Care about Ototoxicity? International archives of otorhinolaryngology 2020-08-11\n",
      "MM Maisa Mendes Pedrosa 1 ['Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.']\n",
      "Chloroquine and COVID-19: Should We Care about Ototoxicity? International archives of otorhinolaryngology 2020-08-11\n",
      "MP Meenalotchini P Gurunthalingam 1 ['Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.']\n",
      "COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings? Journal of family medicine and primary care 2020-08-06\n",
      "S Shobanbabu Varthya 1 ['Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.']\n",
      "COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings? Journal of family medicine and primary care 2020-08-06\n",
      "T Tara McMillan 1 [\"British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.\"]\n",
      "Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. Drugs in context 2020-08-04\n",
      "A Andrea Human 1 [\"British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.\"]\n",
      "Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. Drugs in context 2020-08-04\n",
      "JM Joseph M Lam 1 ['Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, British Columbia, Canada.']\n",
      "Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. Drugs in context 2020-08-04\n",
      "L Lijun Dai 1 ['Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.']\n",
      "Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Archives of pharmacal research 2020-08-03\n",
      "X Xingyu Zhang 1 ['Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.']\n",
      "Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Archives of pharmacal research 2020-08-03\n",
      "Z Zhaohui Zhang 1 ['Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhzhqing1990@163.com.']\n",
      "Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Archives of pharmacal research 2020-08-03\n",
      "Z Zhentao Zhang 1 ['Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhentaozhang@whu.edu.cn.']\n",
      "Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Archives of pharmacal research 2020-08-03\n",
      "F F Rodriguez Salvanés 1 ['Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España; Unidad de Evaluación de Tecnologías Sanitarias, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España; Hospital Universitario de La Princesa. Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "A A Gallego-Arenas 1 ['Gerencia de Atención Primaria, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España; Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "LM L M Sánchez-Gómez 1 ['Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España; Agencia de Evaluación de Tecnologías Sanitarias. ISCIII, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "M M Ruiz-López 1 ['Gerencia de Atención Primaria, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España; Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "B B Sierra García 1 ['Gerencia de Atención Primaria, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España; Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "A A Jurado-López 1 ['Unidad de Evaluación de Tecnologías Sanitarias, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España; Hospital Universitario Clínico San Carlos. Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "P P Arriola-Bolado 1 ['Unidad de Evaluación de Tecnologías Sanitarias, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "M M Cervera Cano 1 ['Unidad de Evaluación de Tecnologías Sanitarias, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "B B Novella-Arribas 1 ['Gerencia de Atención Primaria, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España; Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España; Unidad de Evaluación de Tecnologías Sanitarias, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España. Electronic address: blanca.novella@salud.madrid.org.']\n",
      "[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. Semergen 2020-08-03\n",
      "JAM João Alison de Moraes Silveira 1 ['Drug Research and Development Center, Federal University of Ceara, Coronel Nunes de Melo St., 1000, 60.430-275, Fortaleza-CE, Brazil; Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Coronel Nunes de Melo St., 1127, 60.430-275, Fortaleza-CE, Brazil.']\n",
      "In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. International journal of antimicrobial agents 2020-08-02\n",
      "AD Aline Diogo Marinho 1 ['Drug Research and Development Center, Federal University of Ceara, Coronel Nunes de Melo St., 1000, 60.430-275, Fortaleza-CE, Brazil; Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Coronel Nunes de Melo St., 1127, 60.430-275, Fortaleza-CE, Brazil.']\n",
      "In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. International journal of antimicrobial agents 2020-08-02\n",
      "MEA Maria Elisabete Amaral de Moraes 1 ['Drug Research and Development Center, Federal University of Ceara, Coronel Nunes de Melo St., 1000, 60.430-275, Fortaleza-CE, Brazil; Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Coronel Nunes de Melo St., 1127, 60.430-275, Fortaleza-CE, Brazil.']\n",
      "In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. International journal of antimicrobial agents 2020-08-02\n",
      "MO Manoel Odorico de Moraes Filho 1 ['Drug Research and Development Center, Federal University of Ceara, Coronel Nunes de Melo St., 1000, 60.430-275, Fortaleza-CE, Brazil; Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Coronel Nunes de Melo St., 1127, 60.430-275, Fortaleza-CE, Brazil.']\n",
      "In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. International journal of antimicrobial agents 2020-08-02\n",
      "HSA Helena Serra Azul Monteiro 1 ['Drug Research and Development Center, Federal University of Ceara, Coronel Nunes de Melo St., 1000, 60.430-275, Fortaleza-CE, Brazil; Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Coronel Nunes de Melo St., 1127, 60.430-275, Fortaleza-CE, Brazil.']\n",
      "In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. International journal of antimicrobial agents 2020-08-02\n",
      "RJB Roberta Jeane Bezerra Jorge 1 ['Drug Research and Development Center, Federal University of Ceara, Coronel Nunes de Melo St., 1000, 60.430-275, Fortaleza-CE, Brazil; Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Coronel Nunes de Melo St., 1127, 60.430-275, Fortaleza-CE, Brazil. Electronic address: robertajeane@ufc.br.']\n",
      "In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. International journal of antimicrobial agents 2020-08-02\n",
      "Y Yuanqiu Chen 1 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "J Ji Xiao 1 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "W Weisheng Luo 1 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "F Feng Li 1 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "Y Yuan Wang 1 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "Y Yiliang Wang 1 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "Y Yifei Wang 1 ['Guangzhou Jinan Biomedicine Research and Development Center, College of Life Science and Technology, Jinan University, Guangzhou, China.']\n",
      "Progress in the Research and Development of Anti-COVID-19 Drugs. Frontiers in public health 2020-08-01\n",
      "S Shaimaa Soliman 1 ['Public health and Community Medicine, Menoufia University, Menoufia, Egypt.']\n",
      "Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biological trace element research 2020-11-29\n",
      "ES Eslam Saber Esmail 1 ['Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "M Mai Khalaf 1 ['Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "EF Ehab F Mostafa 1 ['Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.']\n",
      "Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biological trace element research 2020-11-29\n",
      "MA Mohammed A Medhat 1 ['Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.']\n",
      "Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biological trace element research 2020-11-29\n",
      "OA Ossama Ashraf Ahmed 1 ['Internal Medicine Department, Ain-shams University, Cairo, Egypt.']\n",
      "Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biological trace element research 2020-11-29\n",
      "MSA Mohamed Samir Abd El Ghafar 1 ['Department of Anesthesia, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "M Mohamed Alboraie 1 ['Department of Internal Medicine, Al-Azhar University, Cairo, Egypt.']\n",
      "Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biological trace element research 2020-11-29\n",
      "SM Sahar M Hassany 1 ['Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.']\n",
      "Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biological trace element research 2020-11-29\n",
      "R Rakesh Mittal 1 ['Department of Pharmacology, Pt. B D Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.']\n",
      "Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Medical hypotheses 2020-11-29\n",
      "N Neha Raina 1 ['Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, U.P. India.']\n",
      "Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design 2020-11-27\n",
      "S Safikur Rahman 1 ['Munshi Singh College, BR Ambedkar Bihar University, Muzaffarpur, Bihar 845401. India.']\n",
      "Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design 2020-11-27\n",
      "MA Mohammad Amjad Kamal 1 ['King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589. Saudi Arabia.']\n",
      "Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design 2020-11-27\n",
      "R Rodrigo Zoni 1 ['Instituto de Cardiología de Corrientes \"Juana F. Cabral\", Corrientes, Argentina. rodrizoni@yahoo.com.ar.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "M Maria Bangher 1 ['Instituto de Cardiología de Corrientes \"Juana F. Cabral\", Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "S Silvina Villamandos 1 ['Instituto de Cardiología de Corrientes \"Juana F. Cabral\", Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "A Angelina Bobadilla 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "F Fabian Plano 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "C Claudia Campias 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "E Evangelina Chaparro Campias 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "F Fernando Achinelli 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "HA Hector A Guglielmone 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "J Jorge Ojeda 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "F Fernanda Medina 1 ['Instituto de Cardiología de Corrientes \"Juana F. Cabral\", Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "D Diego Farizano Salazar 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "G Gerardo Andino 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "NE Natalia E Ruiz Diaz 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "P Pablo Kawerin 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "E Elba Meza 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "S Silvana Dellamea 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "A Antonia Aquino 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "V Victor Flores 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "CN Carolina N Martemucci 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "MM María Mercedes Vernengo 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "SM Silvina María Martinez 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "JE Juan Emanuel Segovia 1 ['Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "MG María Gabriela Aguirre 1 ['Instituto de Cardiología de Corrientes \"Juana F. Cabral\", Corrientes, Argentina.']\n",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020-11-26\n",
      "V Vijay Luxami 1 ['School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala-147004. India.']\n",
      "Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak. Mini reviews in medicinal chemistry 2020-11-26\n",
      "R Runjhun Tandon 1 ['School of Chemical Engineering and Physical Sciences, Lovely Professional University, Phagwara-144411. India.']\n",
      "Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak. Mini reviews in medicinal chemistry 2020-11-26\n",
      "K Kamaldeep Paul 1 ['School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala-147004. India.']\n",
      "Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak. Mini reviews in medicinal chemistry 2020-11-26\n",
      "A Ambra Di Altobrando 1 ['Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.']\n",
      "Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: Allergic contact dermatitis to fluconazole. Contact dermatitis 2020-11-25\n",
      "A Aurora Alessandrini 1 ['Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.']\n",
      "Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: Allergic contact dermatitis to fluconazole. Contact dermatitis 2020-11-25\n",
      "M Michela Starace 1 ['Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.']\n",
      "Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: Allergic contact dermatitis to fluconazole. Contact dermatitis 2020-11-25\n",
      "BM Bianca M Piraccini 1 ['Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.']\n",
      "Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: Allergic contact dermatitis to fluconazole. Contact dermatitis 2020-11-25\n",
      "C Colombina Vincenzi 1 ['Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.']\n",
      "Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: Allergic contact dermatitis to fluconazole. Contact dermatitis 2020-11-25\n",
      "J Jitender Madan 1 ['Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India.']\n",
      "Decoding the silent walk of COVID-19: Halting its spread using old bullets. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-11-24\n",
      "RK Rupinder Kaur Sodhi 1 ['Department of Pharmacology, Chandigarh College of Pharmacy, Mohali, Punjab, India.']\n",
      "Decoding the silent walk of COVID-19: Halting its spread using old bullets. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-11-24\n",
      "SB Shashi Bala Singh 1 ['Department of Pharmacology, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India.']\n",
      "Decoding the silent walk of COVID-19: Halting its spread using old bullets. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-11-24\n",
      "A Anju Katyal 1 ['Dr. B.R Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India. Electronic address: anju_katyal@yahoo.com.']\n",
      "Decoding the silent walk of COVID-19: Halting its spread using old bullets. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-11-24\n",
      "I Ilana Löwy 1 ['CERMES3 (INSERM/EHESS), Paris, France.']\n",
      "Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. Medical anthropology quarterly 2020-11-20\n",
      "GN Ghada N El-Sarnagawy 1 ['Assistant professor of forensic medicine and clinical toxicology, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "SM Shahinaz M Shalaby 1 ['Pharmacology Department, Tanta Medical School, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "M Mohamed Elbahnasawy 1 ['Emergency Medicine Department, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "A Asem Elfert 1 ['Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "H Hanan Soliman 1 ['Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "F Ferial El-Kalla 1 ['Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "A Ahmed Ghoneim 1 ['Opthalmology Department, Tanta University, Tanta. 0.']\n",
      "Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocrine, metabolic & immune disorders drug targets 2020-11-20\n",
      "K Kamalan Jeevaratnam 1 ['Faculty of Health and Medical Science, University of Surrey, Guildford GU2 7AL, United Kingdom.']\n",
      "Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2020-11-19\n",
      "M Mohd Athar 1 ['Center for Chemical Biology and Therapeutics, InStem, Bangalore, India.']\n",
      "Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2. Journal of biomolecular structure & dynamics 2020-11-18\n",
      "PC P C Jha 1 ['School of Applied Material Sciences, Central University of Gujarat, Gandhinagar, India.']\n",
      "Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2. Journal of biomolecular structure & dynamics 2020-11-18\n",
      "M Michael Whitehouse 1 ['Griffith University Gold Coast campus, PO Box 6168, Woolloongabba, QLD, 4102, Australia. whitehousemd@bigpond.com.']\n",
      "COVID-19 and nutriceutical therapies, especially using zinc to supplement antimicrobials. Inflammopharmacology 2020-11-17\n",
      "A Asmaa AbouBakr 1 ['COvid-19 Research of Assiut University Association (CORAUNA) group.\\nHouse-Officer, Faculty of Medicine, Assiut University, Egypt.']\n",
      "Rheumatoid Arthritis in the Era of COVID-19 Pandemic. Mediterranean journal of rheumatology 2020-11-17\n",
      "J Jordi Heijman 1 ['Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.']\n",
      "Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. Frontiers in physiology 2020-11-17\n",
      "Z Zhangren Chen 1 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "Y Yunyun Wang 1 ['Academic Affairs Office, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "S Simei Ren 1 ['National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Chinese Academy of Medical Sciences, Beijing, China.\\nBeijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, China.\\nGraduate School, Chinese Academy of Medical Sciences and Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "T Tiantian Xu 1 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "X Xin Lai 1 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "J Jinhua Wen 1 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "M Mengjun Zhao 1 ['The First Clinical Medical College of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "C Chuanfei Zeng 1 ['The First Clinical Medical College of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "L Lijuan Du 1 ['The First Clinical Medical College of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "Y Yanmei Zhang 1 ['The First Clinical Medical College of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "L Li Cao 1 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "J Jinfang Hu 1 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "X Xiaohua Wei 1 ['Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "T Tao Hong 1 ['Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.']\n",
      "Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. Frontiers in pharmacology 2020-11-17\n",
      "AP Alan P Robertson 1 ['Department of Biomedical Science, Iowa State University, Ames, IA 50011, USA.']\n",
      "Ivermectin: An Anthelmintic, an Insecticide, and Much More. Trends in parasitology 2020-11-16\n",
      "S Shivani Choudhary 1 ['Department of Biomedical Science, Iowa State University, Ames, IA 50011, USA.']\n",
      "Ivermectin: An Anthelmintic, an Insecticide, and Much More. Trends in parasitology 2020-11-16\n",
      "X Xiaoyu Yan 1 ['School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, 999077, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "X Xiaohan Wang 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.\\nSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "T Ting Cai 1 ['Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, HwaMei Hospital, University of Chinese Academy of Sciences (Ningbo No.2 Hospital), Ningbo, 315010, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "S Shun Zhang 1 ['Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, HwaMei Hospital, University of Chinese Academy of Sciences (Ningbo No.2 Hospital), Ningbo, 315010, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "X Xiaoxu Wang 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.\\nSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "Q Qi Liu 1 ['Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.\\nDepartment of Orthopedics, Peking University Third Hospital, Beijing, 100191, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "J Jing Lin 1 ['Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, HwaMei Hospital, University of Chinese Academy of Sciences (Ningbo No.2 Hospital), Ningbo, 315010, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "Z Zi Xiong 1 ['Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, HwaMei Hospital, University of Chinese Academy of Sciences (Ningbo No.2 Hospital), Ningbo, 315010, China.']\n",
      "Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European journal of clinical pharmacology 2020-11-15\n",
      "MR Mohd Razip Asaruddin 1 ['Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, 94300, Kota Samarahan, Sarawak, Malaysia. amrazip@unimas.my.']\n",
      "Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M BMC research notes 2020-11-13\n",
      "SA Showkat Ahamd Bhawani 1 ['Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, 94300, Kota Samarahan, Sarawak, Malaysia.']\n",
      "Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M BMC research notes 2020-11-13\n",
      "S Samsur Mohamad 1 ['Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, 94300, Kota Samarahan, Sarawak, Malaysia.']\n",
      "Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M BMC research notes 2020-11-13\n",
      "Z Zakariya Kashour 1 ['Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "O Oweida AlDosary 1 ['Infectious Diseases Section, Department of Medical Specialties, King Fahad Medical City, Riyadh, Saudi Arabia.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "M Muhammad Riaz 1 ['Department of Statistics, Quaid Azam University Islamabad, Pakistan.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "H Haytham Tlayjeh 1 ['Department of Intensive Care, King Abdulaziz Medical City, King Saud bin Abdulaziz for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "MA Musa A Garbati 1 ['Infectious Diseases Unit, Department of Medicine, University of Maiduguri, Maiduguri, Nigeria.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "R Rana Tleyjeh 1 ['College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "MH Mouaz H Al-Mallah 1 ['Houston Methodist DeBakey Heart and Vascular Center, Houston, TX.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "MR M Rizwan Sohail 1 ['Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN.\\nDepartment of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "D Dana Gerberi 1 ['Mayo Clinic Libraries, Mayo Clinic, Rochester, MN.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "AA Aref A Bin Abdulhak 1 ['Swedish Heart and Vascular Institute, Swedish Medical Center, Seattle, WA.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "JR John R Giudicessi 1 ['Department of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "MJ Michael J Ackerman 1 ['Division of Heart Rhythm Services, Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN.\\nDepartment of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN.\\nDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "T Tarek Kashour 1 ['Department of Cardiac Sciences, King Fahad Cardiac Center, King Saud University Medical City, Riyadh, Saudi Arabia.']\n",
      "Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes 2020-11-10\n",
      "W Wilson Xu 1 ['Department of Internal Medicine, Cardiology, University of California, Davis, Davis, CA, United States.']\n",
      "Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2020-11-07\n",
      "JL James L Overton 1 ['Department of Internal Medicine, Cardiology, University of California, Davis, Davis, CA, United States.']\n",
      "Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2020-11-07\n",
      "S Shandong Yu 1 ['Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.']\n",
      "Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2020-11-07\n",
      "N Nipavan Chiamvimonvat 1 ['Department of Internal Medicine, Cardiology, University of California, Davis, Davis, CA, United States.\\nDepartment of Veteran Affairs, Northern California Health Care System, Mather, CA, United States.']\n",
      "Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2020-11-07\n",
      "PN Phung N Thai 1 ['Department of Internal Medicine, Cardiology, University of California, Davis, Davis, CA, United States.']\n",
      "Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2020-11-07\n",
      "N Neil Andersson 1 ['Community Information and Epidemiological Technologies']\n",
      "Chloroquine and its derivatives in the management of COVID-19: A scoping review Biomedica : revista del Instituto Nacional de Salud 2020-11-06\n",
      "IM Ismail M Taban 1 ['School of Biosciences, Cardiff University, Cardiff, U.K.\\nDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Misurata University, Misurata, Libya.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "EEM Eltayeb E M Eid 1 ['Department of Pharmaceutical Chemistry & Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "M Muzaffar Iqbal 1 ['Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "O Ozair Alam 1 ['Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, New Delhi, India.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "S Shamshir Khan 1 ['Department of Pharmaceutical Chemistry, Dentistry and Pharmacy College, Buraydah Private Colleges, Buraydah, Al-Qassim.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "D Danish Mahmood 1 ['Department of Pharmacology & Toxicology, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "MJ Md Jamir Anwar 1 ['Department of Pharmacology & Toxicology, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "H Habibullah Khalilullah 1 ['Department of Pharmaceutical Chemistry & Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "MU M U Khan 1 ['Department of Pharmaceutical Chemistry & Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.']\n",
      "An  Journal of biomolecular structure & dynamics 2020-11-03\n",
      "Z Zvi Loewy 1 ['Touro College of Pharmacy, New York, NY, USA.\\nNew York Medical College, Valhalla, NY, USA.']\n",
      "Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. Pharmacogenomics and personalized medicine 2020-10-31\n",
      "S Satyaranjan Biswal 1 ['Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, India.']\n",
      "Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with  Journal of biomolecular structure & dynamics 2020-10-29\n",
      "SK Saroj Kumar Panda 1 ['Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, India.']\n",
      "Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with  Journal of biomolecular structure & dynamics 2020-10-29\n",
      "AK Abhik Kumar Ray 1 ['Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, India.']\n",
      "Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with  Journal of biomolecular structure & dynamics 2020-10-29\n",
      "MK Malay Kumar Rana 1 ['Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, India.']\n",
      "Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with  Journal of biomolecular structure & dynamics 2020-10-29\n",
      "NTP Nguyen Thi Phuong Dung 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "Y Yen Lam Minh 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "LM Le Manh Hung 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NM Nguyen Minh Quan 1 ['Thu Duc Hospital, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NT Nguyen Thanh Dung 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NNQ Ngo Ngoc Quang Minh 1 [\"Children's Hospital 1, Ho Chi Minh City, Vietnam.\"]\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "TC Tran Chanh Xuan 1 ['Cu Chi field hospital, Cu Chi, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NT Nguyen Thanh Phong 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "V Van Ninh Thi Thanh 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "J Joseph Donovan 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.\\nCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "TNH Tran Nguyen Hoang Tu 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "LTH Le Thanh Hoang Nhat 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NT Nguyen Thanh Truong 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "DNH Dinh Nguyen Huy Man 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "HP Huynh Phuong Thao 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NM Nghiêm My Ngoc 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "VT Vo Thanh Lam 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "HH Huynh Hong Phat 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "PM Phan Minh Phuong 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "RB Ronald B Geskus 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.\\nCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "VTN Vo Thi Nhi Ha 1 ['Administration of Science, Technology and Training (ASTT), Ministry of Health, Hanoi, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NN Nguyen Ngo Quang 1 ['Administration of Science, Technology and Training (ASTT), Ministry of Health, Hanoi, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "H Hien Tran Tinh 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.\\nCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "LV Le Van Tan 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "GE Guy E Thwaites 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.\\nCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "JN Jeremy N Day 1 ['Oxford University Clinical Research Unit, University of Oxford, Ho Chi Minh City, Vietnam.\\nCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "NVV Nguyen Van Vinh Chau 1 ['Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.']\n",
      "A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome open research 2020-10-29\n",
      "GF Gijs F Kapel 1 ['Department of Cardiology, Medisch Spectrum Twente, Enschede, The Netherlands.']\n",
      "Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report. European heart journal. Case reports 2020-10-23\n",
      "J Jurren van Opstal 1 ['Department of Cardiology, Medisch Spectrum Twente, Enschede, The Netherlands.']\n",
      "Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report. European heart journal. Case reports 2020-10-23\n",
      "PFHM Pascal F H M van Dessel 1 ['Department of Cardiology, Medisch Spectrum Twente, Enschede, The Netherlands.']\n",
      "Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report. European heart journal. Case reports 2020-10-23\n",
      "P P Colson 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "Y Y Roussel 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "G G Dubourg 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "E E Chabriere 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "S S Honore 1 ['Service de Pharmacie, Hôpital Timone, AP-HM, Marseille, France.\\nLaboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "JM J-M Rolain 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "F F Fenollar 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "PE P-E Fournier 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "JC J-C Lagier 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "P P Parola 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "P P Brouqui 1 ['IHU-Méditerranée Infection, Marseille, France.\\nAix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New microbes and new infections 2020-10-23\n",
      "K Khaled Alswat 1 ['Department of internal medicine, Collage of medicine, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.']\n",
      "Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. Journal of molecular structure 2020-10-22\n",
      "WF Walaa F Alsanie 1 ['Department of Clinical Laboratories Science, Collage of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.']\n",
      "Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. Journal of molecular structure 2020-10-22\n",
      "MM Mohamed M Ibrahim 1 ['Department of Chemistry, Collage of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.\\nChemistry Department, Faculty of Science, Kafrelsheikh University, 33516 Kafr ElSheikh, Egypt.']\n",
      "Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. Journal of molecular structure 2020-10-22\n",
      "A Ali Aldalbahi 1 ['Department of Chemistry, College of Sciences, King Saud University, Riyadh 11451, Saudi Arabia.']\n",
      "Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. Journal of molecular structure 2020-10-22\n",
      "HS Hamdy S El-Sheshtawy 1 ['Chemistry Department, Faculty of Science, Kafrelsheikh University, 33516 Kafr ElSheikh, Egypt.']\n",
      "Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. Journal of molecular structure 2020-10-22\n",
      "A Ashutosh Yadav 1 ['Department of Cardiology, Fortis Hospital, Mohali, Punjab, India.']\n",
      "Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. Indian pacing and electrophysiology journal 2020-10-20\n",
      "P Praveen Kumar-M 1 ['Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.']\n",
      "Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. Indian pacing and electrophysiology journal 2020-10-20\n",
      "A Ankur Gupta 1 ['Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: ag_pgi@yahoo.com.']\n",
      "Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. Indian pacing and electrophysiology journal 2020-10-20\n",
      "K Kenzo Nera 1 ['Center for Social and Cultural Psychology, Université Libre de Bruxelles, Brussels, Belgium.\\nFonds de la Recherche Scientifique (FRS), Bruxelles, Belgium.']\n",
      "Conspiracy Beliefs, Rejection of Vaccination, and Support for hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19 Pandemic Context. Frontiers in psychology 2020-10-20\n",
      "S Sylvain Delouvée 1 ['EA1285 Laboratoire de Psychologie, Cognition, Comportement, Communication (LP3C), University of Rennes, Rennes, France.']\n",
      "Conspiracy Beliefs, Rejection of Vaccination, and Support for hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19 Pandemic Context. Frontiers in psychology 2020-10-20\n",
      "D Didier Collard 1 ['Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "S Sander Van Assen 1 ['Treant Zorggroep, Department of Internal Medicine/Infectious Diseases, Emmen, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "M Martijn Beudel 1 ['Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience Institute, Amsterdam, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "MK Marije K Bomers 1 ['Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "J Jacqueline Buijs 1 ['Zuyderland Medical Center, Department of Internal Medicine, Heerlen/Sittard, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "LR Lianne R De Haan 1 ['Flevoziekenhuis, Department of Internal Medicine, Almere, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "W Wouter De Ruijter 1 ['Noordwest Ziekenhuisgroep, Intensive Care Unit, Alkmaar, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "RA Renée A Douma 1 ['Flevoziekenhuis, Department of Internal Medicine, Almere, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "PW Paul Wg Elbers 1 ['Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Intensive Care Medicine, Amsterdam Medical Data Science, Amsterdam Cardiovascular Sciences, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "A Abraham Goorhuis 1 ['Amsterdam UMC, University of Amsterdam, Department of Infectious Diseases, Amsterdam, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "NC Niels C Gritters van den Oever 1 ['Treant Zorggroep, Intensive Care Unit, Emmen, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "LG Lieve Ghh Knarren 1 ['Viecuri MC Noord-Limburg, Department of Internal Medicine, Venlo, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "HS Hazra S Moeniralam 1 ['St Antonius Ziekenhuis, Department of Internal Medicine and Intensive Care Unit, Nieuwegein, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "RL Remy Lm Mostard 1 ['Zuyderland Medical Center, Department of Pulmonology, Heerlen/Sittard, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "MJ Marian Jr Quanjel 1 ['St Antonius Ziekenhuis, Department of Pulmonology, Nieuwegein, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "AC Auke C Reidinga 1 ['Martini Hospital, Intensive Care Unit, Groningen, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "R Roos Renckens 1 ['Noordwest Ziekenhuisgroep, Department of Internal Medicine, Alkmaar, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "JP Joop Pw Van Den Bergh 1 ['Viecuri MC Noord-Limburg, Department of Internal Medicine, Venlo, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "IN Imro N Vlasveld 1 ['Martini Hospital, Intensive Care Unit, Groningen, the Netherlands; Martini Hospital, Department of Internal Medicine, Groningen, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "JJ Jonne J Sikkens 1 ['Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.']\n",
      "Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020-10-18\n",
      "MS Michael S Sherman 1 ['Drexel University College of Medicine, Philadelphia, PA.']\n",
      "Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest 2020-10-17\n",
      "N Naaz Fatteh 1 ['Broward Health Medical Center, Fort Lauderdale, FL.']\n",
      "Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest 2020-10-17\n",
      "F Fabio Vogel 1 ['Broward Health Medical Center, Fort Lauderdale, FL.']\n",
      "Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest 2020-10-17\n",
      "J Jamie Sacks 1 ['Broward Health Medical Center, Fort Lauderdale, FL.']\n",
      "Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest 2020-10-17\n",
      "JJ Jean-Jacques Rajter 1 ['Broward Health Medical Center, Fort Lauderdale, FL; Florida International University, Miami, FL. Electronic address: covid19@pscflorida.com.']\n",
      "Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest 2020-10-17\n",
      "O Omar Hegazy 1 ['Internal Medicine, Mercy Hospital, Chicago, USA.']\n",
      "Ivermectin: A Closer Look at a Potential Remedy. Cureus 2020-10-17\n",
      "B Burak Erdinc 1 ['Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.']\n",
      "Ivermectin: A Closer Look at a Potential Remedy. Cureus 2020-10-17\n",
      "H Hesham Abowali 1 ['Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.']\n",
      "Ivermectin: A Closer Look at a Potential Remedy. Cureus 2020-10-17\n",
      "N Nayla Ahmed 1 ['Section of Hospital Medicine, Dartmouth-Hitchcock Medical Center']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "N Nausheen Ahmed 1 ['Section of Hematology Oncology, Bone Marrow Transplant and Cellular Therapy, University Of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA.']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "R Ryan Ratts 1 ['Section of Hospital Medicine, Dartmouth-Hitchcock Medical Center']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "S Shine Raju 1 ['Section of Pulmonary and Critical Care, University Hospitals Cleveland Medical Center']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "M Molly Gallogly 1 ['Section of Hematology Oncology, Stem Cell Transplant and Cellular Therapeutics, University Hospitals Seidman Cancer Center']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "M Marcos de Lima 1 ['Section of Hematology Oncology, Stem Cell Transplant and Cellular Therapeutics, University Hospitals Seidman Cancer Center']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "MR Muhammad Rizwan Sohail 1 ['Section of Infectious Diseases and Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, 200 1st St SW, Rochester, MN, 55905, USA. sohailmd@mac.com.']\n",
      "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal 2020-10-17\n",
      "MTI Md Tawkat Islam Khondaker 1 ['Department of Computer Science and Engineering, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "IT Iram Tazim Hoque 1 ['Department of Computer Science and Engineering, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "HRH Hamada R H Al-Absi 1 ['College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "MS Mohammad Saifur Rahman 1 ['Department of Computer Science and Engineering, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "R Reto Guler 1 ['International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.\\nDivision of Immunology and South African Medical Research Council Immunology of Infectious Diseases, Department of Pathology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.\\nWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "T Tanvir Alam 1 ['College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "MS M Sohel Rahman 1 ['Department of Computer Science and Engineering, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh.']\n",
      "Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR medical informatics 2020-10-16\n",
      "SG Sherihan G Abdelhamid 1 ['Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.']\n",
      "Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. Informatics in medicine unlocked 2020-10-15\n",
      "AA AbdelKader A Metwally 1 ['Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.\\nDepartment of Pharmaceutics, Faculty of Pharmacy, Health Sciences Center, Kuwait University, Kuwait.']\n",
      "Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. Informatics in medicine unlocked 2020-10-15\n",
      "BH Brian H Rowe 1 ['Department of Emergency Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.\\nSchool of Public Health, University of Alberta, Edmonton, AB, Canada.']\n",
      "Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. British journal of clinical pharmacology 2020-10-14\n",
      "R R González-Cuevas 1 ['Servicio de Dermatología, Hospital del Salvador, Santiago, Chile. Electronic address: ruben.gonzalez.c@gmail.com.']\n",
      "Familiar Dermatologic Drugs as Therapies for COVID-19. Actas dermo-sifiliograficas 2020-10-13\n",
      "L Lei Chen 1 ['Department of Genetics, Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ, 08854, USA. Electronic address: lchen@dls.rutgers.edu.']\n",
      "Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. European journal of pharmacology 2020-10-09\n",
      "M Maria de Nazaré Correia Soeiro 1 ['Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro. Brazil.']\n",
      "Quinoline-based Compounds as Key Candidates to Tackle Drug Discovery Programs of Microbicidal Agents. Current pharmaceutical design 2020-10-08\n",
      "JC Jaap C Hanekamp 1 ['University College Roosevelt, Lange Noordstraat 1, NL-4331 CB Middelburg, the Netherlands. Electronic address: j.hanekamp@ucr.nl.']\n",
      "Chloroquine commonly induces hormetic dose responses. The Science of the total environment 2020-10-06\n",
      "YN Yannic N Hanekamp 1 ['University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.']\n",
      "Chloroquine commonly induces hormetic dose responses. The Science of the total environment 2020-10-06\n",
      "R Rachna Kapoor 1 ['Saint Francis Hospital and Medical Center, Hartford, CT, United States of America.']\n",
      "Chloroquine commonly induces hormetic dose responses. The Science of the total environment 2020-10-06\n",
      "G Gaurav Dhawan 1 ['University of Massachusetts, Human Research Protection Office, Research Compliance, University of Massachusetts, Mass Venture Center, Hadley, MA 01035, United States of America.']\n",
      "Chloroquine commonly induces hormetic dose responses. The Science of the total environment 2020-10-06\n",
      "E Evgenios Agathokleous 1 ['Key Laboratory of Agrometeorology of Jiangsu Province, Institute of Ecology, School of Applied Meteorology, Nanjing University of Information Science & Technology, Nanjing 210044, China. Electronic address: evgenios@nuist.edu.cn.']\n",
      "Chloroquine commonly induces hormetic dose responses. The Science of the total environment 2020-10-06\n",
      "RM R M Brohet 1 ['Department of Epidemiology and Statistics, Isala Academy, Zwolle, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "REP R E P Theunissen 1 ['Isala, Zwolle, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "C C Koster 1 ['Isala, Zwolle, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "R R Rood 1 ['Diakonessen Hospital, Utrecht, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "DWM D W M Verhagen 1 ['Medisch Centrum Jan van Goyen, Amsterdam, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "K K Brinkman 1 ['OLVG, Amsterdam, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "RJ R J Hassing 1 ['Rijnstate, Arnhem, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "A A Dofferhoff 1 ['Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "R R El Moussaoui 1 ['Maasstad Hospital Rotterdam, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "G G Hermanides 1 ['Rode Kruis Hospital, Beverwijk, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "J J Ellerbroek 1 ['Reinier de Graaf Gasthuis, Delft, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "N N Bokhizzou 1 ['BovenIJ Hospital, Amsterdam, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "H H Visser 1 ['Beatrix Hospital Gorinchem, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "M M van den Berge 1 ['Admiraal de Ruiter Hospital, Goes, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "H H Bax 1 ['Erasmus MC Rotterdam, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "DF D F Postma 1 ['University Medical Center Groningen, Groningen, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "PHP P H P Groeneveld 1 ['Isala, Zwolle, The Netherlands.']\n",
      "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "MA Muhammad Abdul Hadi 1 ['School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.']\n",
      "Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "AMN Albaraa Mohammed N Marran 1 ['Department of Pharmaceutical Care, Prince Mohammed Bin Nasser Hospital, Jizan, Saudi Arabia.']\n",
      "Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-10-03\n",
      "HA Hamid A Merchant 1 ['School of Applied Sciences, University of Huddersfield, Huddersfield, UK.']\n",
      "The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological reports : PR 2021-03-30\n",
      "SS Syed Shahzad Hasan 1 ['School of Applied Sciences, University of Huddersfield, Huddersfield, UK.\\nSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia.']\n",
      "The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological reports : PR 2021-03-30\n",
      "M Massimiliano Peana 1 ['Department of Chemistry and Pharmacy, University of Sassari, Via Vienna 2, 07100, Sassari, Italy. peana@uniss.it.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Applied microbiology and biotechnology 2021-01-31\n",
      "S Sadaf Noor 1 ['Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Applied microbiology and biotechnology 2021-01-31\n",
      "R Roman Lysiuk 1 ['Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.\\nCONEM Ukraine Life Science Research Group, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Applied microbiology and biotechnology 2021-01-31\n",
      "A Alain Menzel 1 ['Laboratoires Réunis, Junglinster, Luxembourg.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Applied microbiology and biotechnology 2021-01-31\n",
      "A Asma Gasmi Benahmed 1 ['Académie Internationale de Médecine Dentaire Intégrative, Paris, France.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Applied microbiology and biotechnology 2021-01-31\n",
      "G Geir Bjørklund 1 ['Council for Nutritional and Environmental Medicine (CONEM), Toften 24, 8610, Mo i Rana, Norway. bjorklund@conem.org.']\n",
      "Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Applied microbiology and biotechnology 2021-01-31\n",
      "DJ David J Blok 1 ['Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "M Martin Walker 1 [\"London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk Place, London W2\\xa01PG, UK.\\nLondon Centre for Neglected Tropical Disease Research (LCNTDR), Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, Hatfield AL9\\xa0 7TA, UK.\"]\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "P Philip Milton 1 [\"London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk Place, London W2\\xa01PG, UK.\\nMRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk Place, London W2\\xa01PG, UK.\"]\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "AD Adrian D Hopkins 1 ['Neglected and Disabling Diseases of Poverty Consultant, Kent, UK.']\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "LC Louise C Hamill 1 ['Sightsavers, 35 Perrymount Road, Haywards Heath, RH16\\xa03BW, UK.']\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "P Philip Downs 1 ['Sightsavers, 35 Perrymount Road, Haywards Heath, RH16\\xa03BW, UK.']\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "SJ Sake J de Vlas 1 ['Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "WA Wilma A Stolk 1 ['Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "MG Maria-Gloria Basáñez 1 [\"London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk Place, London W2\\xa01PG, UK.\\nMRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk Place, London W2\\xa01PG, UK.\"]\n",
      "What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene 2021-01-31\n",
      "H Helen Guo 1 ['Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, 94720, USA.']\n",
      "Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Advances in biomarker sciences and technology 2021-01-30\n",
      "B B Tuzun 1 [' ']\n",
      "Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratislavske lekarske listy 2021-01-28\n",
      "A A Aktas 1 [' ']\n",
      "Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratislavske lekarske listy 2021-01-28\n",
      "K K Sayin 1 [' ']\n",
      "Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratislavske lekarske listy 2021-01-28\n",
      "H H Ataseven 1 [' ']\n",
      "Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratislavske lekarske listy 2021-01-28\n",
      "LN Li-Na Chen 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Artemisinin Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "SQ Shui-Qing Qu 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "SQ Shuo-Qiu Deng 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Artemisinin Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "H Hui Liu 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "X Xi Wang 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Pharmacy, Shanxi Medical University Taiyuan 030001, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "XG Xiao-Gang Weng 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "YJ Ya-Jie Wang 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "XX Xiao-Xin Zhu 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "YJ Yu-Jie Li 1 ['Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Artemisinin Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.']\n",
      "[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021-01-27\n",
      "A Andrés Blanco-Di Matteo 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "I Iñigo Pineda 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "A Alejandro Fernandez-Montero 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "M Mariano Rodríguez-Mateos 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "C Carlota Jordán-Iborra 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "E Ester Laso 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "JC Juan C Gabaldón-Figueira 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "JR José R Yuste 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "JL Jose L Del Pozo 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "NR N Regina Rabinovich 1 ['ISGlobal, Hospital Clínic']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "V Verena Schöning 1 ['Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "M Mirian Fernández-Alonso 1 ['Clínica Universidad de Navarra, Pamplona, Spain.']\n",
      "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021-01-27\n",
      "G Graciela Vecchioli 1 ['INCAM S.A, Cañuelas, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "L Laura Ceballos 1 ['Laboratorio de Farmacología, Centro de Investigación Veterinarias de Tandil (CIVETAN), CONICET-CICPBA-UNCPBA, Facultad de Ciencias Veterinarias, Universidad Nacional Del Centro de La Provincia de Buenos Aires, Tandil, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "F Francisco Errecalde 1 ['INCAM S.A, Cañuelas, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "M Mariana Ballent 1 ['Laboratorio de Farmacología, Centro de Investigación Veterinarias de Tandil (CIVETAN), CONICET-CICPBA-UNCPBA, Facultad de Ciencias Veterinarias, Universidad Nacional Del Centro de La Provincia de Buenos Aires, Tandil, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "G Gustavo Marín 1 ['Cátedra de Farmacología Básica, General y Farmacodinamia, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "M Martín Daniele 1 ['Cátedra de Farmacología, Farmacotecnia y Terapéutica, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "E Esteban Turic 1 ['Biogenesis Bagó SRL, Garín, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "E Eduardo Spitzer 1 ['Laboratorio Elea Phoenix S.A., Buenos Aires, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "F Fernando Toneguzzo 1 ['Laboratorio Elea Phoenix S.A., Buenos Aires, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "S Silvia Gold 1 ['Laboratorio Elea Phoenix S.A., Buenos Aires, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "A Alejandro Krolewiecki 1 ['Instituto de Investigaciones de Enfermedades Tropicales, Universidad Nacional de Salta, Orán, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "L Luis Alvarez 1 ['Laboratorio de Farmacología, Centro de Investigación Veterinarias de Tandil (CIVETAN), CONICET-CICPBA-UNCPBA, Facultad de Ciencias Veterinarias, Universidad Nacional Del Centro de La Provincia de Buenos Aires, Tandil, Argentina.']\n",
      "Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences 2021-01-26\n",
      "A A Neuberger 1 ['Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.\\nDivision of Internal Medicine, Rambam Health Care Campus, Haifa, Israel.\\nDivision of Internal Medicine, Unit of Infectious Diseases, Rambam Healthcare Campus, Haifa, Israel.']\n",
      "From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Journal of travel medicine 2021-01-23\n",
      "AJ A J Domb 1 ['Institute of Drug Research, School of Pharmacy-Faculty of Medicine & Institute of Criminology']\n",
      "From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Journal of travel medicine 2021-01-23\n",
      "N N Petersiel 1 ['Division of Internal Medicine, Unit of Infectious Diseases, Rambam Healthcare Campus, Haifa, Israel.']\n",
      "From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Journal of travel medicine 2021-01-23\n",
      "E E Schwartz 1 ['Sheba Medical Center, Geographic Medicine and Tropical Diseases, Ramat Gan, Israel.\\nFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.']\n",
      "From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Journal of travel medicine 2021-01-23\n",
      "ACWH Aïtchéou Cadnel Wilfried Houedenou Noudohounsi 1 ['Intensive Care Unit, University Hospital Center Hubert Koutoukou MAGA, Cotonou, Benin.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "LF Lounceny Fatoumata Barry 1 ['Neurosurgery Department, Ignace Deen University Hospital Center, Conakry, Guinea.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "MMUD Mahugnon Maurel Ulrich Dénis Noudohounsi 1 ['Intensive Care Unit, University Hospital Center Hubert Koutoukou MAGA, Cotonou, Benin.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "LD Lauréano Déo-Gratias Legba 1 ['Intensive Care Unit, University Hospital Center Hubert Koutoukou MAGA, Cotonou, Benin.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "IS Ibrahima Sory Souare 1 ['Neurosurgery Department, Ignace Deen University Hospital Center, Conakry, Guinea.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "F Fatoumata Kaba 1 ['Neurosurgery Department, Ignace Deen University Hospital Center, Conakry, Guinea.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "DS Dismand Stephan Houinato 1 ['Public Health Physician, Research Project Manager, Brazzaville, Congo.']\n",
      "COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). The Pan African medical journal 2021-01-16\n",
      "R Rajiv Chawla 1 ['Department of Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, New Delhi, India.']\n",
      "Cancer in corona times. Saudi journal of anaesthesia 2021-01-16\n",
      "G Giuliana Scarpati 1 ['Department of Medicine, Surgery and Dentistry, \"Scuola Medica Salernitana\", Unit of Anesthesiology, University of Salerno, Baronissi, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "C Carmine Sellitto 1 ['Department of Medicine, Surgery and Dentistry, \"Scuola Medica Salernitana\", Unit of Pharmacology, University of Salerno, Baronissi, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "V Valeria Conti 1 ['Department of Medicine, Surgery and Dentistry, \"Scuola Medica Salernitana\", Unit of Pharmacology, University of Salerno, Baronissi, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "AM Anna Maria Spera 1 ['Department of Medicine, Surgery and Dentistry, \"Scuola Medica Salernitana\", Unit of Infectious Diseases, University of Salerno, Baronissi, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "T Tiziana Ascione 1 ['Department of Medicine, Service of Infectious Diseases, Cardarelli Hospital, Naples, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "O Ornella Piazza 1 ['Department of Medicine, Surgery and Dentistry, \"Scuola Medica Salernitana\", Unit of Anesthesiology, University of Salerno, Baronissi, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "A Amelia Filippelli 1 ['Department of Medicine, Surgery and Dentistry, \"Scuola Medica Salernitana\", Unit of Pharmacology, University of Salerno, Baronissi, Italy.']\n",
      "Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of experimental pharmacology 2021-01-15\n",
      "J Jianbing Hu 1 [\"State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, People's Republic of China. 378704627@qq.com.\"]\n",
      "Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in current chemistry (Cham) 2021-01-12\n",
      "D Dian Li 1 [\"Department of Modern Economy and Trade, Hunan Vocational College of Engineering, Changsha, 410151, People's Republic of China.\"]\n",
      "Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in current chemistry (Cham) 2021-01-12\n",
      "W Weijun Yang 1 [\"State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, People's Republic of China. wjyang@hnu.edu.cn.\"]\n",
      "Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in current chemistry (Cham) 2021-01-12\n",
      "SF Shuang-Feng Yin 1 [\"State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, People's Republic of China.\"]\n",
      "Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in current chemistry (Cham) 2021-01-12\n",
      "R Renhua Qiu 1 [\"State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, People's Republic of China. qiurh@qq.com.\"]\n",
      "Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in current chemistry (Cham) 2021-01-12\n",
      "F Faruku Bande 1 ['Department of Veterinary Microbiology, Faculty of Veterinary Medicine, Bayero University Kano, Kano, Nigeria.']\n",
      "Therapeutic options for COVID-19: a quick review. Journal of chemotherapy (Florence, Italy) 2021-01-12\n",
      "A Aminu Ishaka 1 ['Department of Medical Biochemistry, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.']\n",
      "Therapeutic options for COVID-19: a quick review. Journal of chemotherapy (Florence, Italy) 2021-01-12\n",
      "AA Aminatu Abubakar Sani 1 ['Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Usmanu Danfodiyo University, Sokoto, Nigeria.']\n",
      "Therapeutic options for COVID-19: a quick review. Journal of chemotherapy (Florence, Italy) 2021-01-12\n",
      "K Karla Georges 1 ['Deparment of Basic Veterinary Sciences, School of Veterinary Medicine, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.']\n",
      "Therapeutic options for COVID-19: a quick review. Journal of chemotherapy (Florence, Italy) 2021-01-12\n",
      "F Fariba Pourkarim 1 ['Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacology research & perspectives 2021-01-10\n",
      "S Samira Pourtaghi-Anvarian 1 ['Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacology research & perspectives 2021-01-10\n",
      "T Taher Entezari-Maleki 1 ['Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacology research & perspectives 2021-01-10\n",
      "T Touraj Asvadi-Kermani 1 ['Department of Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.']\n",
      "Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacology research & perspectives 2021-01-10\n",
      "M Masoud Nouri-Vaskeh 1 ['Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.\\nNetwork of Immunity in Infection, Malignancy and Autoimmunity (NIIMA, Universal Scientific Education and Research Network (USERN, Tehran, Iran.']\n",
      "Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacology research & perspectives 2021-01-10\n",
      "B Bijan Keikhaei 1 ['Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.']\n",
      "Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? Naunyn-Schmiedeberg's archives of pharmacology 2021-01-09\n",
      "A Ali Saeedi-Boroujeni 1 ['Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.\\nImmunologyToday, Universal Scientific Education and Research Network (USERN), Tehran, Iran.']\n",
      "Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? Naunyn-Schmiedeberg's archives of pharmacology 2021-01-09\n",
      "MR Mohammad-Reza Mahmoudian-Sani 1 ['Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. mohamadsani495@gmail.com.']\n",
      "Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? Naunyn-Schmiedeberg's archives of pharmacology 2021-01-09\n",
      "J Jinxin Zheng 1 ['National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, China.\\nKey Laboratory of Parasite and Vector Biology, Ministry of Health, Shanghai, 200025, China.\\nChinese Center for Tropical Diseases Research, Shanghai, 200025, China.\\nWHO Collaborating Centre for Tropical Diseases, Shanghai, 200025, China.\\nNational Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, 200025, China.\\nSchool of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "S Shang Xia 1 ['National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, China.\\nKey Laboratory of Parasite and Vector Biology, Ministry of Health, Shanghai, 200025, China.\\nChinese Center for Tropical Diseases Research, Shanghai, 200025, China.\\nWHO Collaborating Centre for Tropical Diseases, Shanghai, 200025, China.\\nNational Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, 200025, China.\\nSchool of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "S Shan Lin 1 ['College of Information Engineering, Nanjing University of Finance & Economics, Nanjing, 210003, Jiangsu, China.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "X Xinyi Wang 1 ['National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, China.\\nKey Laboratory of Parasite and Vector Biology, Ministry of Health, Shanghai, 200025, China.\\nChinese Center for Tropical Diseases Research, Shanghai, 200025, China.\\nWHO Collaborating Centre for Tropical Diseases, Shanghai, 200025, China.\\nNational Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, 200025, China.\\nSchool of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "Y Yang Liu 1 ['Department of Computer Science, Hong Kong Baptist University, Hong Kong, China.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "XN Xiao-Nong Zhou 1 ['National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, China.\\nKey Laboratory of Parasite and Vector Biology, Ministry of Health, Shanghai, 200025, China.\\nChinese Center for Tropical Diseases Research, Shanghai, 200025, China.\\nWHO Collaborating Centre for Tropical Diseases, Shanghai, 200025, China.\\nNational Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, 200025, China.\\nSchool of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "J Jiming Liu 1 ['Department of Computer Science, Hong Kong Baptist University, Hong Kong, China. jiming@comp.hkbu.edu.hk.']\n",
      "Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infectious diseases of poverty 2021-01-09\n",
      "I Ian Huang 1 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "E Erwan Martanto 1 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "TA Teddy Arnold Sihite 1 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "ES Eka Surya Nugraha 1 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "S Susantina Prodjosoewojo 1 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "L Laniyati Hamijoyo 1 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "Y Yovita Hartantri 1 ['Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.']\n",
      "Lethal Arrhythmia ( Clinical medicine insights. Case reports 2021-01-07\n",
      "A Alireza Malektojari 1 ['Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "S Sara Ghazizadeh 1 ['Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "M Mehdi Hassaniazad 1 ['Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "P Parivash Davoodian 1 ['Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "H Habib Dadvand 1 ['Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "AR Amin Reza Nikpoor 1 ['Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "S Sara Nikoofal-Sahlabadi 1 ['Department of Pharmaceutics, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "S Sara Kahoori 1 ['Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "M Mojtaba Sepandi 1 ['Department of Epidemiology and Biostatistics, Faculty of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "S Soheil Hassanipour 1 ['Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "M Mohammad Fathalipour 1 ['Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. m.fathalipour@hums.ac.ir.']\n",
      "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021-01-06\n",
      "AS Aneesa Shahul S 1 ['Department of Pulmonary Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "MK M K Garg 1 ['Department of General Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "VL Vijaya Lakshmi Nag 1 ['Department of Microbiology, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "PK Pradeep Kumar Bhatia 1 ['Department of Anaesthesiology & Critical Care, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "N Naveen Dutt 1 ['Department of Pulmonary Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "N Nishant Chauhan 1 ['Department of Pulmonary Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "J Jaykaran Charan 1 ['Department of Pharmacology, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "S Shahir Asfahan 1 ['Department of Pulmonary Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "P Praveen Sharma 1 ['Department of Biochemistry, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "P Pankaj Bhardwaj 1 ['Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "M Mithu Banerjee 1 ['Department of Biochemistry, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "P Pawan Garg 1 ['Department of Diagnostic & Interventional Radiology, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "B Binit Sureka 1 ['Department of Diagnostic & Interventional Radiology, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "GK Gopal Krishna Bohra 1 ['Department of General Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "M Maya Gopalakrishnan 1 ['Department of General Medicine, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "S Sanjeev Misra 1 ['Department of Surgical Oncology, All India Institute of Medical Sciences Jodhpur, India.']\n",
      "Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. Advances in respiratory medicine 2021-01-05\n",
      "DP Dominique P Germain 1 ['Division of Medical Genetics, University of Versailles, AP-HP Paris Saclay University, Paris, France.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "JP João Paulo Oliveira 1 ['Centro Hospitalar Universitário de São João & Faculdade de Medicina da Universidade do Porto, Porto, Portugal.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "AP Alessandro P Burlina 1 ['Neurology Unit, St Bassiano Hospital, Bassano del Grappa, Italy.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "GH Gustavo Horacio Cabrera 1 ['Santa Maria de la Salud, San Isidro, Provincia de Buenos Aires, Argentina.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "GR Geu-Ru Hong 1 ['Department of Cardiology, Yonsei University Severance Hospital, Seoul, Korea.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "RJ Robert J Hopkin 1 [\"Division of Human Genetics, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.\"]\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "DM Dau-Ming Niu 1 ['Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "M Mark Thomas 1 ['Department of Nephrology, Royal Perth Hospital, Perth, Australia.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "H Hernán Trimarchi 1 ['Nephrology service, British Hospital, Buenos Aires, Argentina.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "WR William R Wilcox 1 ['Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "JM Juan Manuel Politei 1 ['Department of Neurology, Fundacion Para el Estudio de Enfermedades Neurometabolicas (FESEN), Buenos Aires, Argentina.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "A Alberto Ortiz 1 ['Unidad de Dialisis, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, IRSIN and REDINREN, Madrid, Spain.']\n",
      "Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clinical kidney journal 2021-01-05\n",
      "N Nishant Shekhar 1 ['Department of Pharmacology, Post Graduate Institute of Medical Education and Reseasrch (PGIMER), Chandigarh, 160012, India.']\n",
      "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological reports : PR 2021-01-04\n",
      "S Saurabh Sharma 1 ['Department of Pharmacology, Post Graduate Institute of Medical Education and Reseasrch (PGIMER), Chandigarh, 160012, India.']\n",
      "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological reports : PR 2021-01-04\n",
      "P Phulen Sarma 1 ['Department of Pharmacology, Post Graduate Institute of Medical Education and Reseasrch (PGIMER), Chandigarh, 160012, India.']\n",
      "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological reports : PR 2021-01-04\n",
      "A Ajay Prakash 1 ['Department of Pharmacology, Post Graduate Institute of Medical Education and Reseasrch (PGIMER), Chandigarh, 160012, India.']\n",
      "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological reports : PR 2021-01-04\n",
      "B Bikash Medhi 1 ['Department of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "C Casey Ross 1 ['McKinney Family Medicine, McKinney, 75070, TX, USA.']\n",
      "Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular medicine 2021-01-04\n",
      "V Vanessa Pickard 1 ['McKinney Family Medicine, McKinney, 75070, TX, USA.']\n",
      "Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular medicine 2021-01-04\n",
      "E Erica Smith 1 ['McKinney Family Medicine, McKinney, 75070, TX, USA.']\n",
      "Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular medicine 2021-01-04\n",
      "C Cortney Hanson 1 ['McKinney Family Medicine, McKinney, 75070, TX, USA.']\n",
      "Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular medicine 2021-01-04\n",
      "PA Peter A McCullough 1 ['Baylor University Medical Center, Dallas, 75226, TX, USA.\\nBaylor Heart and Vascular Institute, Dallas, 75226, TX, USA.\\nBaylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, 75226, TX, USA.']\n",
      "Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular medicine 2021-01-04\n",
      "D Dominic Snijders 1 ['Department of Pulmonary Disease, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands.']\n",
      "QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular toxicology 2021-01-03\n",
      "CW Claudia W van Gemeren 1 ['Intensive Care Unit, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands.']\n",
      "QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular toxicology 2021-01-03\n",
      "HJ Hylke Jan Kingma 1 ['Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands.\\nDepartment of Hospital Pharmacy, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands.']\n",
      "QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular toxicology 2021-01-03\n",
      "SFL Steven F L van Lelyveld 1 ['Department of Internal Medicine, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands.']\n",
      "QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular toxicology 2021-01-03\n",
      "TJ Thijs J Giezen 1 ['Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands.\\nDepartment of Hospital Pharmacy, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands.']\n",
      "QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular toxicology 2021-01-03\n",
      "SK Saurabh K Das 1 ['Department of Critical Care, Artemis Hospital, Gurugram, Haryana, India.']\n",
      "Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021-01-02\n",
      "R Rudrashish Haldar 1 ['Department of Anesthesia, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.']\n",
      "Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021-01-02\n",
      "H Hillol Sarkar 1 ['Department of Medicine, Fakhruddin Ali Ahmed Medical College and Hospital, Joti Gaon, Assam, India.']\n",
      "Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021-01-02\n",
      "R Resma Tewari 1 ['Department of Critical Care, Artemis Hospital, Gurugram, Haryana, India.']\n",
      "Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021-01-02\n",
      "S Sumit Ray 1 ['Department of Critical Care, Medical Services, Artemis Hospital, Gurugram, Haryana, India.']\n",
      "Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021-01-02\n",
      "C Cansu Yanginlar 1 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "RGH Rik G H Lindeboom 1 ['Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "S Siroon Bekkering 1 ['Department of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "MMT Mandy M T van Leent 1 ['Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.\\nDepartment of Medical Biochemistry, Amsterdam University Medical Centers, Amsterdam, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "B Baranca Buijsers 1 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "I Inge Jonkman 1 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "M Mark de Graaf 1 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "M Marijke Baltissen 1 ['Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "LA Lieke A Lamers 1 ['Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "NP Niels P Riksen 1 ['Department of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "ZA Zahi A Fayad 1 ['Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "WJM Willem J M Mulder 1 ['Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.\\nLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.\\nDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "LB Luuk B Hilbrands 1 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "LAB Leo A B Joosten 1 ['Department of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "MG Mihai G Netea 1 ['Department of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.\\nDepartment of Immunology and Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "M Michiel Vermeulen 1 ['Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "J Johan van der Vlag 1 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "R Raphaël Duivenvoorden 1 ['Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.\\nBiomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.']\n",
      "Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell reports. Medicine 2020-12-31\n",
      "NO Nancy Odurowah Duah-Quashie 1 ['Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.\\nWest African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana.']\n",
      "Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. Journal of tropical pediatrics 2020-12-29\n",
      "RO Rana O Zareef 1 ['Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.']\n",
      "Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Frontiers in pharmacology 2020-12-29\n",
      "SN Sally N Al Hassan 1 ['Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.']\n",
      "Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Frontiers in pharmacology 2020-12-29\n",
      "F Fadi Bitar 1 ['Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.\\nPediatric Department, Division of Pediatric Cardiology, American University of Beirut Medical Center, Beirut, Lebanon.']\n",
      "Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Frontiers in pharmacology 2020-12-29\n",
      "AH Ali H Eid 1 ['Department of Basic Medical Sciences, College of Medicine, Q.U. Health. Qatar University, Doha, Qatar.\\nBiomedical and Pharmaceutical Research Unit, Q.U. Health, Qatar University, Doha, Qatar.']\n",
      "Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Frontiers in immunology 2021-04-17\n",
      "M Mariam Arabi 1 ['Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.\\nPediatric Department, Division of Pediatric Cardiology, American University of Beirut Medical Center, Beirut, Lebanon.']\n",
      "Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Frontiers in pharmacology 2020-12-29\n",
      "R Renu Vyas 1 ['MIT School of Bioengineering Sciences & Research, Pune, India.']\n",
      "Computational Studies of Hydroxychloroquine and Chloroquine Metabolites as Possible Candidates for Coronavirus (COVID-19) Treatment. Frontiers in pharmacology 2020-12-29\n",
      "SM Sandro Massao Hirabara 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: sandro.hirabara@cruzeirodosul.edu.br.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "TAD Tamires Afonso Duarte Serdan 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: tamiresd.serdan@gmail.com.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "RB Raquel Bragante Gritte 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: r.gritte@hotmail.com.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "T Talita Souza-Siqueira 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: biomedtalitasouza@gmail.com.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "R Renata Gorjao 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: renata.gorjao@cruzeirodosul.edu.br.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "LN Laureane Nunes Masi 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: laure_masi@hotmail.com.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "MM Marina Masetto Antunes 1 ['Department of Pharmacology and Therapeutics, State University of Maringá, PR, Brazil. Electronic address: antunes.mah@gmail.com.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "V Vinicius Cruzat 1 ['Faculty of Health, Torrens University Australia, Melbourne, Australia. Electronic address: vinicius.cruzat@laureate.edu.au.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "TC Tania Cristina Pithon-Curi 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: tania.pithon-curi@cruzeirodosul.edu.br.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "R Rui Curi 1 ['Interdisciplinary Post-Graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo, SP, Brazil. Electronic address: ruicuri59@gmail.com.']\n",
      "4-Aminoquinoline compounds from the Spanish flu to COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020-12-29\n",
      "M Marmar Vaseghi 1 ['UCLA Cardiac Arrhythmia Center, University of California, Los Angeles, CA, USA; Neurocardiology Research Center of Excellence, University of California, Los Angeles, CA, USA.']\n",
      "Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights. Redox biology 2020-12-29\n",
      "BD Bryan D Hayes 1 ['Harvard Medical School, Boston, Massachusetts; Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts; Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "CM Crystal M North 1 ['Harvard Medical School, Boston, Massachusetts; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "JS Justin S Becker 1 ['Harvard Medical School, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "AZ Andrew Z Fenves 1 ['Harvard Medical School, Boston, Massachusetts; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "G Guibenson Hyppolite 1 ['Harvard Medical School, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "S Sara Khosrowjerdi 1 ['Harvard Medical School, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "D Daniel Sinden 1 ['Harvard Medical School, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "DA Dana A Stearns 1 ['Harvard Medical School, Boston, Massachusetts; Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts.']\n",
      "Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. The Journal of emergency medicine 2020-12-24\n",
      "A Afzal Hussain 1 ['Department of Pharmacognosy, College of Pharmacy, King Saud University, PO Box 2457, Riyadh, 11451, Saudi Arabia. Electronic address: afzal.hussain.amu@gmail.com.']\n",
      "Impact of repurposed drugs on the symptomatic COVID-19 patients. Journal of infection and public health 2020-12-21\n",
      "MF Mohamed F Alajmi 1 ['Department of Pharmacognosy, College of Pharmacy, King Saud University, PO Box 2457, Riyadh, 11451, Saudi Arabia. Electronic address: malajmii@ksu.edu.sa.']\n",
      "Impact of repurposed drugs on the symptomatic COVID-19 patients. Journal of infection and public health 2020-12-21\n",
      "MT Md Tabish Rehman 1 ['Department of Pharmacognosy, College of Pharmacy, King Saud University, PO Box 2457, Riyadh, 11451, Saudi Arabia.']\n",
      "Impact of repurposed drugs on the symptomatic COVID-19 patients. Journal of infection and public health 2020-12-21\n",
      "S Samira Amir 1 ['Department of Chemistry, College of Science and General Studies, Alfaisal University, PO Box 50927, Riyadh 11533, Saudi Arabia.']\n",
      "Impact of repurposed drugs on the symptomatic COVID-19 patients. Journal of infection and public health 2020-12-21\n",
      "N Nicola Veronese 1 ['Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "M Mario Barbagallo 1 ['Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "F Francesca Ometto 1 ['Rheumatological Unit, Local Health Unit 1, 6, Veneto Region, Italy.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "L Lee Smith 1 ['The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom. Electronic address: lee.smith@anglia.ac.uk.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "S Shahina Pardhan 1 ['Vision and Eye Research Institute, School of Medicine, Anglia Ruskin Univerity, Cambridge, United Kingdom.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "Y Yvonne Barnett 1 ['School of Life Scinces, Anglia Ruskin University, Cambridge, United Kingdom.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "PC Petre Cristian Ilie 1 [\"Research and Innovation Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, United Kingdom.\"]\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "P Pınar Soysal 1 ['Department of Geriatric Medicine, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "E Erik Lagolio 1 ['Emergency Medicine (A&E)']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "PK Peter Konstantin Kurotschka 1 ['Department of Medical Sciences and Public Health, Faculty of Medicine and Surgery, University of Cagliari, Cagliari, Italy.\\nRegional Health Trust of Sardinia Region, Cagliari, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "R Roberto Tonelli 1 ['Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; Respiratory Intensive Care Unit, University Hospital of Modena, Modena, Italy.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "J Jacopo Demurtas 1 ['Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; Primary Care Department, USL Toscana Sud Est-Grosseto, Grosseto, Italy.']\n",
      "An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-15\n",
      "M Muhammad Raafey 1 ['Department of Cell and Molecular Medicine, Rush University, Chicago, IL.']\n",
      "Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. American journal of clinical pathology 2020-12-15\n",
      "G Gene Kim 1 ['Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL.']\n",
      "Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. American journal of clinical pathology 2020-12-15\n",
      "J Jerermy Treger 1 ['Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL.']\n",
      "Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. American journal of clinical pathology 2020-12-15\n",
      "P Peter Pytel 1 ['Department of Pathology, University of Chicago, Chicago, IL.']\n",
      "Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. American journal of clinical pathology 2020-12-15\n",
      "A Aliya N Husain 1 ['Department of Pathology, University of Chicago, Chicago, IL.']\n",
      "Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. American journal of clinical pathology 2020-12-15\n",
      "JJ Jefree J Schulte 1 ['Department of Pathology, University of Chicago, Chicago, IL.\\nDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison.']\n",
      "Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. American journal of clinical pathology 2020-12-15\n",
      "Q Qianqian Jia 1 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "H Huaxin Zhou 1 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "L Liyang Zhang 1 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "S Saisai Wang 1 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "P Peida Liang 1 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "Y Yanni Lv 1 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "S Shengli Han 1 [\"School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an 710061, China; Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an 710115, China. Electronic address: slhan2008@mail.xjtu.edu.cn.\"]\n",
      "Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2020-12-15\n",
      "V Vida Duti 1 ['IRC-Ghana, Cantoments-Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "SD Stephen Dajaan Dubik 1 ['School of Allied Health Sciences, University for Development Studies, Tamale, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "KE Kingsley Ebenezer Amegah 1 ['Department of Health Information, Hohoe Municipal Hospital, Hohoe, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "S Selorm Kutsoati 1 ['Ga East Municipal Health Directorate, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "E Ebenezer Oduro-Mensah 1 ['Ga East Municipal Hospital, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "P Peter Puplampu 1 ['Department of Medicine, Korle Bu Teaching Hospital, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "M Martha Gyansa-Lutterodt 1 ['Technical Coordination Directorate, Ministry of Health, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "DM Delese Mimi Darko 1 ['Food and Drug Authority, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "KO Kwame Ohene Buabeng 1 ['Department of Pharmacy Practice, Kwame Nkrumah University of Science and Technology, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "A Anthony Ashinyo 1 ['National AIDS/STI Control Programme, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "AA Anthony Adofo Ofosu 1 ['Ghana Health Service, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "NA Nyonuku Akosua Baddoo 1 ['National AIDS/STI Control Programme, Ghana Health Service, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "SK Samuel Kaba Akoriyea 1 ['Institutional Care Division, Ghana Health Service Headquarters, Private Mail Bag, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "F Francis Ofei 1 ['Department of Medicines, School of Medicine and Dentistry, University of Cape Coast.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "P Patrick Kuma-Aboagye 1 ['Office of the Director General, Ghana Health Service Headquarters, Accra, Ghana.']\n",
      "Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. The Pan African medical journal 2020-12-10\n",
      "FP Frederick Peter Guengerich 1 ['Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States.']\n",
      "Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. Current drug metabolism 2020-12-10\n",
      "R Rickie Patani 1 ['Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.\\nThe Francis Crick Institute, London, United Kingdom.']\n",
      "Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective. Frontiers in neurology 2020-12-08\n",
      "P Paolo Paganetti 1 ['Neurodegeneration Research Group, Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Torricella-Taverne, Switzerland.\\nFaculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.']\n",
      "Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective. Frontiers in neurology 2020-12-08\n",
      "MM Mohammad Mahbubul Karim 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "AG Allen G Ross 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "MS Mohammad Sharif Hossain 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "JD John D Clemens 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "MK Mariya Kibtiya Sumiya 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "CS Ching Swe Phru 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "M Mustafizur Rahman 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "K Khalequ Zaman 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "J Jyoti Somani 1 ['Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "R Rubina Yasmin 1 ['Mugda Medical College and Hospital, Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "MA Mohammad Abul Hasnat 1 ['Kurmitola General Hospital, Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "A Ahmedul Kabir 1 ['Dhaka Medical College and Hospital, Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "AB Asma Binte Aziz 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "WA Wasif Ali Khan 1 ['International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh. Electronic address: wakhan@icddrb.org.']\n",
      "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020-12-06\n",
      "P Przemyslaw Kapala 1 ['Ewdomed Ewa Szulecka Foundation and Home Hospice, Al. Wojska Polskiego 6, 05-520 Konstancin-Jeziorna, Poland.']\n",
      "Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Medical hypotheses 2020-12-06\n",
      "M Marlena Kiedrowska 1 ['Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.']\n",
      "Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Medical hypotheses 2020-12-06\n",
      "A Anna Skoczynska 1 ['Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.']\n",
      "Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Medical hypotheses 2020-12-06\n",
      "A Aleksandra Czerw 1 ['Department of Health Economics and Medical Law, Faculty of Health Sciences, Medical University of Warsaw, ul. Zwirki i Wigury 61, 02-091 Warsaw, Poland.']\n",
      "Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Medical hypotheses 2020-12-06\n",
      "A Andrzej Deptała 1 ['Clinical Department of Oncology and Hematology, Central Clinical Hospital of the Ministry of the Anterior and Administration in Warsaw, ul. Woloska 137, 02-507 Warsaw, Poland; Division of Cancer Prevention, Faculty of Health Sciences, Medical University of Warsaw, ul. Zwirki i Wigury 61, 02-091 Warsaw, Poland.']\n",
      "Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Medical hypotheses 2020-12-06\n",
      "A Anabela Maia 1 ['Rhode Island College, 600 Mount Pleasant Avenue, Providence, RI, USA.']\n",
      "A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. International journal of antimicrobial agents 2020-12-02\n",
      "TM Thelma Mpoku Alalbila 1 ['School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana.']\n",
      "Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. Therapeutic innovation & regulatory science 2020-12-02\n",
      "V Varsha Bangalee 1 ['College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.']\n",
      "Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. Therapeutic innovation & regulatory science 2020-12-02\n",
      "F Frasia Oosthuizen 1 ['College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.']\n",
      "Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. Therapeutic innovation & regulatory science 2020-12-02\n",
      "X Xinyu Zhuang 1 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "H He Zhang 1 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "Y Yiquan Li 1 [\"Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, 130117, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "Y Yilong Zhu 1 [\"Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, 130117, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "C Chenchen Ge 1 [\"Agricultural College, Yanbian University, Yanji, 133002, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "J Jianan Cong 1 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "T Tingyu Li 1 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "M Mingyao Tian 1 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China. linjiaxiaoya@163.com.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "N Ningyi Jin 1 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China. lixiao06@mails.jlu.edu.cn.\\nAcademician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, 130117, People's Republic of China. lixiao06@mails.jlu.edu.cn.\\nJiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, People's Republic of China. lixiao06@mails.jlu.edu.cn.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "X Xiao Li 1 [\"Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, People's Republic of China. skylee6226@163.com.\\nAcademician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, 130117, People's Republic of China. skylee6226@163.com.\\nJiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, People's Republic of China. skylee6226@163.com.\"]\n",
      "Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology journal 2021-03-01\n",
      "JC Jean-Christophe Lagier 1 ['IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n",
      "P Philippe Brouqui 1 ['IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n",
      "JP Jean-Paul Casalta 1 ['IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "V Véronique Jacomo 1 ['Eurofins Biomnis, Lyon, France.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n",
      "B Bernard La Scola 1 ['IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.']\n",
      "Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2021-02-27\n",
      "M Madhavi Ampajwala 1 ['Village Health Partners, Plano, TX, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "C Christopher Chappel 1 ['Chappel Group, Kissimmee, FL, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "AB Andre B Gvozden 1 ['Gvozden Pediatrics, Millersville, MD, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "M Melanie Hoppers 1 ['Clinical Research Solutions, Jackson, TN, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "M Melody Wang 1 ['Department of Global Health, University of Washington, Seattle, WA, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "R Robert Rosen 1 ['Ardmore Family Practice, Winston-Salem, NC, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "S Stephen Young 1 ['Tricore Reference Laboratories, Albuquerque, NM, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "E Edward Zissman 1 [\"Children's Research, LLC, Altamonte Springs, FL, USA.\"]\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "M Michalina Montano 1 ['Department of Global Health, University of Washington, Seattle, WA, USA.']\n",
      "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infectious diseases and therapy 2021-02-26\n",
      "N Negin Soroush 1 ['Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. European journal of preventive cardiology 2021-02-25\n",
      "MA M Arfan Ikram 1 ['Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. European journal of preventive cardiology 2021-02-25\n",
      "JA Jan A Kors 1 ['Department of Medical Informatics, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. European journal of preventive cardiology 2021-02-25\n",
      "M Maryam Kavousi 1 ['Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. European journal of preventive cardiology 2021-02-25\n",
      "BH Bruno H Stricker 1 ['Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.']\n",
      "QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. European journal of preventive cardiology 2021-02-25\n",
      "Y Yassine Otheman 1 ['Faculty of Medicine and pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco.']\n",
      "Psychiatric side effects of chloroquine in COVID-19 patients: two case reports. The Pan African medical journal 2021-02-25\n",
      "C Chafik El Kettani 1 ['Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.']\n",
      "Psychiatric side effects of chloroquine in COVID-19 patients: two case reports. The Pan African medical journal 2021-02-25\n",
      "AK Ashok K Shakya 1 ['Department of Pharmaceutical Sciences, Pharmacological and Diagnostic Research Center, Al-Ahliyya Amman University, Amman, Jordan.']\n",
      "Therapeutic Strategies in the Management of COVID-19. Frontiers in molecular biosciences 2021-02-23\n",
      "Y Yasir Waheed 1 ['Foundation University Medical College, Foundation University Islamabad, Islambad, Pakistan.']\n",
      "Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. Journal of molecular liquids 2021-02-23\n",
      "S Saba Ismail 1 ['Foundation University Medical College, Foundation University Islamabad, Islambad, Pakistan.']\n",
      "Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. Journal of molecular liquids 2021-02-23\n",
      "MH Muzammil Hasan Najmi 1 ['Foundation University Medical College, Foundation University Islamabad, Islambad, Pakistan.']\n",
      "Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. Journal of molecular liquids 2021-02-23\n",
      "JK Jawad Khaliq Ansari 1 ['Foundation University Medical College, Foundation University Islamabad, Islambad, Pakistan.']\n",
      "Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. Journal of molecular liquids 2021-02-23\n",
      "K Ken Furuya 1 ['Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.']\n",
      "Multidrug treatment for COVID-19. Drug discoveries & therapeutics 2021-02-23\n",
      "H Houman Goudarzi 1 ['Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.']\n",
      "Multidrug treatment for COVID-19. Drug discoveries & therapeutics 2021-02-23\n",
      "CO C O Bode 1 ['Department of Surgery, Faculty of Clinical Sciences, College of Medicine & Lagos University Teaching Hospital, Lagos, Nigeria.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "AA A A Ajayi 1 ['Division of Hypertension and Clinical pharmacology, Keck Department of Medicine, Baylor College of Medicine Houston Texas, TX 77030 USA.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "FM F M Alakaloko 1 ['Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "IE I E Akase 1 ['Department of Medicine, Lagos University Teaching Hospital.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "E E Otrofanowei 1 ['Department of Medicine, Faculty of Clinical Sciences, College of Medicine/Lagos University Teaching Hospital.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "OB O B Salu 1 ['Centre for Human and Zoonotic Virology, Central Research Laboratory/Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "WL W L Adeyemo 1 ['Department of Oral and Maxillofacial Surgery, College of Medicine, University of Lagos.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "AO A O Ademuyiwa 1 ['Department of Surgery, Faculty of Clinical Sciences, College of Medicine & Lagos University Teaching Hospital, Lagos, Nigeria.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "S S Omilabu 1 ['Centre for Human and Zoonotic Virology, Central Research Laboratory/Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos.']\n",
      "Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians 2021-02-19\n",
      "P Pablo Méndez-Hernández 1 ['Secretaría de Salud de Tlaxcala, Dirección de Atención Especializada a la Salud, Tlaxcala, Mexico; Unidad de Investigación Epidemiológica y en Servicios de Salud, Delegación Morelos, Instituto Mexicano del Seguro Social, Blvd. Benito Juárez No. 31, Colonia Centro, Cuernavaca, Morelos, Mexico; Universidad Autónoma de Tlaxcala, Facultad de Ciencias de la Salud, Tlaxcala, Mexico. Electronic address: pmendezh@hotmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "YN Yvonne N Flores 1 ['Unidad de Investigación Epidemiológica y en Servicios de Salud, Delegación Morelos, Instituto Mexicano del Seguro Social, Blvd. Benito Juárez No. 31, Colonia Centro, Cuernavaca, Morelos, Mexico; UCLA Department of Health Policy and Management and Kaiser Permanente Center for Health Equity, Fielding School of Public Health, Los Angeles, CA, 90095, United States; UCLA Cancer Prevention and Control Research Center, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, United States. Electronic address: ynflores@ucla.edu.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "P Patricia Osorno-Romero 1 ['Secretaría de Salud de Tlaxcala, Dirección de Atención Especializada a la Salud, Tlaxcala, Mexico. Electronic address: patubeda@hotmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "CR Christian Ronal Sancho-Hernández 1 ['Secretaría de Salud de Tlaxcala, Hospital General de Nativitas, Tlaxcala, Mexico.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "E Elizabeth Cuecuecha-Rugerio 1 ['Secretaría de Salud de Tlaxcala, Dirección de Atención Especializada a la Salud, Tlaxcala, Mexico. Electronic address: epidemiologia_2013@hotmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "A Adrián Nava-Zamora 1 ['Secretaría de Salud de Tlaxcala, Dirección de Atención Especializada a la Salud, Tlaxcala, Mexico. Electronic address: adriancalidad@hotmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "DR Diego Rolando Hernández-Galdamez 1 ['INCAP Research Center for the Prevention of Chronic Diseases (CIIPEC), Institute of Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala. Electronic address: diego.hgz@gmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "DK Daniela Karola Romo-Dueñas 1 ['Red Nacional de Registros de Cáncer, Guanajuato, Mexico; Instituto de Salud Pública del estado de Guanajuato (ISAPEG), Unidad de Vigilancia Epidemiológica Hospitalaria (UVEH), Hospital General León, Guanajuato, Mexico. Electronic address: danielakarola.rd@gmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "J Jorge Salmerón 1 ['Research Center on Policies, Population, and Health. Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico. Electronic address: jorge.salmec@gmail.com.']\n",
      "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-02-13\n",
      "CS Carolina Santos Vengrus 1 ['School of Medicine, Pontifical Catholic University of Paraná, Londrina, Brazil.']\n",
      "Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. Pathogens and global health 2021-02-13\n",
      "BM Bruno Matos Aquino 1 ['School of Medicine, Pontifical Catholic University of Paraná, Londrina, Brazil.']\n",
      "Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. Pathogens and global health 2021-02-13\n",
      "A Alcindo Cerci Neto 1 ['School of Medicine, Pontifical Catholic University of Paraná, Londrina, Brazil.\\nSection of Pulmonology, Department of Medicine, Health Science Centre, State, University of Londrina, Londrina, Brazil.']\n",
      "Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. Pathogens and global health 2021-02-13\n",
      "R Razieh Ghodsi 1 ['Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, . Iran.']\n",
      "Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An in Silico Study. Medicinal chemistry (Shariqah (United Arab Emirates)) 2021-02-11\n",
      "F Farzin Hadizadeh 1 ['Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, . Iran.']\n",
      "Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An in Silico Study. Medicinal chemistry (Shariqah (United Arab Emirates)) 2021-02-11\n",
      "KD Kielan D McAlinden 1 ['Department of Laboratory Medicine, School of Health Sciences, University of Tasmania, Launceston, Tasmania, 7248, Australia.']\n",
      "Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? European journal of pharmacology 2021-02-06\n",
      "DA Deepak A Deshpande 1 ['Center for Translational Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Jane & Leonard Korman Respiratory Institute, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA.']\n",
      "Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? European journal of pharmacology 2021-02-06\n",
      "A Anshika Gupta 1 ['Computational Toxicology Facility, CSIR- Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India.']\n",
      "Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in biology and medicine 2021-02-04\n",
      "S Shristee Gupta 1 ['Computational Toxicology Facility, CSIR- Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India.']\n",
      "Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in biology and medicine 2021-02-04\n",
      "P Prakrity Singh 1 ['Computational Toxicology Facility, CSIR- Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India.']\n",
      "Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in biology and medicine 2021-02-04\n",
      "S Shraddha Pandit 1 ['Computational Toxicology Facility, CSIR- Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India.']\n",
      "Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in biology and medicine 2021-02-04\n",
      "SS Shweta Singh Chauhan 1 ['Computational Toxicology Facility, CSIR- Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India.']\n",
      "Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in biology and medicine 2021-02-04\n",
      "R Ramakrishnan Parthasarathi 1 ['Computational Toxicology Facility, CSIR- Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India. Electronic address: partha.ram@iitr.res.in.']\n",
      "Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in biology and medicine 2021-02-04\n",
      "M Mika Turkia 1 ['Qualitative Research, Helsinki, Finland.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "M Mohd Adnan 1 [\"Laboratory of General Biology, Department of Biology, University of Ha'il, Ha'il 81451, Saudi Arabia.\"]\n",
      "Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism. Molecules (Basel, Switzerland) 2021-02-03\n",
      "F Fevzi Bardakci 1 [\"Laboratory of General Biology, Department of Biology, University of Ha'il, Ha'il 81451, Saudi Arabia.\\nLaboratory of Genetics, Department of Biology, Aydin Adnan Menderes University, Aydin 09010, Turkey.\"]\n",
      "Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism. Molecules (Basel, Switzerland) 2021-02-03\n",
      "MM Mousa M Alreshidi 1 [\"Laboratory of General Biology, Department of Biology, University of Ha'il, Ha'il 81451, Saudi Arabia.\\nMolecular Diagnostic and Personalized Therapeutics Unit, University of Ha'il, Ha'il 81451, Saudi Arabia.\"]\n",
      "Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism. Molecules (Basel, Switzerland) 2021-02-03\n",
      "JM Jorge M Pascual 1 ['Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "W Wendelyn Bosch 1 ['Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "DD David D Thiel 1 ['Department of Urology, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "D Dawn Francis 1 ['Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "JD John D Casler 1 ['Department of Otorhinolaryngology/Audiology, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "A Aziza Nassar 1 ['Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "MA Mark A Parkulo 1 ['Division of Community Internal Medicine, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "AN Ajani N Dunn 1 ['Hospital Operations, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "TS T'Nita S Waters 1 ['Division of Quality Management Services, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "CH Christopher H Hasse 1 ['Surgical & Procedural Operations, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "B Brian Zargham 1 ['Innovation, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "TL Tera L Gross 1 ['Department of Nursing, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "CJ Carla J Johnson 1 ['Planning Services, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "AW Alice W Rigdon 1 ['Department of Finance, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "CJ Charles J Bruce 1 ['Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "KR Kent R Thielen 1 ['Chief Executive Officer, Mayo Clinic, Jacksonville, FL.']\n",
      "Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic. Mayo Clinic proceedings. Innovations, quality & outcomes 2021-02-02\n",
      "I I Ramdani 1 ['Biochemistry and Microbiology Department, Mouloud Mammeri University of Tizi-Ouzou, Algeria.']\n",
      "Chloroquine and COVID-19: role as a bitter taste receptor agonist? New microbes and new infections 2021-02-02\n",
      "R R Chahed 1 ['Cabinet Médical Privé, Spécialité de Pneumologie, Tizi-Ouzou, Algeria.']\n",
      "Chloroquine and COVID-19: role as a bitter taste receptor agonist? New microbes and new infections 2021-02-02\n",
      "O Oscar Alcazar 1 ['Diabetes Research Institute, University of Miami, Miami, FL, United States.']\n",
      "Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Frontiers in pharmacology 2021-02-02\n",
      "P Peter Buchwald 1 ['Diabetes Research Institute, University of Miami, Miami, FL, United States.\\nDepartment of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL, United States.']\n",
      "Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Frontiers in pharmacology 2021-02-02\n",
      "HM H M Elkhair 1 ['Imam Mohammad Ibn Saud Islamic University (IMSIU), College of Science, Physics department, P.O. Box 90950, Riyadh 11623, Saudi Arabia.\\nDepartment of Physics, Al Neelain University, P. O. Box 12702, Khartoum 11121, Sudan.']\n",
      "Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19. Journal of molecular structure 2021-02-02\n",
      "RM Raphael M Kronberg 1 ['Department of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.\\nMathematical Modelling of Biological Systems, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "P Pawel Stachura 1 ['Department of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "PN Philipp N Ostermann 1 ['Institute of Virology, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "L Lisa Müller 1 ['Institute of Virology, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "H Heiner Schaal 1 ['Institute of Virology, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "S Sanil Bhatia 1 ['Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "JN Jakob N Kather 1 ['Department of Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "A Arndt Borkhardt 1 ['Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "AA Aleksandra A Pandyra 1 ['Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "KS Karl S Lang 1 ['Institute of Immunology, Medical Faculty, University of Duisburg-Essen, 45147 Essen, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "PA Philipp A Lang 1 ['Department of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.']\n",
      "Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. Viruses 2021-05-01\n",
      "G Gorka Orive 1 ['NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de La Universidad 7, Vitoria-Gasteiz, 01006, Spain.\\nBiomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.\\nUniversity Institute for Regenerative Medicine and Oral Implantology']\n",
      "Ivermectin & COVID-19: Let's keep a One Health perspective. Sustainable chemistry and pharmacy 2021-04-27\n",
      "U Unax Lertxundi 1 ['Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba Mental Health Network, Araba Psychiatric Hospital, Pharmacy Service, C/Alava 43, 01006, Vitoria-Gasteiz, Alava, Spain.']\n",
      "Ivermectin & COVID-19: Let's keep a One Health perspective. Sustainable chemistry and pharmacy 2021-04-27\n",
      "MJ Md Jahir Raihan 1 ['Department of Chemistry, Jagannath University, Dhaka, 1100 Bangladesh.']\n",
      "The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2. Structural chemistry 2021-04-20\n",
      "AML Amy May Lin Quek 1 ['Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Neurology, Department of Medicine, National University Hospital, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "DSQ Delicia Shu Qin Ooi 1 [\"Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Pediatric Endocrinology, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, Singapore.\"]\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "S Sharmila Sengupta 1 ['Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "SR Satish Ramapatna Lakshminarasappa 1 ['Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "CY Chieh Yang Koo 1 ['Department of Cardiology, National University Heart Centre, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "JBY Jimmy Bok Yan So 1 ['Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "BC Boon Cher Goh 1 ['Department of Hematology-Oncology, National University Cancer Institute, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "KS Kwok Seng Loh 1 ['Department of Otolaryngology-Head and Neck Surgery, National University Hospital, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "D Dale Fisher 1 ['Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "HL Hock Luen Teoh 1 ['Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Neurology, Department of Medicine, National University Hospital, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "J Jie Sun 1 ['Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "AR Alex R Cook 1 ['Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "PA Paul Anantharajah Tambyah 1 ['Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "M Mikael Hartman 1 ['Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.']\n",
      "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021-04-18\n",
      "M Maya Wehbe 1 ['Department of Internal Medicine, Basingstoke & North Hampshire Hospital, Basingstoke, United Kingdom.']\n",
      "Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Frontiers in immunology 2021-04-17\n",
      "R Rabah Iratni 1 ['Department of Biology, College of Science, United Arab Emirates University, Al-Ain, United Arab Emirates.']\n",
      "Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Frontiers in immunology 2021-04-17\n",
      "G Gianfranco Pintus 1 ['Department of Medical Laboratory Sciences, College of Health Sciences, and Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.\\nDepartment of Biomedical Sciences, University of Sassari, Sassari, Italy.']\n",
      "Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Frontiers in immunology 2021-04-17\n",
      "H Hassan Zaraket 1 ['Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.\\nCenter for Infectious Disease Research (CIDR), Faculty of Medicine, American University of Beirut, Beirut, Lebanon.']\n",
      "Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Frontiers in immunology 2021-04-17\n",
      "HM Hadi M Yassine 1 ['Biomedical Research Center, Q.U. Health, Qatar University, Doha, Qatar.']\n",
      "Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Frontiers in immunology 2021-04-17\n",
      "S Salvatore Crisafulli 1 ['Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.\\nItalian Society of Pharmacology, Milan, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "PG Paolo Giorgi Rossi 1 ['Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "P Pamela Mancuso 1 ['Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "C Carlo Salvarani 1 ['Unit of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy.\\nDepartment of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "F Fabiola Atzeni 1 ['Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "R Rosa Gini 1 ['Agenzia Regionale di Sanità della Toscana, Florence, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "U Ursula Kirchmayer 1 ['Department of Epidemiology ASL Roma 1, Lazio Regional Health Service, Rome, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "V Valeria Belleudi 1 ['Department of Epidemiology ASL Roma 1, Lazio Regional Health Service, Rome, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "O Olivia Leoni 1 ['Epidemiology Observatory-Department of Health of Lombardy Region, Milan, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "M Monica Ludergnani 1 ['Epidemiology Observatory-Department of Health of Lombardy Region, Milan, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "E Eliana Ferroni 1 ['Azienda Zero of the Veneto Region, Padua, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "S Susanna Baracco 1 ['Azienda Zero of the Veneto Region, Padua, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "M Marco Massari 1 ['Pharmacoepidemiology Unit, National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "G Gianluca Trifirò 1 ['Italian Society of Pharmacology, Milan, Italy.\\nDepartment of Diagnostics and Public Health, University of Verona, Verona, Italy.']\n",
      "Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford, England) 2021-04-16\n",
      "T Tongya Yu 1 [\"Department of Respiratory and Critical Care Medicine, Shanghai 10th People's Hospital, Shanghai, China.\"]\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "J Jinghua Zhu 1 [\"Department of Surgery, Chibi People's Hospital, Chibi, China.\"]\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "Y Yinjia Wang 1 [\"Department of Intensive Care Unit Medicine, The First People's Hospital of Kunming, Kunming, China.\"]\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "Y Yanxia Yang 1 [\"Department of Respiratory and Critical Care Medicine, The First People's Hospital of Kunming, Kunming, China.\"]\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "K Kaiwu Zhao 1 [\"Department of Infectious Disease, The First People's Hospital of Kunming, Kunming, China.\"]\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "Y Yongning Yi 1 ['Department of Respiratory and Critical Care Medicine, The 4th Hospital of Kunming City, Anning, China.']\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "J Juan He 1 ['920th Hospital Pharmacy of Joint Logistics Support Force, Kunming, China. hheejuan@126.com.']\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "C Chao Li 1 [\"Department of Respiratory and Critical Care Medicine, The First People's Hospital of Kunming, Kunming, China. kmdocli@163.com.\"]\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "J Jian He 1 ['Department of Respiratory and Critical Care Medicine, The 4th Hospital of Kunming City, Anning, China. ignatias@163.com.']\n",
      "Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Annals of palliative medicine 2021-04-15\n",
      "AK Anu Kunnath Ramachandran 1 ['Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.']\n",
      "The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Medicine in drug discovery 2021-04-14\n",
      "SR Sumit Raosaheb Birangal 1 ['Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.']\n",
      "The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Medicine in drug discovery 2021-04-14\n",
      "S Saleem Akbar 1 ['Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.']\n",
      "The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Medicine in drug discovery 2021-04-14\n",
      "B Bahar Ahmed 1 ['Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.']\n",
      "The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Medicine in drug discovery 2021-04-14\n",
      "A Alex Joseph 1 ['Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.']\n",
      "The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Medicine in drug discovery 2021-04-14\n",
      "J Jingfang Mu 1 ['State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Wuhan, 430071, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "S Shengke Li 1 ['State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "Y Yaohui Fang 1 ['State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Wuhan, 430071, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "Q Qianyun Liu 1 ['State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "X Xiangjun Zhang 1 ['State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "H Hiotong Kam 1 ['State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "SMY Simon M Y Lee 1 ['State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "Y Yu Chen 1 ['State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "F Fei Deng 1 ['State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Wuhan, 430071, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "X Xi Zhou 1 ['State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Wuhan, 430071, China.\\nState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "R Ruibing Wang 1 ['State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.']\n",
      "Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation. Chinese chemical letters = Zhongguo hua xue kuai bao 2021-04-13\n",
      "H Hansel Mundaca 1 ['Instituto de Salud Global (ISGlobal), Barcelona, Spain.']\n",
      "Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials 2021-04-11\n",
      "C Cesar Ugarte-Gil 1 ['School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.\\nTropical Medicine Institute Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.']\n",
      "Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials 2021-04-11\n",
      "P Patricia Leon 1 ['Hospital Nacional Cayetano Heredia, Lima, Peru.']\n",
      "Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials 2021-04-11\n",
      "G German Malaga 1 ['School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.\\nHospital Nacional Cayetano Heredia, Lima, Peru.']\n",
      "Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials 2021-04-11\n",
      "CP Cesar P Carcamo 1 ['School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.']\n",
      "Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials 2021-04-11\n",
      "SR Sandra Rocha Gadellha 1 ['Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brazil.']\n",
      "Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis. European journal of internal medicine 2021-04-10\n",
      "MB Mittermayer Barreto Santiago 1 ['Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.']\n",
      "Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis. European journal of internal medicine 2021-04-10\n",
      "M Marta Jiménez-García 1 ['Department of Ophthalmology, Antwerp University Hospital (UZA), Antwerp, Belgium.\\nFaculty of Medicine and Health Sciences, Antwerp University, Antwerp, Belgium.']\n",
      "What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. European journal of ophthalmology 2021-04-09\n",
      "S Sarah Hershko 1 ['Department of Ophthalmology, Antwerp University Hospital (UZA), Antwerp, Belgium.\\nFaculty of Medicine and Health Sciences, Antwerp University, Antwerp, Belgium.']\n",
      "What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. European journal of ophthalmology 2021-04-09\n",
      "I Irene Altemir-Gómez 1 ['Ophthalmology Department, University Hospital Miguel Servet (HUMS), Zaragoza, Spain.\\nAragon Health Research Institute (IISA), Zaragoza, Spain.']\n",
      "What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. European journal of ophthalmology 2021-04-09\n",
      "A Ana Tobarra-López 1 ['Department of Community Nursing, Preventive Medicine and Public Health and History of Science, Public Health Research Group, University of Alicante, Spain.\\nDepartment of Optics, Pharmacology and Anatomy, Science Faculty, University of Alicante, Spain.\\nAlicante Health and Biomedical Research Institute (ISABIAL), Alicante University General Hospital, Alicante, Spain.']\n",
      "What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. European journal of ophthalmology 2021-04-09\n",
      "D Denis Xavier 1 [\"Department of Pharmacology, St. John's Medical College, Bengaluru, Karnataka, India.\"]\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "SK Sandhya K Kamat 1 ['Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "SJ Sujith J Chandy 1 ['Department of Pharmacology & Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "RK Raakhi K Tripathi 1 ['Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "YC Yashashri C Shetty 1 ['Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "JM John Michael Raj 1 [\"Department of Biostatistics, St. John's Medical College, Bengaluru, Karnataka, India.\"]\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "S Sandeep Kaushal 1 ['Department of Pharmacology, Dayanand Medical College & Hospital, Ludhiana, Punjab, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "S S Balakrishnan 1 ['Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "S Shubham Atal 1 ['Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "SK Santanu K Tripathi 1 ['Department of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "DK Dinesh K Badyal 1 ['Department of Pharmacology, Christian Medical College, Ludhiana, Punjab, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "H Harihar Dikshit 1 ['Department of Pharmacology, Indira Gandhi Institute of Medical Science, Patna, Bihar, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "SS Sukalyan Saha Roy 1 ['Department of Pharmacology, Indira Gandhi Institute of Medical Science, Patna, Bihar, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "N Niyati Trivedi 1 ['Department of Pharmacology, Medical College Baroda, Vadodara, Ahmedabad, Gujarat, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "S Suparna Chatterjee 1 ['Department of Pharmacology, Institute of Postgraduate Medical Education & Research, Kolkata, West Bengal, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "C Chetna Desai 1 ['Department of Pharmacology, B.J. Medical College, Ahmedabad, Gujarat, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "CD C D Tripathi 1 ['Department of Pharmacology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "NN Nirmala N Rege 1 ['Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "P Pooja Gupta 1 ['Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "R R Raveendran 1 ['Department of Pharmacology, Jawaharlal Institute of Postgraduate Education & Research, Puducherry, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "R Rajni Kaul 1 ['Division of Basic Medical Sciences, New Delhi, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "NA Nilima A Kshirsagar 1 ['National Chair Clinical Pharmacology, Indian Council for Medical Research, New Delhi, India.']\n",
      "Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. The Indian journal of medical research 2021-04-06\n",
      "LE Luis Eduardo Bravo 1 ['Universidad del Valle, Facultad de Salud, Escuela de Medicina, Departamento de Patología, Cali, Colombia.\\nRegistro Poblacional de Cáncer, Cali, Colombia.']\n",
      "COVID-19: The Ivermectin African Enigma. Colombia medica (Cali, Colombia) 2021-04-03\n",
      "E Edgar Muñoz 1 ['University of Texas , Health Science Center San Antonio, Texas, USA.']\n",
      "COVID-19: The Ivermectin African Enigma. Colombia medica (Cali, Colombia) 2021-04-03\n",
      "EKG Elvia Karina Grillo Ardila 1 ['Universidad del Valle, Facultad de Salud, Doctorado en Salud, Cali, Colombia.']\n",
      "COVID-19: The Ivermectin African Enigma. Colombia medica (Cali, Colombia) 2021-04-03\n",
      "E Esteban Guerrero 1 ['Barbara&Frick. Bogotá. Colombia.']\n",
      "COVID-19: The Ivermectin African Enigma. Colombia medica (Cali, Colombia) 2021-04-03\n",
      "RS Russell S Gonnering 1 ['Department of Ophthalmology and Visual Sciences, The Medical College of Wisconsin, Milwaukee, 53226 WI, USA.']\n",
      "Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations. Reviews in cardiovascular medicine 2021-04-02\n",
      "I Ivan Rodriguez 1 ['Department of Accounting and Finance, Gary M. Owen College of Business, Eastern Michigan University, Ypsilanti, 48197 MI, USA.']\n",
      "Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations. Reviews in cardiovascular medicine 2021-04-02\n",
      "Q Qianying Zhang 1 ['Department of Economics and Business Administration, Hillsdale College, Hillsdale, 49242 MI, USA.']\n",
      "Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations. Reviews in cardiovascular medicine 2021-04-02\n",
      "BB Bruce B Berry 1 ['Community Physicians, Froedtert and the Medical College of Wisconsin, Milwaukee, 53226 WI, USA.']\n",
      "Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations. Reviews in cardiovascular medicine 2021-04-02\n",
      "EI E I Solntseva 1 ['Research Center of Neurology, Moscow, Russia. synaptology@mail.ru.']\n",
      "Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons. Bulletin of experimental biology and medicine 2021-04-01\n",
      "RV R V Kondratenko 1 ['Research Center of Neurology, Moscow, Russia.']\n",
      "Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons. Bulletin of experimental biology and medicine 2021-04-01\n",
      "VG V G Skrebitsky 1 ['Research Center of Neurology, Moscow, Russia.']\n",
      "Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons. Bulletin of experimental biology and medicine 2021-04-01\n",
      "A Alfonso Scarpa 1 ['Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "E Egidio De Bonis 1 ['Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "M Matteo Cavaliere 1 ['Otolaryngology Department, University Hospital \"San Giovanni di Dio e Ruggi D\\'Aragona\" Salerno, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "P Pasquale Viola 1 ['Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre for Cochlear Implants and ENT Diseases, University \"Magna Graecia\", Catanzaro, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "FM Federico Maria Gioacchini 1 ['ENT Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "M Massimo Ralli 1 ['Department of Sense Organs, University \"Sapienza\", Rome, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "C Cassandro Ettore 1 ['Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "C Cassandro Claudia 1 ['Department of Surgical Sciences, University of Turin, Turin, Italy.']\n",
      "Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. American journal of otolaryngology 2021-03-30\n",
      "ZU Zia Ul Mustafa 1 ['Department of Pharmacy, District Headquarters Hospital, Pakpattan, Pakistan.']\n",
      "The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological reports : PR 2021-03-30\n",
      "KA Katarzyna Anna Majewska 1 ['Department of Clinical Auxology and Pediatric Nursing, Poznan University of Medical Sciences, Poznań, Poland.']\n",
      "Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective. Annals of agricultural and environmental medicine : AAEM 2021-03-30\n",
      "M Monika Naskręcka 1 ['Department of Mathematical Economics, Institute of Informatics and Quantitative Economics, University of Economics and Business, Poznań, Poland.']\n",
      "Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective. Annals of agricultural and environmental medicine : AAEM 2021-03-30\n",
      "B Bogna Grygiel-Górniak 1 ['Department of Rheumatology and Internal Medicine, Poznan University of Medical Sciences, Poznań, Poland.']\n",
      "Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective. Annals of agricultural and environmental medicine : AAEM 2021-03-30\n",
      "M Motahareh Piri 1 ['Department of Biology, Faculty of Sciences, University of Zabol, Zabol, Iran.']\n",
      "Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19. Global medical genetics 2021-03-23\n",
      "S Sarvin Jabbari 1 ['Department of Animal Biology, Molecular Genetics Subdivision, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.']\n",
      "Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19. Global medical genetics 2021-03-23\n",
      "M Mohammad Khalaj-Kondori 1 ['Department of Animal Biology, Molecular Genetics Subdivision, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.']\n",
      "Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19. Global medical genetics 2021-03-23\n",
      "AA Amr A Alhossary 1 ['Rehabilitation Research Institute of Singapore, Nanyang Technological University, Singapore, Singapore.']\n",
      "Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. Frontiers in microbiology 2021-03-23\n",
      "AS Ahmed S Abdel-Moneim 1 ['Microbiology Department, Virology Division, College of Medicine, Taif University, Taif, Saudi Arabia.']\n",
      "Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. Frontiers in microbiology 2021-03-23\n",
      "MM Mônica Maria Bastos Paoliello 1 ['Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461, Bronx, New York, United States.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "AQC Alice de Queiroz Constantino Miguel 1 ['University Hospital of the Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "AF Anderson Ferreira da Cunha 1 ['Department of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "CC Caio Cesar de Melo Freire 1 ['Department of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "FF Fábio Fernandes Neves 1 ['Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "LR Lucimar Retto da Silva de Avó 1 ['Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "MG Meliza Goi Roscani 1 ['Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "SS Sigrid De Sousa Dos Santos 1 ['Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "SGF Silvana Gama Florêncio Chachá 1 ['Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.']\n",
      "Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology reports 2021-03-17\n",
      "S Shikha Thakur 1 ['Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India.']\n",
      "Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2021-03-17\n",
      "    Mayank 1 ['Shobhaben Pratapbhai Patel']\n",
      "Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2021-03-17\n",
      "R Ramarao Poduri 1 ['Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: ramaraop@yahoo.com.']\n",
      "Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2021-03-17\n",
      "P Paul Marik 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "P Pierre Kory 1 [\"Pulmonary and Critical Care Medicine, Aurora St. Luke's Medical Center, Milwaukee, USA.\"]\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "L Leland Shapiro 1 ['Department of Internal Medicine, Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and University of Colorado Anschutz Medical Campus in Aurora, CO Supported by the Emily Foundation, Boston, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "R Raphael Thomadsen 1 ['Department of Marketing, Washington University, St. Louis, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "J Jose Iglesias 1 ['Department of Internal Medicine, Jersey Shore University Medical Center, Hackensack Meridian School of Medicine at Seton Hall, Neptune, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "S Stephen Ditmore 1 ['Health Reporting, Parkchester Times, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "M Marc Rendell 1 ['The Rose Salter Medical Research Foundation, Newport Coast, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "J Joseph Varon 1 ['United Memorial Medical Center, University of Texas School of Medicine, Houston, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "M Michael Dubé 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "N Neha Nanda 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "G Gino In 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "D Daniel Arkfeld 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "P Preet Chaudhary 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "VM Vito M Campese 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "DL Diana L Hanna 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "DE David E Sawcer 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "G Glenn Ehresmann 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "D David Peng 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "M Miroslaw Smogorewski 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "A April Armstrong 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "R Rajkumar Dasgupta 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "F Fred Sattler 1 ['Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "D Denise Brennan-Rieder 1 ['CoronaTracker Community Research Group, Canada.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "C Cristina Mussini 1 ['Department of Infectious Disease, University of Modena and Reggio Emilia, Modena, Italy.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "O Oriol Mitja 1 ['Department of Internal Medicine, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "V Vicente Soriano 1 ['Director, Centro Medico, UNIR Health Sciences School & Medical Center, Madrid, Spain.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "N Nicolas Peschanski 1 ['Department of Emergency Medicine, UniversityHospital of Rennes, Rennes, France.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "G Gilles Hayem 1 ['Department of Rheumatology, Hôpital Paris Saint-Joseph, Paris, France.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "M Marco Confalonieri 1 ['Department of Respiratory Diseases, Azienda Ospedaliero-Universitaria Di Trieste, Trieste, Italia.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "MC Maria Carmela Piccirillo 1 ['Department of Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italia.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "A Antonio Lobo-Ferreira 1 ['Unidade De Investigação Cardiovascular (Unic), Faculdade De Medicina, Da Universidade Do Porto, Centro Hospitalar Universitário De São João, Porto, and Hospital Rainha Santa Isabel, Marco De Canaveses, Portugal.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "I Iraldo Bello Rivero 1 ['Department of Clinical Investigations, Center for Genetic Engineering and Biotechnology, Havana, Cuba.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "EH Eivind H Vinjevoll 1 ['Department of Anesthesiology, Volda Hospital HMR, Norway.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "D Daniel Griffin 1 ['Department of Internal Medicine, Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and University of Colorado Anschutz Medical Campus in Aurora, CO Supported by the Emily Foundation, Boston, USA.\\nDepartment of Internal Medicine and Department of Biochemistry and Molecular Biophysics, ProHEALTH, an OPTUM Company, Columbia University, College of Physicians and Surgeons, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "IF Ivan Fn Hung 1 ['Department of Internal Medicine, Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and University of Colorado Anschutz Medical Campus in Aurora, CO Supported by the Emily Foundation, Boston, USA.']\n",
      "The time to offer treatments for COVID-19. Expert opinion on investigational drugs 2021-03-16\n",
      "YH Yusra Habib Khan 1 ['Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Kingdom of Saudi Arabia.']\n",
      "Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert review of anti-infective therapy 2021-03-16\n",
      "A Aisha Khokhar 1 ['Insitute of Pharmacy, Lahore College for Women University, Lahore 54000, Punjab, Pakistan.']\n",
      "Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert review of anti-infective therapy 2021-03-16\n",
      "TH Tauqeer Hussain Mallhi 1 ['Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Kingdom of Saudi Arabia.']\n",
      "Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert review of anti-infective therapy 2021-03-16\n",
      "NH Nasser Hadal Alotaibi 1 ['Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Kingdom of Saudi Arabia.']\n",
      "Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert review of anti-infective therapy 2021-03-16\n",
      "M Maria Rasheed 1 ['Insitute of Pharmacy, Lahore College for Women University, Lahore 54000, Punjab, Pakistan.']\n",
      "Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert review of anti-infective therapy 2021-03-16\n",
      "EB Eda Baldan Toker 1 ['Department of Virology, Bursa Uludag University, Faculty of Veterinary Medicine, 16059, Bursa, Turkey. Electronic address: edabaldan@uludag.edu.tr.']\n",
      "Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro. Virus research 2021-03-14\n",
      "O Ozer Ates 1 ['Department of Virology, Bursa Uludag University, Faculty of Veterinary Medicine, 16059, Bursa, Turkey.']\n",
      "Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro. Virus research 2021-03-14\n",
      "R Roberta Castellani 1 ['Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.']\n",
      "Pregnancy and COVID-19: Do not overlook malaria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021-03-14\n",
      "C Cristina Zanardini 1 ['Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.']\n",
      "Pregnancy and COVID-19: Do not overlook malaria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021-03-14\n",
      "E Enrico Sartori 1 ['Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.']\n",
      "Pregnancy and COVID-19: Do not overlook malaria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021-03-14\n",
      "F Federico Prefumo 1 ['Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.']\n",
      "Pregnancy and COVID-19: Do not overlook malaria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021-03-14\n",
      "B Barbara Saccani 1 ['Department of Infectious and Tropical Diseases, ASST Spedali Civili, Brescia, Italy.']\n",
      "Pregnancy and COVID-19: Do not overlook malaria. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021-03-14\n",
      "S Sjors Maassen 1 ['Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.']\n",
      "What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. Journal of molecular cell biology 2021-03-12\n",
      "MV Maksim V Baranov 1 ['Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.']\n",
      "What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. Journal of molecular cell biology 2021-03-12\n",
      "G Geert van den Bogaart 1 ['Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.\\nDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.']\n",
      "What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. Journal of molecular cell biology 2021-03-12\n"
     ]
    }
   ],
   "source": [
    "authors_search_results = {}\n",
    "\n",
    "for article_doi in articles_of_interest:\n",
    "    article_info = dict_articles[article_doi]\n",
    "    authors_search_results = add_first_author(authors_search_results,\n",
    "                                              article_info['First_Author'],\n",
    "                                              article_doi)\n",
    "    authors_search_results = add_other_authors(authors_search_results,\n",
    "                                          article_info['Other_Authors'],\n",
    "                                          article_doi)\n",
    "    \n",
    "authors_search_results = dict(sorted(authors_search_results.items(), key=lambda item: item[1]['Score'],reverse=True))\n",
    "\n",
    "for key,values in authors_search_results.items():\n",
    "    print(key, values['Score'], values['Affiliation'])\n",
    "    for article_doi in values['Articles']:\n",
    "        article_info = dict_articles[article_doi]\n",
    "        print(article_info['Title'],article_info['Journal'],article_info['Publication_Date'])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
